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Abstract 
 
The carbon-carbon double bond (C=C) is one of the most valuable functionalities available 
to synthetic chemists. Capable of a vast number of chemical transformations, molecules 
containing a C=C bond (olefins) are highly utilised as intermediates to a variety of diverse 
structures. In an effort to develop a catalytic olefination protocol that surpasses current 
methodologies, our group recently developed a Catalytic Wittig Reaction (CWR) that 
employs an organophosphine as the active catalytic species. Although a significant 
development, the first-generation CWR suffers from several drawbacks: (i) poor substrate 
diversity, (ii) high reaction temperature, (iii) potentially arduous purification and iv) low E/Z 
selectivity. This thesis outlines the steps taken to overcome these issues. Employment of a 
masked form of a strong base proved critical in facilitating semi-stabilised and non-
stabilised ylides. An alternative method investigated was the concept of ylide-tuning, where 
the phosphine structure was altered to facilitate easier ylide formation. This concept proved 
successful in using a mild base for semi-stabilised ylide formation. Development of a 
pseudo-catalytic pulse olefination technique enabled ketones to be used as substrates in the 
CWR. The new protocols were used in the preparation of 39 different compounds and were 
also shown to proceed efficiently on multigram scale. The next issue that was addressed was 
the siloxane byproduct removal. The polymeric silane polymethylhydrosiloxane (PMHS) 
was successfully incorporated into the CWR resulting in a cheaper, greener process with 
significantly easier purification. A total of 25 compounds were prepared using the protocols 
optimised for PMHS. Lastly, the properties of phosphine structure were examined to 
determine a possible structural modification which could be used to design a selective CWR 
catalyst. Varying the properties of the 1-substituent provided no significant change in E/Z 
ratio. Aided by literature evaluation, a phosphine was identified which was significantly 
more E-selective in the CWR for all three ylide classes. Based on the results obtained, 
structures were proposed of second-generation pre-catalysts which could potentially result 
in an E-selective catalytic olefination facilitating all ylide classes.  
 
 
 
 
 
 
1 
1 Introduction 
1.1 Olefins: Versatile Building Blocks and Functional Molecules 
Olefins (alkenes) are molecules which contain a carbon-carbon double bond. The reactivity 
of a C=C bond makes alkenes capable of a broad range of chemical transformations. For 
this reason they are considered important building blocks of many molecules. Figure 1 
shows a selection of some functional groups which can be constructed from alkenes. This 
shows how complex molecules can be constructed from relatively simple starting materials 
via short chemical syntheses.  
 
Figure 1: Some useful transformations of olefins 
 
The difficulty involved in building a complicated molecule can sometimes be avoided if an 
alternate synthetic route via an alkene intermediate can be utilised. In the total synthesis of 
Eunicenone A (scheme 1, 1), Corey et al. demonstrates the power of an alkene intermediate 
in two key steps.[1] Scheme 1 shows the Diels-Alder cycloaddition which not only 
constructed the 6-membered ring, but also formed 3 new chiral centres with 97% ee and 
endo:exo ratio of  >98:2.  
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Scheme 1: Alkene intermediates in the total synthesis of eunicenone A 
 
Pericyclic reactions of this nature are a very useful way to selectively form chiral centres 
without the need for transition metal catalysts or expensive chiral reagents. The newly 
formed double bond was later transformed into an epoxide enabling one of eunicenone A’s 
two chiral centres to be constructed. Another example of selective epoxidation of an alkene 
was demonstrated in the synthesis of (+)-parviflorin (scheme 2, 3), a compound known to 
possess anti-tumor properties.[2]  
 
 
Scheme 2: Alkene intermediates in the total synthesis of (+)-parviflorin 
 
Using the Sharpless epoxidation method to form the diepoxide intermediate 2 in ~97% ee 
(99% ee after recrystallization) ensured that a selective synthesis of 3 could be carried out. 
AMF-26 (figure 2, 4) has been recently identified by Ohashi, Yamori et al. as a potential 
anti-cancer agent, known to induce cell death by disruption of the Golgi apparatus.[3] The 
Si
OMe
R
Br
O
oxazaborolidine
Si
OMe
R
Br
CHO
(i)
(ii)
R OH
O
O
R OH
O
O
O
steps
O
R
HO
CO2Me
Al(OtBu)3
tBuOOH
Eunicenone A
R = E,E-farnesyl
1
OH
OH
L-(+)-DET
Ti(O-iPr)4
TBHP
OH
OH
O
O
steps
O
HO
O
HO
OH O
O
3
2
(+)-Parviflorin
3
 
 
 
 
3 
first total synthesis of 4 utilised an intramolecular Diels-Alder (IMDA) reaction as a key 
step to form the core structure.[4] The IMDA precursor was prepared by Wittig reaction, and 
the subsequent IMDA formed four of AMF-26’s seven chiral centres. An allylic phosphate 
fragment, constructed via a second Wittig reaction, was coupled to the core structure by a 
Horner-Wadsworth-Emmons (HWE) olefination to form the diene moiety. 
 
 !
Figure 2: Bonds formed by classic olefination reactions 
 
In 2008 Carter and co-workers disclosed the total synthesis of Amphidinolides B1 and B2 
(figure 2, 5a and 5b), two macrolides which are highly cytotoxic to cancer cells.[5] An 
alkene fragment prepared by a HWE reaction was used to introduce a chiral diol portion. A 
Wittig reaction was utilised to form the tri-substituted alkene moiety. Upon oxidation of the 
alcohol to form the aldehyde functionality, spontaneous HWE olefination occurred. Driven 
to completion by addition of DIPEA, this one-pot process formed the closed-ring 
macrocycle. In 2003 Williams et al. demonstrated a total synthesis of the macrolide 
Phorboxazole A (figure 2, 6) which incorporated four olefiation steps.[6] The first olefination 
was a HWE reaction of an aldehyde with a phosphonate to couple two key fragments in 
88% yield and >95:5 E/Z selectivity. Attachment of the next major fragment was facilitated 
by forming a phosphonium salt using PBu3 which subsequently reacted with the aldehyde 
substituent in a Wittig reaction. Again the olefination process was highly efficient in joining 
the fragments, proceeding in almost quantitative yield with the E/Z ratio >95:5 as before. 
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4 
Formation of the diene portion of 6 was achieved using the Julia-Kocienski olefination 
conditions. The choice of heteroaromatic sulfone used for this process was shown to 
significantly impact the selectivity. Use of an N-phenyltetrazole sulphone primarily 
produced the Z-alkene. By switching the functionality to a benzothiazole sulphone the 
desired E double bond was constructed in 98% yield, E/Z >95:5. Lastly, a HWE type 
reaction at the end of the synthesis resulted in formation of the macrocycle of 6, subsequent 
deprotection and hydrolysis steps produced the target molecule. For this olefination the Z-
isomer was required, so Williams et al. utilised conditions similar to those of Still and 
Gennari.[7] A potassium base (K2CO3) and 18-crown-6 were used to produce the double 
bond in quantitative yield. On this occasion the Z-isomer was favoured (Z:E 4:1) and 
chromatographic purification post-deprotection allowed separation of the two diastereomers. 
This total synthesis clearly highlights the importance of olefination processes. The coupling 
of major fragments of 6 and formation of essential carbon-carbon double bonds was 
achieved efficiently and with controlled E/Z selectivity. Importantly, the olefinations all 
proceeded smoothly without adverse effects on the stereocentres of 6, of which there are 
many. These few examples are minute compared to the wide range of alkene compounds 
which encompass an important biological function. If such compounds are to be made 
available to treat patients it is vital that suitable cost-effective synthetic methods are 
employed to make them. For this reason a significant amount of research continues to go 
into the development of olefination protocols. 
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1.2 Olefin Synthesis 
1.2.1 Julia-Lythgoe/Julia-Kocienski Olefination[8] 
In 1973 Julia and Paris demonstrated a method for selective synthesis of alkenes.[8b] A study 
by Kocienski and Lythgoe explored the scope of the process and gave rise to what is known 
as the Julia-Lythgoe olefination.[9] 
 
Scheme 3: Julia-Lythgoe olefination 
 
The Julia-Lythgoe olefination involves reacting a phenyl sulphone with an aldehyde or 
ketone to form an alkene (scheme 3). A strong base is generally required for the initial step 
which is the formation of the sulphonium anion. Reaction of the sulphonium anion with the 
carbonyl forms an alkoxide intermediate. Subsequent reduction using sodium amalgam 
results in formation of the alkene. Free rotation of the carbon-carbon single bond during the 
reduction step leads to formation of the more thermodynamically stable alkene, hence the 
high E-selectivity of the reaction. This selective process was used in 1993 in the first total 
synthesis of the antibiotic indolizomycin (scheme 4, 7), where Danishefsky and co-workers 
described the compound as “one of the most unstable products that has ever been obtained 
by total synthesis”.[10] 
 
Scheme 4: Julia-Lythgoe olefination used in the synthesis of Indolizomycin 
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6 
Construction of the trienyl side chain was a key part of the total synthesis. Reaction of a 
phenyl sulphone with the aldehyde functionality of the core molecule structure and 
subsequent reduction with sodium amalgam formed the new carbon-carbon double bond 
stereoselectively. This allowed the (E,E,E)-triene portion of Indolizomycin to be constructed 
with relative ease. The modified Julia olefination is similar to the traditional Julia-Lythgoe 
olefination but employs heteroaromatic sulphones instead of the phenyl-substituted type 
(scheme 5).[11] Deprotonation with a base and reaction with the carbonyl forms the alkoxide 
intermediate as before.  
 
Scheme 5: Modified Julia olefination 
 
On this occasion, however, the alkoxide undergoes a rapid Smiles rearrangement to a 
sulphonate. Loss of sulphur dioxide and a metallo-benzothiazolone spontaneously forms the 
alkene. This offers the advantage of a one-pot synthesis and removes the need to use sodium 
amalgam or an alternative reducing agent. However, the process does not undergo a free-
radical reduction as in the traditional Julia-Lythgoe olefination so there is no stabilisation to 
form the favoured E-alkene. This ensures that steric interactions of the substituents are no 
longer useful in imparting selective control of the alkene product. Polarity of the reaction 
environment has been shown to impact the selectivity, meaning that experimenting with 
alternate solvents can offer stereo-control. Choice of metal counterion can also affect the 
outcome. A key step in the synthesis of (-)-spirotryprostatin B 8 was the formation of the tri-
substituted C=C double bond (scheme 6).[12] 
 
Scheme 6: Julia-Kocienski olefination used in the total synthesis of (-)-spirotryprostatin 
S
N
S
R1
O
O
S
N
S
R1
O
O
OR2
R3 M Smiles
Rearrangement
-SO2 S
N
O M
R2 R3
R1
+
(i)
(ii)
Base
R2 R3
O
NHN
O
O
N
Boc
H
CHO
CO2Me NN
N N
S
OOPh
NHN
O
O
N
Boc
H
CO2Me
LiHMDS
steps
NHN
O N
O
O
H
(-)-Spirotryprostatin B
18
8
 
 
 
 
7 
Applying the traditional Julia-Lythgoe methods resulted in just 11% yield of the desired 
product, and also caused inversion of the chiral centre at C-18 (scheme 6). This issue was 
overcomeby employing the Kociensky-modified conditions. The double bond was formed 
without affecting the chirality at C-18 and the yield was significantly increased to 78%.  
1.2.2 Peterson Reaction[13] 
In 1968 D.J. Peterson devised a method of alkene synthesis which possessed interesting 
selectivity options.[13b] The process involves reacting an α-silyl carbanion with a carbonyl 
compound to produce a β-hydroxysilane. An elimination step results in the formation of the 
alkene (scheme 7). The power of this reaction is the ability to form either the E- or Z-alkene 
from the same β-hydroxysilane by choosing either acidic or basic conditions for the 
elimination step.  
 
Scheme 7: Peterson olefination 
 
This control offered by the Peterson reaction is overshadowed by the initial step, which 
inevitably produces both diastereomers of the β-hydroxysilane. Immediate elimination at 
this stage would result in formation of both the E- and Z-alkene, regardless of the conditions 
used. It is therefore often necessary to separate the two β-hydroxysilane diastereomers prior 
to the elimination step. Deslongchamps and co-workers made use of the Peterson olefination 
to construct the D-ring of (+)-maritimol (scheme 8, 9).[14]  
 
Scheme 8: Peterson reaction used in the synthesis of (+)-maritimol 
 
The double bond was constructed without affecting the chirality of the α-carbon. The 
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8 
case separation of the two diastereomers was performed with relative ease by flash column 
chromatography. As the next step required reduction of this new double bond to produce an 
alkyl nitrile, this separation was necessary so that appropriate reduction conditions could be 
applied to each diastereomer. 
1.2.3 Heck Reaction[15] 
In 1969 Richard Heck discovered a method of alkene synthesis by reacting an aryl 
palladium acetate compound with an alkene, a development which led to the award of the 
Nobel Prize in Chemistry to Heck, Negishi and Suzuki in 2010.[15b] New alkenes were 
produced by replacing a substituent of the reacting alkene with the aryl group. 
 
Scheme 9: Heck reaction 
 
The aryl-palladium complex was formed in situ from an aryl-mercury compound and 
palladium acetate. The original substitution reaction was a stoichiometric process. This 
work was soon improved separately by Heck and Nolley[16] and Mizoroki et al.[17] resulting 
in an olefination process using a palladium catalyst (Heck reaction, scheme 9). This 
catalytic process had the added advantage of replacing the mercury compounds with simple 
aryl/vinyl halides. Although published later than Mizoroki’s work, the work by Heck was 
important in showing that milder reaction conditions could be used. The Heck conditions 
used an amine base, no solvent and proceeded at a lower temperature than Mizoroki’s 
process. Also, fewer equivalents of the reacting alkene and base were required. 
 
Scheme 10: Mechanism of the Heck reaction 
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9 
The proposed reaction mechanism consists of four key steps; (I) reductive elimination to 
form the reactive Pd(0) species, (II) oxidative addition of the aryl halide to the Pd, (III) 
insertion of the alkene into the Ar-Pd bond and (IV) β-hydride elimination to produce the 
alkene product (scheme 10). A base is required to activate the palladium from Pd(II) to a 
reactive Pd(0) state. Typically a secondary or tertiary amine is used, alternatively an acetate 
base can be used (eg. KOAc used by Mizoroki). In modern Heck reactions it has been 
shown that inorganic bases such as Na2CO3 and K2CO3 are more appropriate choices as it is 
believed that amines coordinate to the palladium via the nitrogen lone pair.[18] This creates a 
steric block at the metal centre which interferes with subsequent reaction steps. In the Pd(0) 
state the metal is more reactive and it spontaneously inserts into the carbon-halide bond of 
the aryl halide, oxidising the palladium back to the Pd(II) state. The choice of halide 
significantly impacts the rate at which this step occurs, or if it can occur at all. Aryl iodides 
are the most reactive owing to having the lowest bond strength: Ar-I < Ar-Br < Ar-Cl.[19] 
Originally Heck and others used aryl iodides. Modification of the catalyst was necessary to 
facilitate the Heck reaction of aryl bromides and chlorides. The reacting alkene then 
coordinates to the palladium via a π-electron donation. The aryl group forms a covalent 
bond with the alkene. This step can be termed a migration (of the aryl group) or an insertion 
(of the alkene into the R-Pd bond). Rotation to the trans orientation to minimise steric 
clashing of the R substituents ensures a more stable transition state. Then a transfer of a 
hydride anion (H-) to the Pd centre occurs along with the formation of the new carbon-
carbon double bond (β-hydride elimination). Of course, for this step to occur it is essential 
for the alkene reactant to contain β-hydrogens. Generally the Heck reaction works best with 
mono-substituted alkenes as substrates. The other limitation imposed by the β-hydride 
elimination process is that the scope of halide substrates is also narrowed. Soon after the 
reactions first reported by Heck and Mizoroki, the use of different ligands on the Pd was 
explored. In 1974 Dieck and Heck examined a range of phosphines, phosphites, arsines and 
amines as ligands and discovered that triphenylphosphine PPh3 resulted in significantly 
improved Heck olefinations.[20] The new catalyst was produced in situ by reacting Pd(OAc)2 
with PPh3. Using phosphine ligands on the Pd allowed the Heck reaction of aryl bromides to 
be carried out, while the rates of previously conducted reactions of aryl iodides were 
increased with the new catalyst. Importantly, the presence of the phosphine ligands also 
resulted in a certain degree of stereoselectivity. Early Heck reactions offered no selectivity, 
producing equal amounts of E and Z alkene product. The Pd(PPh3)2-catalysed process 
proceeded with a preference for formation of the E-alkene. This was a significant discovery, 
and immediate work went into exploring the use different phosphines as ligands. In 1978 
Ziegler and Heck showed that aryl iodides and bromides containing electron-donating 
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substituents could undergo the Heck olefination by replacing PPh3 with P(o-tolyl)3.[21] Iodo- 
and bromo-phenols and amines were adequate substrates, and even 2-amino-5-
hydroxyiodobenzene reacted with styrene in 50% yield. This study not only showed that 
electron-rich bromides could be used, but importantly demonstrated that the Heck reaction 
could tolerate reactive functional groups without adverse side reactions. This is a useful 
property of a synthetic process, especially if is to be used in a multi-step synthesis. Later 
work by Hii and co-workers showed that there is a direct correlation between the Hammett 
paramaters of ligand substituents with the relative reaction rate.[22] The Heck reaction has 
been used to produce chiral materials enantioselectively.  
 
Figure 3: Chiral ligands used in the first asymmetric Heck reactions 
 
Chiral bidentate phosphine ligands were used successfully to catalyse epoxidations, 
hydrogenations and some cross-coupling reactions. It was therefore logical to employ them 
in the Heck process. The first asymmetric Heck-type reactions were performed 
independently by Shibasaki and co-workers[23] and Overman and co-workers[24] in 1989. A 
cis-decalin derivative was synthesised by Shibaski and co-workers via intramolecular Heck 
reaction using the bidentate ligand DIPHOS (figure 3, 10). Optimisation led to an 
asymmetric synthesis of several cis-decalin derivatives using (R)-BINAP 11 as the ligand 
and Ag2CO3 as an inorganic base. Overman’s group found that another chiral bis-phosphine 
ligand (R,R)-DIOP 12 in conjunction with triethylamine were efficient reagents for 
intramolecular Heck reactions. Although enantioselectivity was far from ideal in both cases 
(36-46% ee for Shibaski, 45% ee for Overman) this work marked the first successful use of 
the Heck reaction to selectively produce a chiral compound. A review by Dounay and 
Overman illustrates several examples asymmetric Heck couplings used in natural product 
synthesis.[25] In 2005 a team from Pfizer compared the use of the Sonagashira, Suziki and 
Heck reactions in their ~100 kg synthesis of anti-cancer compound CP-724,714 (scheme 11, 
13).[26] The Heck reaction proved far superior in overall reaction yield. Another important 
characteristic was that a low catalyst loading (2 mol %) was sufficient, resulting in low 
quantities of Pd waste post-reaction. 
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Scheme 11: Heck coupling used in the synthesis of CP-724,714 
 
1.2.4 Olefin Metathesis[27] 
Olefin metathesis is a catalytic olefination process which utilises two alkenes as starting 
materials.  
 
Scheme 12: Olefin metathesis 
 
Given its name in 1967 by Calderon et al.,[28] olefin metathesis has been used industrially 
since the 1960s, notably by Shell Higher Olefin Process using a nickel-phosphine based 
catalyst[29] and the Phillips Triolefin Process using molybdenum or tungsten oxide on 
silica.[30] In 1971 a mechanism was proposed by Chauvin and Herisson (scheme 13).[31] A 
metal-carbene catalyst reacts with an alkene via a 2+2 cycloaddition process to form a 
cyclic metallocyclobutane intermediate. Retro 2+2 cycloaddition of this species forms a new 
metal-carbene, which reacts with the other alkene substrate in similar fashion. This results in 
formation of new olefins by swapping the substituents of the olefin substrates.  
 
Scheme 13: Chauvin’s mechanism of olefin metathesis 
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This paved the way for the development of well-defined metathesis catalysts. Early research 
of olefin metathesis explored the use of tungsten (Grubbs, Katz and Schrock)[32][33][34] or 
titanium (Tebbe)[35] based catalysts. Modern metathesis utilises catalyst structures centred on 
molybdenum (Schrock, 14)[36] and ruthenium (Grubbs and Hovedya, 15-17, figure 
4).[37][38][39] The ruthenium-based compounds are easier to handle due to their greater 
stability to oxygen and moisture. The applications of metathesis are many, with several 
variations on the traditional cross-metathesis enabling a wide variety of new structures to be 
constructed (scheme 14). In 2005 Chauvin, Grubbs and Schrock shared the Nobel Prize in 
Chemistry for their contributions to the development of olefin metathesis. 
 
Figure 4: Conventional metathesis catalysts 
 
Recently extensive efforts have been made in enhancing the selectivity. In 2011 Schrock, 
Hoveyda and co-workers demonstrated an efficient Z-selective CM process.[40] High Z-
selectivity was achieved by using stereogenic-at-Mo complexes which bear a bulky 
aryloxide ligand which is free to rotate about the Mo-O bond (figure 5, 18). Initially, yields 
of Z-olefin were low and were improved by using 5 equivalents of the enol ether substrate. 
 
Scheme 14: Ring-opening, ring-closing and enyne metathesis 
 
However, when an expensive enol ether is the starting material, using a large excess 
becomes impractical, as illustrated in the group’s preparation of natural product 20. Using 
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overcome by performing the reaction at reduced pressure to remove the volatile ethylene in 
situ. 
 
Figure 5: Z-Selective metathesis catalyst 
 
The method was used to prepare a variety of Z-olefins in good yield, and was successfully 
applied to the synthesis of natural product 20.  
 
Scheme 15: Z-Selective metathesis reaction used in the synthesis of 20 
 
The use of chiral ligands in asymmetric metathesis is another phenomenon of current 
interest. Typical processes involve a ROM or RCM reaction of a symmetrical achiral 
alkene/diene which results in formation of a new chiral centre. A recent review by Blechert 
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asymmetric metathesis reactions.[41]  
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Scheme 16: RCM used in the synthesis of vaniprevir 
 
A review by Nicolaou et al. highlights several examples of the use of olefin metathesis 
reactions in natural product synthesis.[42] Metathesis has also gained popularity in industrial 
preparations of pharmaceutical APIs such as HIV protease inhibitor vaniprevir (scheme 16, 
21)[43] and Hepatitis C protease inhibitor BILN 2061 (scheme 17, 22).[44][45] 
 
Scheme 17: RCM used in the synthesis of BILN 2061 
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1.3 Wittig and Related Reactions[46] 
1.3.1 Witig Reaction 
In 1953, some years prior to the discovery of the aforementioned olefination processes, G. 
Wittig and G. Geissler demonstrated an alkene synthesis by reaction of an aldehyde with a 
phosphonium ylide 23 (scheme 18).[47] This was the birth of the Wittig reaction, a milestone 
in the history of synthetic chemistry. In 1979 Wittig shared the Nobel Prize in Chemistry 
with H. C. Brown for their development of phosphorus and boron compounds respectively. 
Phosphonium ylides, were first made by Staudinger and Meyer early in the 20th century 
from a phosphonium salt.[48] Phosphonium salts can be readily produced by reacting a halide 
with triphenylphosphine. Deprotonation of the phosphonium salt with a base forms the 
ylide. These compounds can be viewed as the ylide form with a carbanion and phosphorus 
cation, or the ylene form with a carbon-phosphorus double bond. The nucleophilic 
carbanion readily reacts with a carbonyl (usually an aldehyde) and forms a 4-membered 
oxaphosphetane ring. The ring quickly collapses via a retro [2+2] cycloaddition to form the 
alkene and triphenylphosphine oxide.  
 
Scheme 18: Wittig reaction 
Ylides are divided into three categories based on the electronic properties of their 
substituents (figure 6). Stabilised ylides contain strongly electron-withdrawing substituents. 
Examples of such substituents include ester, cyano and EWG-substituted aromatic groups. 
The negative charge on the deprotonated carbon is stabilised by the substituent through 
resonance effects and to a lesser extent inductive effects.. This stabilisation makes ylides of 
this type relatively easy to form by deprotonation, i.e. the phosphonium salt is more acidic. 
Their stability also means that in some cases the ylide can be isolated, instead of being 
formed in situ during a reaction. However, the stabilisation renders the carbanion less 
nucleophilic making stabilised ylides less reactive. 
 
Figure 6: Classes of phosphonium ylides 
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Semi-stabilised ylides contain substituents which stabilise the carbanion by resonance 
effects. Typical substituents are benzylic or allylic groups. This makes them slightly more 
difficult to form than their stabilised counterparts, but more reactive. Non-stabilised contain 
no stabilising groups. Formation of ylides from alkyl phosphonium salts can be difficult and 
generally requires a strong base such as BuLi. The nature of the ylide has a significant 
impact on the stereoselectivity in the Wittig reaction. Stabilised ylides react to primarily 
produce the E-alkene, while reactions of non-stabilised ylides favour formation of the Z-
alkene. To better understand why this is occurs it is important to gain a deeper insight into 
the reaction mechanism.  
1.3.2 Mechanism and Selectivity 
The first mechanism of the reaction was suggested by Wittig and Schöllkopf in 1954.[49] 
They proposed that the phosphonium ylide reacted with the aldehyde in a stepwise fashion, 
initially producing a betaine (scheme 19, 24).  
 
Scheme 19: Betaine mechanism of the Wittig reaction 
 
The free rotation about the carbon-carbon single bond added some freedom to the 
intermediate. Through bond rotation the betaine could arrange itself to two different 
conformational structures and hence form two different oxaphosphetanes – one with the 
substituents (R1 and R2) on the same face of the ring (cis), and one where they are on 
opposite faces (trans). If the major intermediate is the oxaphosphetane with the substituents 
on the same face, the major product will be the Z-alkene, and likewise for favoured E-alkene 
formation. Betaine intermediates were never successfully characterised so their existence 
could only be proposed without providing direct evidence. In 1988 Vedejs and Marth set out 
to determine an alternate reaction mechanism which accounted for the selectivity based on 
different ylide types.[50][51]  
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Figure 7: Harvey-Aggarwal model of Wittig transition states 
 
The proposed mechanism suggests that the oxaphosphetane ring is formed in a one-step 
(concerted) process. This mechanism is kinetically controlled (as opposed to 
thermodynamic control) which agrees with Z-selective Wittig reactions. The E/Z selectivity 
in this case would be primarily influenced by the relative stabilities of the transition states 
leading to the ring formation. Vedejs stated that the fact that numerous ylides with different 
properties can undergo this reaction makes it impossible to suggest one transition state. The 
steric effects of ylide substituents significantly determine whether a planar or puckered 
transition state was preferred. Later computational studies by Harvey, Aggarwal and co-
workers used density functional theory (DFT) calculations to support this theory.[52] The 
computational model also showed that electronic properties of the substituents also played a 
major role in selectivity for reactions of stabilised ylides. The electron-withdrawing 
properties of a stabilised ylide substituent create a strong dipole moment. This, coupled with 
the avoidance of 1,2 steric interactions, ensures that a puckered transition state is preferred 
for stabilised ylides, but with a smaller pucker angle than that of non-stabilised ylides. 
Wittig reactions of these ylides therefore favour formation of the E-alkene. A recent review 
by Gilheany and Byrne provides a thorough evaluation of several proposed mechanisms of 
the Wittig reaction.[53] 
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1.3.3 Schlosser Modification 
In 1966 Schlosser and Christmann modified the Wittig reaction to selectively produce E-
alkenes from non-stabilised ylides.[54] Whether the true mechanism of the Wittig reaction 
occurs via the betaine route or direct oxaphosphetane formation, both proposed pathways 
result in formation of the oxaphosphetane intermediate. Schlosser and Christmann decided 
to adapt this step to a reversible process (scheme 20).  
 
Scheme 20: Schlosser-modified Wittig reaction 
 
The presence of a lithium halide disconnects the phosphorus-oxygen bond to form a 
relatively stable lithio-betaine. Further deprotonation of the betaine with a lithium base (eg. 
PhLi) forms a carbanion. Free rotation of the carbon-carbon bond enables this structure to 
equilibrate to form the most stable trans conformation. Protonation with an acid such as 
HCl or an alcohol such as tBuOH re-forms the lithio-betaine. 
 
Scheme 21: (i) Schlosser and (ii) Wittig reactions used in the synthesis of dolatrienoic acid 
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predominantly produce the E-alkene. By making the intermediate formation step a 
reversible process, more equilibration and stabilisation is allowed to occur, and thus the 
more stable product is produced. The protonation step leads to the trans-betaine, which later 
forms a di-substituted alkene. However, by using various electrophiles instead of protons, 
the Schlosser-modified Wittig reaction can be used to form tri-substituted alkenes. This was 
demonstrated by Schlosser et al. in 1971, a process which he termed SCOOPY (α-
Substitution plus Carbonyl Olefination via β-Oxido Phosphorus Ylides).[55] A more modern 
study by Hodgson and Arif shows that tri-substitued E-bromo and iodoalkenes can be 
selectively produced by SCOOPY reactions.[56] In this case the halide is trans to the R group 
of the aldehyde. This demonstrates the power of the Schlosser modified reaction, whereby a 
carbon-carbon double bond and a carbon-halide bond are selectively formed in the one 
process. The nature of the R substituent significantly influenced the selectivity. When R = 
CH3 the reaction produced the alkene with an E/Z ratio of <1:99, but as the steric bulk of the 
R substituent was increased, the E-selectivity increased also. This highlights the importance 
of having a range of olefination conditions available, as different methods will produce 
different results depending on the substrates. An example is observed in the total synthesis 
of dolatrienoic acid 28 by Pettit and Duffield (scheme 21).[57] The final step involved the 
coupling of  aldehyde fragment 27 to phosphorus ylide 26 to form an E-double bond. This 
was successfully conducted using a classic Wittig reaction. However, when Wittig 
conditions were employed in an earlier step to form E-alkene fragment 25, the Z form was 
preferred in a ratio of 1:9. By using the Schlosser modified conditions instead the fragment 
was predominantly formed as an E-alkene. 
1.3.4 Horner-Wadsworth-Emmons Reaction 
In 1958 Horner et al. discovered that alkenes could be synthesised using a Wittig-type 
reaction by replacing the phosphonium ylide with a phosphonate stabilised carbanion 29.[58] 
Later in 1961 Wadsworth and Emmons, realising the potential of Horner’s discovery, 
demonstrated the importance of the reaction.[59] This was the beginning of the Wittig-Horner 
or Horner-Wadsworth-Emmons reaction which has been a valuable alternative to the 
classical Wittig reaction since its discovery (HWE reaction, scheme 22).  
 
Scheme 22: Horner-Wadsworth-Emmons reaction 
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The phosphonate carbanions are generally easier and less expensive to prepare than 
corresponding ylides. A common method of phosphonate preparation is the Michaelis-
Arbuzov reaction, which produces a phosphonate by heating a trialkyl phosphite in the 
presence of an alkyl halide.[60] The vast options of alkyl halides which are commercially 
available and inexpensive ensure that numerous phosphonates can be readily synthesised. 
As with ylide formation, the carbanion of the phosphonate is formed by deprotonation using 
a suitable base. The HWE was utilised by Miller and co-workers during the preparation of 
3-(hydroxymethyl)carbacephalosporin 30, with potential antibiotic properties (scheme 
23).[61] An intramolecular HWE reaction of phosphonate and ketone functionalities formed 
the 6-membered ring portion of the cephalosporin core structure. The ketone reacted 
smoothly at room temperature in 2 hours to form one diastereomer of the product in 85% 
yield.  
 
Scheme 23: Intramolecular HWE reaction used in the synthesis of 30 
 
The HWE olefination generally produces E-alkenes selectively. As the steric bulk of the R 
substituent of the phosphonate is increased, the preference for E-alkene formation also 
increases. The use of metal counter-ions has been shown to influence the HWE reaction. In 
one study HWE reactions were successfully carried out using LiCl and DBU as a base.[62] 
The chelation of the lithium cation to the oxygen lone electron pairs added stabilisation to 
the phosphonate carbanion, thus enabling the deprotonation to occur readily using a tertiary 
amine base. However, the selectivity of the reaction is also significantly influenced by 
chelation of metal cations, in particular lithium and magnesium. A study by Davies and co-
workers showed that MeMgBr can be used similarly as a base for HWE reactions.[63] Their 
comparison with the LiCl/DBU conditions showed that both methods offered high E/Z 
selectivity (many >99:1, some >180:1 for MeMgBr), but the new conditions resulted in 
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greater conversion of reactant to product. In 1983 Still and Gennari devised a method for Z-
selective olefination using phosphonate carbanions (scheme 24).[7] 
 
Scheme 24: Still-Gennari modified HWE reaction 
 
Using trifluoroalkoxy substituents on the phosphorus, a strong base and 18-crown-6 the Z-
alkene is formed predominantly. Electron-withdrawing groups are required to stabilise the 
phosphonate carbanion. A potassium base (e.g. KHMDS) is used in combination with 18-
crown-6, as this crown ether is ideally suited in size to capture the potassium cations, with 
the subsequent anion acting as the base. This ensures that there is minimal chelation of the 
potassium cation to the oxygen atoms. It is believed that these conditions result in a quicker 
formation of the oxaphosphetane, which is irreversible. This kinetic control results in high 
Z-selectivity. 
1.3.5 Non-Classical Wittig-Type Reactions 
The wide substrate scope is an attractive property of the Wittig reaction. Phosphonium 
ylides can be easily prepared from phosphonium salts, which can be produced from halides. 
A substantial amount of structurally diverse halides are commercially available. A vast 
range of aldehydes and ketones are also either commercially available or can be readily 
synthesised, for example by oxidation of an alcohol. Although ketones are less reactive than 
aldehydes, they will undergo Wittig-type reactions. This can be aided by activating the 
ketone, i.e. making it more electrophilic and thus more reactive towards the carbanion of the 
ylide. Varying the temperature, base and solvent can also help affect the reactivity. 
Examples of reactions employing this methodology exist for carbonyl substrates other than 
aldehydes and ketones (scheme 25). Lin and co-workers demonstrated the preparation of 
substituted furans using an intramolecular Wittig reaction of esters.[64] Numerous tetra-
substituted furans of type 31 were prepared in good yield. P.J. Murphy and co-workers, who 
also synthesised substituted furans using esters,[65] demonstrated the use of lactones as 
Wittig substrates.[66] Various substituted lactone substrates were shown to form bicyclic 
dihydrofurans in high yield. In 1978 Woodward and co-workers used the intramolecular 
Wittig reaction of thiol esters to synthesise a range of penems (scheme 25, 32), a form of β-
lactam antibiotics.[67] As expected, methyl ketones (R = CH3) reacted smoothly under mild 
conditions (10 h, 70°C) while bulkier alkyl substituents were far less compliant with the 
isopropyl ketone (R = iPr) only giving a 6% yield after 8 days (80-100°C). Strongly 
electron-withdrawing substituents assisted in activating the ketone to make it more 
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electrophilic, with R = p-nitrobenzyl producing the desired penem in 90% yield (17 h, 
55°C). 
 
Scheme 25: Some examples of non-classical Wittig reactions 
 
Amides are another subclass of compound which is part of the carbonyl group. In 1981 
Weinreb and Nahm devised a method of ketone production which involved formation of an 
amide (called a Weinreb amide) from an acid chloride.[68] The Weinreb amide would then 
react with a Grignard reagent or organolithium compound to produce a ketone. Alternatively 
the amide could be reduced with LiAlH4 to produce an aldehyde. An interesting Wittig 
reaction of amides was performed by J.A. Murphy et al. for the preparation of ketones 
(scheme 25, 33) via Weinreb amides.[69] Instead of using a strong reducing agent or 
Grignard, the amide was subjected to a Wittig reaction to convert it to an alkene. Mild 
hydrolysis of the alkene would then form the ketone. Good yields were obtained for various 
substituted amides and the new conditions were far more tolerable than those of the 
conventional Weinreb process.   
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essential to prepare the desired compound. The epothilones are a class of compounds which 
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function similar to the highly popular paclitaxel (Taxol®) by stabilising the microtubules of 
cells during mitosis and thus initiating apoptosis (programmed cell death).[70] In 2008 Keck 
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et al. synthesised epothilone B.[71] The initial plan was to form the main framework of 
epothilone B 37 via ring-closing metathesis but this method proved unsuitable. An alternate 
synthetic route was devised which utilised two Wittig reactions (scheme 26). 
 
Scheme 26: Wittig reactions used in the synthesis of epothilone B 
 
The first of these was used to construct a tri-substituted olefin fragment 34. The resulting 
C=C double bond would eventually be used to form the epoxide of epothilone B in the final 
step of the synthesis. The Wittig reaction produced the desired intermediate in 94% yield 
with an E/Z ratio of >95:5. After the ylide 35 and aldehyde 36 fragments were both 
prepared, it was necessary to couple them together via a second Wittig reaction. This step, 
along with the macrolactonisation which soon followed, was essential to form the 
framework of the epothilone. Again good yield of alkene was obtained using the Wittig 
reaction (87%) and only the desired Z-diastereomer was formed. In the total synthesis of 
Spongistatin 1 (38), Ley and co-workers also used a Wittig reaction to combine two 
complex fragments to prepare the overall framework of the natural product.[72] Applying 
these conditions resulted in formation of the Z-alkene in 50% yield. In 2009 Fenical, 
Hughes and co-workers showed that ammosamides 39 and 40 are capable of interacting 
with the protein myosin.[73] This property is of value to medicinal chemists as myosin plays 
a pivotal role in cell division, so natural products which display activity against it may have 
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potential as anti-cancer therapeutics. Soon after discovering this activity of the 
ammosamides, Fenical and Hughes then demonstrated a total synthesis of the compounds 
from commercially available isatin (scheme 28).[74] A Wittig reaction (86% yield) and 
subsequent condensation formed a quinolone ring. Nitration and conversion of the hydroxyl 
group to a chloride resulted in the ammosamide scaffold. The two nitro groups and chloride 
substituent are functional groups which can be readily converted/substituted to prepare an 
array of ammosamide structures. The Wittig reaction was useful in constructing the fused 
heteroatomic ring structures. 
 
Scheme 27: Wittig reaction used in the synthesis of spongistatin 1 
 
 
O
O
Cl
OTBS
H
OPMB
H
PMBO
OTBS
OMe H
OPMB
O
O
O
O
O
O
O
H
AcO
H
CHO
TBSO
OMe
OTES
AcO
O
O
Cl
OTBS
H
OPMB
H
PMBO
OTBS
OMe H
OPMB
PPh3I
O
O
O
O
O
CO2All
H
AcO
H
OTES
AcO
OMe
TBSO
MeLi
O
O
Cl
OH
H
OH
H
HO
OH
OH H
O
O
O
O
O
O
H
AcO
H
OH
AcO
OMe
HO
O
Spongistatin 1
steps
+
38
 
 
 
 
25 
 
Scheme 28: Wittig reaction used in the synthesis of ammosamide core 
 
Scheme 29: Wittig reactions used in the synthesis of (+)-discodermolide 
 
Another natural product which displays anti-tumour properties is (+)-discodermolide (44). 
In a complex synthesis of the compound by Smith et al., the Wittig reaction again proved to 
be an essential synthetic tool (scheme 29).[75] Retrosynthetic analysis showed a route to 44 
via coupling of three fragments, all of which were constructed in multistep processes. 
Preparation of the B fragment involved a Wittig reaction to form the tri-substituted alkene 
moiety 41. The reaction yielded 84% of the desired intermediate with a Z:E ratio of 8.5:1. 
This formed the first of (+)-discodermolide’s two Z-alkene functionalities. The second 
Wittig reaction was the challenging coupling of the phosphonium salt 42 to aldehyde 43. 
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The reaction was highly efficient, forming the new double bond in 76% yield and with high 
Z-selectivity (Z:E ratio of >49:1).   
 
Scheme 30: Wittig reaction used in the synthesis of CRTH2 receptor antagonist 
 
This Wittig reaction proved vital in achieving this multistep gram-scale synthesis. Recently, 
Shu et al. developed an optimised industrial route to produce the CRTH2 receptor 
antagonist 48.[76] The reaction of the acid chloride derived from 45 with Wittig reagent 46 
formed an allene intermediate 47, which was subsequently converted to a tri-substituted 
olefin. Alcohols of type 50 are important precursors to several anti-cancer compounds 
developed by Vertex Pharmaceutical Inc.[77] The original synthesis of intermediate 49 was 
carried out by Heck reaction but the low reaction yield and high cost rendered this method 
impractical. By switching to a double Wittig reaction to form diene 49, an efficient high-
yielding synthesis of 50 was achieved (scheme 31). 
 
 Scheme 31: Double Wittig reaction used in the synthesis of precursor 50 
 
Lacidipine (51), a calcium channel blocker, is synthesised using the Wittig reaction to form 
the C=C double bond.[78] The entire synthesis of 51 proceeded without any chromatographic 
purification (scheme 32). Careful adjustment of reagent equivalents and reaction 
temperature produced high chemoselectivity in the Wittig reaction, with minimal reaction of 
the second aldehyde group. The advantages of the major stoichiometric olefination 
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limitations associated with these methodologies. Each stoichiometric process requires the 
synthesis of a precursor in order to carry out the olefination – sulphone (Julia-lythgoe/Julia-
Kocienski), α-silyl carbanion (Peterson), phosphonium ylide (Wittig) or a phosphonate 
(HWE). 
 
Scheme 32: Wittig reaction used in the synthesis of lacidipine 
 
This adds an extra step to the overall synthetic process. Diastereoselectivity can also be an 
issue. Applying certain conditions to a particular combination of substrates can be 
performed to obtain high E/Z selectivity in several cases. However, this may not always be 
possible. For example the Wittig reaction of non-stabilised ylides (obtained from alkyl 
halides) usually favours formation of the Z-alkene. If the E-alkene was the desired product, 
the selective Wittig reaction of such halides becomes a major challenge. Another major 
issue associated with the stoichiometric processes is waste production. For each process a 
stoichiometric quantity of reactants are required. For example the Wittig reaction requires 1 
molar equivalent (usually excess) of PPh3 to form the phosphonium salt. Not only is this 
costly as more starting material is required, but it also means that a stoichiometric amount of 
waste byproduct is produced. In the case of the classic Wittig reaction the byproduct is 
triphenylphosphine oxide. Labourious chromatographic purifiation can be required to fully 
remove the byproducts, which is costly and time-consuming. A catalytic process has the 
potential to overcome all of these issues. Employing a catalyst would reduce quantities of 
reagents and waste, resulting in a less expensive and more environmentally friendly process. 
The current catalytic olefination methods (Heck and metathesis reactions) require transition 
metal catalyst and a olefin as the starting material. Development of a catalytic olefination 
process with a wide substrate scope would be highly advantageous. Tuning of the catalyst 
by modifying steric and electronic factors would result in a more selective process. These 
reasons ensure that the development of a catalytic olefination process is essential for 
synthetic and medicinal chemists. 
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1.4 Catalytic Wittig Reactions 
1.4.1 Early Catalytic Wittig Reactions  
Of the many olefination processes that currently exist, those of the catalytic variety possess 
a distinct advantage over their stoichiometric variants in that waste is minimised. 
Unfortunately all of the catalytic olefination processes discussed require the use of a 
transition metal catalyst. Complexes of such metals are known to be toxic to the 
environment even in small quantities which is a concern for disposal of waste metal 
catalysts and their associated byproducts. The relative scarcity of these metals result in a 
significantly higher cost compared to similar quantities of organic compounds. The 
substrate diversity of the Heck reaction and olefin metathesis is also somewhat limited due 
to the requirement of an olefin starting material. A catalytic olefination protocol with a wide 
substrate scope would be of great benefit to synthetic chemists.  In order to create such a 
process, several attempts have been made at devising a catalytic Wittig reaction. Such a 
process would have several advantages over the stoichiometric Wittig reaction. Removal of 
triphenylphosphine oxide byproduct would no longer be an issue. Perhaps a more interesting 
enhancement offered by a catalytic Wittig reaction would be the possibility of tuning the 
phosphine structure. It has been widely observed that varying the nature of the substituents 
at the phosphorus centre can lead to significant changes in the outcome of the reaction, in 
particular the E/Z selectivity of the olefin. As only a catalytic quantity of phosphine would 
be used it would be cost effective to explore the possibility of tuning the phosphine structure 
to alter the selectivity of the reaction. To make the reaction catalytic the triphenylphosphine 
oxide byproduct would have to be recycled back to triphenylphosphine. In isolation this 
appears a straightforward step but to reduce the phosphine oxide in the presence of other 
reactive reagents would necessitate a mild reducing agent.  
 
Scheme 33: Catalytic Wittig-type reactions using arsenic and tellurium-based catalysts 
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With a bond strength of 132 kcal/mol, mild methods for P=O reduction proved difficult. To 
overcome this, the phosphorus was replaced with tellurium or arsenic resulting in a weaker 
bond and thus a more favoured oxide reduction (Te=O bond strength: 94 kcal/mol, Ar=O 
bond strength: 106 kcal/mol). In 1989 Shi, Huang et al. demonstrated the first catalytic 
Wittig-type reaction using tributylarsine[79] and dibutyltelluride[80] (scheme 33). 
Triphenylphosphite functioned as the reducing agent to convert the oxide to the active 
catalytic species. Although several examples of olefins were synthesised in good yield and 
selectivity, the high toxicity associated with arsenic[81] and tellurium[82] ensured the 
processes would not be widely adopted, particularly in industrial production. 
1.4.2 First Organocatalytic Wittig Reaction 
 
 
Scheme 34: Catalytic Wittig reaction (CWR) using an organophosphorus catalyst 
 
In 2009 O’Brien et al. developed the first organocatalytic Wittig reaction which utilised a 
phosphine catalyst.[83] By employing cyclic phosphine oxide 52 as the pre-catalyst instead of 
triphenylphosphine oxide, reduction could be achieved using diphenylsilane. Contrary to 
previous experiments using chlorosilanes, the reduction proceeded with retention of 
configuration at the phosphorus centre. This factor may be of importance if later generation 
phosphine catalysts contain chiral moieties. 19 examples of olefins were synthesised from a 
variety of alkyl, aryl and heterocyclic aldehydes and activated bromides. A more thorough 
discussion of the CWR highlighted the necessity of the 5-membered ring in the pre-catalyst 
structure to obtain a viable rate of phosphine oxide reduction.[84] The full report also 
included slightly improved conditions whereby the insoluble sodium carbonate base was 
replaced with DIPEA and in total 50 olefin compounds were produced in good to high yield. 
This represented the beginning of the development of a versatile, environmentally friendly 
olefination process. 
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1.5 Thesis Proposal 
There are four key obstacles which must be overcome if the CWR is to be adopted as a 
useful methodology: 
(i) Substrate scope 
One of the initial reasons for the need of a new catalytic olefination process was the limited 
scope of the Heck and metathesis reactions. While a reasonable variety of aldehydes were 
used in the CWR, the reaction was limited to halides activated by strong electron 
withdrawing groups (esters, ketones, lactones and nitriles). Expansion of the protocol to 
include semi-stabilised and non-stabilised ylides would be a major advance in the CWR.  
(ii) Purification 
Another attractive prospect offered by the CWR is the omission of difficult phosphine oxide 
removal. While this has been achieved, there now exists a new byproduct which must be 
removed. The reduction of the phosphine oxide results in oxidation of the silane to a silanol. 
At the end of the reaction this is found to be in the form of a cyclic siloxane (figure 8, 53).  
 
Figure 8: Siloxane byproduct 
 
Removal of the siloxane 53 derived from diphenylsilane can be challenging, requiring 
arduous column chromatography. Replacement of diphenylsilane with an alternative which 
can be removed more easily by chromatography or ideally by crystallisation/filtration would 
make the CWR a much more user-friendly process. 
(iii) Temperature 
The first CWR required high tempertures to ensure a viable rate of phosphine oxide 
recycling. Lowering of this temperature would be advantageous; energy cost would be 
reduced for industrial scale applications and temperature labile compounds could be 
tolerated as starting materials. A lower reaction temperature relies on easier phosphine oxide 
reduction. This can be achieved either by modification of the phosphine oxide and/or silane 
structures to increase the rate of reduction or by including an additional reagent which 
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would influence the reaction. Recently, our group discovered that by using a catalytic 
amount of an ammonium benzoate species (formed in situ) the rate of reduction of 
phosphine oxides by silanes increased dramatically without compromising the retention of 
the phosphorus centre. This led to the development of the room temperature (RT) CWR 
using cyclic phosphines, and also allowed acyclic phosphines to be used at high 
temperatures.[85] 
 
Scheme 35: Acid-enhanced CWR at RT or using acyclic phosphines 
 
Simultaneously, Beller and co-workers discovered that using a catalytic amount of 
phosphoric acid in conjunction with a silane significantly increased the rate of phosphine 
oxide reduction.[86] The development of the RT-CWR will not be discussed in this thesis. 
 (iv) E/Z selectivity 
The E/Z selectivity of the first CWR reactions ranged from 60:40 to >95:5. Probing the 
reaction showed that post-reaction isomerisation of the Z-olefin catalysed by the phosphine 
led to high selectivity. This effect was only observed for certain di-substituted ketone and 
ester-substituted olefins. The nature of the phosphonium ylide is known to play an important 
role in the eventual E/Z selectivity of the Wittig reaction.This is highlighted by the varying 
selectivities for the three ylide classes.  
 
Figure 9: Propsed CWR pre-catalyst structure 
 
The CWR offers the possibility to investigate the effect of varying the electronic and/or 
steric nature of the substituents at the phosphorus centre in order to increase the kinetic E/Z 
selectivity. The primary objective will be to screen pre-catalysts of type 53 (figure 9) where 
the properties of the 1-substituent R are varied. 
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2 Expanding the Substrate Scope: Tuning the 
Phosphorus Ylide 
2.1 CWR Utilising Semi-Stabilised Ylides 
A significant limitation of the CWR is that a strong electron-withdrawing substituent on the 
halide component is required. This limits the process to highly activated halides. 
Development of a protocol which could facilitate semi-stabilised ylides derived from 
benzylic and/or allylic halides would vastly widen the scope of the reaction. While two 
examples in the first CWR contained benzylic ylides, a strong EWG on the phenyl ring was 
required.[83] The key barrier to facilitating semi-stabilised ylides is the formation of the 
ylides via deprotonation of the phosphonium salt.  
 
Figure 10: Experimental pKa values (in DMSO) of some triphenylphosphonium ylide 
precursors[87] 
  
The choice of base to perform this reaction is critical. For stabilised ylides the ylide-forming 
proton of the phosphonium salt typically had a pKa of ~9, therefore Na2CO3 and DIPEA 
were ideally suited to form the ylide. Formation of benzylic ylides bearing an EWG was 
also possible with these mild bases. In the case of semi-stabilised ylides, the pKa of the 
ylide-forming proton is 17-19 (DMSO) so a stronger base is required (figure 10). 
Conventional Wittig reactions have employed bases such as NaOtBu, NaHMDS, NaOH and 
nBuLi to form semi-stabilised ylides. These strong bases are likely to react with the silane 
and halide reagent rendering them incompatible with the CWR. A publication in 2010 by 
Zhou et al. demonstrated Wittig reactions of MBH adducts with no base present.[88] 
Deprotonation is critical for ylide formation, so the likely occurrence is that phosphonium 
salt formation proceeds with the loss of the BocO- group which then acts as the base to form 
the ylide (scheme 36). 
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Scheme 36: “Base-free” Wittig reaction 
 
 
Scheme 37: Preparation of NaOBoc 54 
 
NaOBoc (scheme 37, 54) was prepared and tested in the synthesis of stilbene 55. Pleasingly, 
the base was compatible with the CWR and the reaction proceeded in good yield (table 1).  
Table 1: Optimisation of solvent using 54 
  
Entry Solvent Yield % E/Z[a] 
1 Acetonitrile (ACN) 37 66:34 
2 Dimethyl carbonate (DMC) 38 66:34 
3 1,2-Dimethoxyethane (DME) 49 66:34 
4 1,4-Dioxane 53 66:34 
5 tButyl acetate (tBuOAc) 54 66:34 
6 2-Methyl tetrahydrofuran (2-MeTHF) 73 66:34 
7 Cyclopentyl methyl ether (CPME) 75 66:34 
8 Toluene 81 66:34 
   9[b] Toluene 74 80:20 
   10[c] Toluene 80 80:20 
[a] E/Z ratio was determined by 1H NMR spectroscopy of the unpurified reaction mixture. 
[b] Result obtained using PCb at 100 °C. [c] Result obtained using PCb at 110 °C. 
 
A solvent study revealed toluene to be the optimum solvent, with CPME and 2-methyl THF 
also resulting in good yields of stilbene. Other changes to the original protocol are the use of 
PCb as the pre-catalyst which gave increased E/Z selectivity (table 1, entry 9) and an 
increase of temperature to 110°C which gave a slight increase in yield (entry 10). The exact 
role of 54 remains unclear. We believe that 54 itself does not have the necessary pKa to 
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carry out the deprotonation, and that instead it acts as a masked form of NaOtBu (scheme 
38). Mechanistic studies have yet to be conducted. 
 
Scheme 38: Masked form of NaOtBu 
 
54 proved successful in the CWR of benzylic halides. Allylic bromides initially reacted 
poorly due to decomposition under high temperature and/or reaction with the base. This was 
overcome by portion-wise addition of the halide. Secondary halides also reacted efficiently 
to form tri-substituted olefins (table 2). 
 Table 2: Substrate study of semi-stabilised ylides using 54 
  
 
[a] E/Z ratio was determined by 1H NMR spectroscopy of the unpurified reaction mixture. 
[b] Conditions A: all-in reaction, B: portion-wise addition (see appendix A for details). 
[c] Following treatment with iodine at 110 °C (5 h) isomerisation to E/Z >95:5 was 
achieved. 
[d] 27 mmol scale, see appendix A for details. 
 
While 54 proved to be an ideal candidate in the CWR of semi-stabilised ylides, another 
approach was investigated. Instead of using a stronger base to carry out the deprotonation of 
the phosphonium salt, we considered lowering the pKa of the ylide-forming salt. If the pKa 
was lowered significantly it would be possible to use a mild, commercially available base. 
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As only a catalytic quantity of phosphine is used in the CWR it is cost-effective to modify 
its structure to alter the properties of the catalyst. Previous studies showed that the five-
membered ring is critical for efficient reduction of phosphine oxide[84] so we considered 
altering the electronics by adding electron-withdrawing substituents to the phenyl ring in the 
1-position. 
 
 
Figure 11: Library of pre-catalysts PCa-f 
 
The idea is that withdrawal of electron density from the phosphorus centre will lower the 
pKa of the ylide-forming proton sufficiently so that a mild base (DIPEA) could carry out the 
deprotonation. The drawback to adding EWGs is that the nucleophilicity of the phosphine 
and phosphine oxide will be lowered. This will likely impact the rate of phosphine oxide 
reduction and the rate of phosphonium salt formation. To compensate for this the reaction 
temperature was increased to 140 °C. A library of pre-catalysts (figure 11, PCa-f) was 
prepared and tested in the synthesis of stilbene (table 3). 
Table 3: Phosphine oxide screening using DIPEA and ylide tuning. 
 
Entry Pre-catalyst T°C Conversion (Yield %)[a] E/Z[b] 
1 PCa 100 trace - 
2 PCb 140 55 (37) 75:25 
3 PCa 140 65 (43) 80:20 
4 PCc 140 88 (61) 75:25 
5 PCd 140 91 (72) 82:18 
6 PCe 140 94 (66) 82:18 
7 PCf 140 91 (72) 78:22 
[a] Conversions were determined by 1H NMR spectroscopy. 
[b] E/Z ratio was determined by 1H NMR spectroscopy of the unpurified reaction mixture. 
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Table 4: Optimisation of solvent using DIPEA. 
 
Entry Solvent Conversion (%)[a] E/Z[b] 
1 Cyclopentyl methyl ether (CPME) 75 81:19 
2 tButyl acetate (tBuOAc) 84 81:19 
3 Dimethyl carbonate (DMC) 87 75:25 
4 Toluene 91 82:18 
5 2-Methyl tetrahydrofuran (2-MeTHF) 92 77:23 
6 α,α,α−Trifluorotoluene (CF3Ph) 100 79:21 
[a] Conversions were determined by 1H NMR spectroscopy.  
[b] E/Z ratio was determined by1H NMR spectroscopy of the unpurified reaction mixture. 
 
A clear trend is observed: as more EWGs are added to the pre-catalyst the reaction yields 
increase. Use of PCd as pre-catalyst gave a high yield (table 3, entry 5). However, a point is 
reached where addition of more EWGs fails to increase the yield (entries 6 and 7). This 
highlights the importance of finding a balance between lowering the pKa of the 
phosphonium salt whilst maintaining viable rates of phosphine oxide reduction and 
phosphonium salt formation. A solvent study focusing on the use of green solvents showed 
that high conversions were obtained using toluene, 2-methyl THF and α,α,α-
trifluorotoluene. No significant change in E/Z selectivity was observed by altering the 
solvent system. A substrate study was carried out to demonstrate the use of the CWR of 
semi-stabilised ylides utilising the concept of ylide-tuning (table 5). A wide array of aryl 
and heteroaryl aldehydes and organohalides were successfully tolerated. A notable example 
is DMU-212 (77), a resveratrol analogue which has been shown to possess more potent anti-
cancer properties than resveratrol.[89] Compounds similar to 70 can be used as building 
blocks to prepare photochromic and conductive materials.[90] An aldehyde containing a 1-2 
oxazole was employed in the synthesis of 72; these heterocyclic fragments are found in 
some compounds of importance in medicinal chemistry.[91] Compounds similar to 73 can be 
used to form 1H-indoles,[92] which are also found in several pharmaceutical agents. The use 
of DIPEA is a significant achievement as this is the mildest base used to date for the 
formation of semi-stabilised ylides. For allylic and secondary benzylic halides 54 remains 
the base of choice. These halides react rapidly with DIPEA at high temperature and poor 
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O
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yield of olefins were obtained even when using slow addition of the halide. The E/Z 
selectivity ranged from non-selective to 80:20, but was typically between 66:34 and 70:30.  
Table 5: Substrate study of semi-stabilised ylides using DIPEA. 
 
 
[a] E/Z ratio was determined by 1H NMR spectroscopy of the unpurified reaction mixture. 
[b] Following treatment with iodine at 110 °C (5 h) isomerisation to E/Z >95:5 was 
achieved. 
[c] 23 mmol scale, see appendix A for details. 
Pleasingly, many of the compounds isomerised fully to E/Z >95:5 when heated in the 
presence of a trace of iodine. Other isomerisation methods for stilbene derivatives including 
the use of acid or metal catalysis were not investigated. Further purification was not 
necessary after workup and pure E-olefin could be obtained with minimal loss of yield. This 
demonstrates that for the majority of the compounds prepared the intrinsic E/Z selectivity is 
trivial if the pure E-isomer is required.  
2.2 CWR Utilising Ketones 
The CWR of semi-stabilised ylides facilitates the use of benzylic and allylic halides which 
significantly enhances the substrate scope of the reaction. A further enhancement would be 
to employ ketones instead of aldehydes. This would be a useful method of preparing tri-
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substituted olefins. The difficulty in using ketones lies with their low reactivity compared to 
aldehydes and their tendency to enolise.[93] The choice of pre-catalyst is important for the 
CWR of ketones. While PCd proved useful to facilitate easier ylide formation, the lowered 
nucleophilicity would be a problem when reacting the ylide with a ketone. PCb was chosen 
as the pre-catalyst as it would produce the most nucleophilic ylide. The first attempt to react 
acetophenone with benzyl bromide using PCb and 54 was met with failure, and the halide 
reactant was fully consumed (table 6, entry 1). Using potion-wise addition of the halide 
resulted in α-alkylation of the ketone instead of formation of 78 (table 6, entry 2).  
Table 6: Development of the pulse olefination technique. 
 
Entry Halide 
(equiv) 
Base 
(equiv) 
Conditions t 
(h) 
Conv. 
(Yield 
%)[a] 
E/Z[b] 
1 1.50 2.0 All-in 24 0[c] - 
2 1.50 2.0 Portion-wise addition of halide (8 
additions, 1 h intervals) 
24 91[d] - 
3 1.05 2.0 Pulse olefination: halide (7 
additions), base (2 x 1.0 equiv., 0 h 
and after 4th addition of halide); 
Heating cycle: 30 min at RT, 1.5 h 
heating 
24 65 (58) 65:35 
4 1.23 2.0 Pulse olefination: halide (7 
additions), base (4 x 0.5 equiv., 0 h 
and after 3rd, 4th and 6th additions of 
halide); Heating cycle: 30 min at 
RT, 1.5 h heating 
24 52 65:35 
5 1.20 3.0 Pulse olefination: halide (8 
additions), base (3 x 1.0 equiv., 0 h 
and after 3rd and 6th additions of 
halide); Heating cycle: 30 min at 
RT, 2.2 h heating[e] 
31 75 (72) 63:37 
6 1.35 3.5 Pulse olefination: halide (9 
additions), base (3 x 1.0 equiv., 0 h 
and after 3rd and 6th additions of 
halide, 1 x 0.5 equiv. after 8th 
addition of halide); Heating cycle: 
30 min at RT, 2.2 h heating[e] 
36 97 (87) 66:34 
[a] Conversions were determined by 1H NMR spectroscopy, based on residual ketone. 
Isolated yields shown in parentheses.  
[b] E/Z ratio was determined by 1H NMR spectroscopy of the unpurified reaction mixture. 
[c] No halide or silane remaining.  
[d] The only product observed was 1,3-diphenylpropanone, which is the result of α-
deprotonation of the ketone.  
[e] Stirred for 10 h at 110 °C between 5th and 6th cycles. Additional diphenylsilane (0.3 
equiv.) was added after this time. 
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The success of the CWR of ketones relied on minimising the amount of halide in solution. 
This was achieved by the development of a pseudo-catalytic pulse-olefination technique 
whereby the halide is added portion-wise at room temperature to form the phosphonium 
salt. Once the phosphonium salt has formed the reaction mixture is heated to 110 °C for the 
subsequent steps of the catalytic cycle to occur. This procedure is repeated until all portions 
of the halide are added. Employing PCb as the pre-catalyst is important for this process as it 
ensures a high rate of phosphine oxide reduction and phosphonium salt formation are 
achieved. Using the pulse-olefination technique a range of olefins was prepared from aryl, 
heteroaryl and aliphatic ketones (table 7). 
Table 7: Substrate study of semi-stabilised ylides with ketones using pulse olefination 
technique. 
 
 
[a] E/Z ratio was determined by1H NMR spectroscopy of the unpurified reaction mixture.  
[b] 35 mmol scale, see appendix A for details. 
 
E/Z selectivity was low for all substrates. However, the conventional Wittig reaction and 
even the Heck reaction of ketones typically proceeds with low selectivity compared to 
similar reactions of aldehydes.[93][94]  
2.3 CWR Utilising Non-Stabilised Ylides 
Expansion to include non-stabilised ylides presents two key challenges: 
1) Formation of the phosphonium salt  
2) Deprotonation of the phosphonium salt to form the ylide 
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The deprotonation issue can be approached similarly to that of the semi-stabilised ylides. A 
match between pKa of phosphonium salt and base must be achieved. For semi-stabilised 
ylides this was achieved by either increasing the pKa of the base (using 54) or by lowering 
the pKa of the ylide-forming proton (using PCd). To facilitate formation of non-stabilised 
ylides the natural progression is to combine these two methods i.e. use PCd in conjunction 
with 54. 
Table 8: Substrate study of non-stabilised ylides. 
 
 
[a] E/Z ratio was determined by1H NMR spectroscopy of the unpurified reaction mixture. 
See appendix A for sequence of reagent additions. 
 
Initial application of these conditions using bromoethane indicated that phosphonium salt 
formation was an issue. This was not unexpected as preparation of phosphonium salts from 
PPh3 and alkyl halides typically requires several hours under reflux. Replacing PCd with 
PCb as pre-catalyst could alleviate this problem, however the more electron-deficient 
phosphine is vital for efficient deprotonation to occur. The other option is to use iodides as 
the halide component instead of bromides or chlorides. Iodide is a better leaving group than 
bromide so the rate of salt formation should increase. Using (2-iodoethyl)benzene as the 
halide source, 88 was prepared in 73 % yield, albeit requiring 20 mol % catalyst loading and 
48 h reaction time. Adding an extra equivalent of halide enabled good yields of olefin to be 
obtained when using iodoethane (table 8, 90 and 92). Moderate yields of olefin were 
achieved using an aliphatic aldehyde (91) and using citronellyl iodide (89). The combination 
of ylide tuning and a masked base was successful in facilitating non-stabilised ylides in the 
CWR. Using iodides as the halide source was necessary for phosphonium salt formation. 
This is a minor setback in that a wider variety of alkyl bromides and chlorides are 
commercially available. However, alkyl iodides can be conveniently prepared by treating 
the corresponding alcohol with PPh3 and iodine in the presence of imidazole.[95] 
R1 H
O
I R2+ R
2
R1
Yield, E/Z[a]
PCd (20 mol %)
toluene, 140-150 °C, 48 h
1.2 equiv Ph2SiH2
3.5 equiv 54
1.0-1.2 equiv 1.0-2.0 equiv
sealed tube
O
O
92, 68%, 60:40
MeO
90, 63%, 55:45
Cl
88, 73%, 55:45
O
O
O
O
89, 53%, 55:45
91, 50%, 60:40 93, 75%, 60:40
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3 Waste Removal: Use of a Polymeric Silane 
3.1 PMHS in the CWR of Stabilised Ylides 
Expansion of the CWR to include all ylide types as well as ketones is a major improvement 
on the original protocol. The next major development is identification of the optimum 
silane. The CWR is superior to the conventional Wittig reaction in that triphenylphosphine 
oxide removal is not an issue. However, the stoichiometric amount of phosphine has been 
replaced with a stoichiometric amount of silane. The reduction of the phosphine oxide 
results in oxidation of the silane to a silanol. At the end of the reaction this is found to be in 
the form of a cyclic siloxane. Removal of the siloxane derived from diphenylsilane can be 
challenging, requiring arduous column chromatography. Replacement of diphenylsilane 
with an alternative which can be removed more easily by chromatography or ideally by 
crystallisation/filtration would make the CWR a much more user-friendly process. An ideal 
candidate is polymethylhydrosiloxane (PMHS), a cheap, commercially available polymeric 
reducing agent. 
 
Figure 12: Polymethylhydrosiloxane (PMHS) 
 
If PMHS is compatible in the CWR, removal of the byproduct would be possible by 
filtration. The overall cost would also be reduced dramatically, with PMHS (€9.00 / 25 g, 
Aldrich 176206) costing substantially less than the equivalent amount of diphenylsilane 
(€125.00 / 25 g, Aldrich 148482).[96] In addition, the overall process would be more 
environmentally friendly. A recent study by Huijbregts and co-workers showed that the 
overall energy demand and greenhouse gas emissions of the CWR are significantly lower 
than the classic Wittig reaction.[97] Furthermore, the study showed that a CWR using PMHS 
instead of diphenylsilane would lower the energy and emission figures significantly, 
resulting in a truly green process. For PMHS to be considered for the CWR it must be able 
to carry out phosphine oxide reduction at a suitable rate. Using 10 mol % of pre-catalyst, for 
the reaction to be complete in 24 h 50 % of phosphine oxide must be reduced in less than 1 
h. To achieve a viable rate of reduction 50 molar equivalents of PMHS with respect to 
phosphine oxide were used. While not as efficient as diphenylsilane, at 100 °C reduction of 
PCb by PMHS proceeds at a rate deemed appropriate for the CWR (graph 1). However, 
when PMHS was applied to the CWR, solubility became an issue. Initially the siloxane was 
O Si O
H
SiSi
n
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soluble, but as the reaction proceeded and the polymeric chains became oxidised, the 
siloxane became insoluble and the reaction ceased to proceed efficiently. 
 
Graph 1: Reduction of PCb by PMHS at 100 °C. 
Conversions were determined by 31P NMR spectroscopy. 
 
Table 9: Substrate study of stabilised ylides using PMHS. 
  
  
[a] E/Z ratio was determined by1H NMR spectroscopy of the unpurified reaction mixture. 
[b] 7.7 mmol scale, see appendix A for details. 
Pre-catalyst was PCba or PCgb 
Reaction solvent was CPME or 2-methyl THF (see appendix A for details). Diluting the 
reaction mixture significantly enhanced the yields. A brief examination of solvents showed 
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R1 H
O PCba or PCgb 10 mol %
Yield %, E/Z[a]
1.3 equiv DIPEA
1.1-1.3 equiv solvent, 100 °C, 24 h1.0 equiv
5.0 equiv PMHS
R1
R2
R3
Br
R3
R2
sealed tube
P
OnOct
P
OnBu
PCgPCb
CO2Me
94, 86%, >95:5a
CN
95, 75%, 66:34a
CO2Me
97, 89%, 88:12b
Cl
CN
96, 70%, 80:20b
Cl
100, 84%, >95:5b
O
O
O
105, 71%, 70:30a
CO2Me
99, 99%, 75:25a
102, 95%, 75:25b
CO2MeO
101, 99%, 75:25a
CO2MeS
Br
CO2Me
98, 90%, 92:8a
CO2MeN
Boc
103, 70%, 42:58b
CO2Me
104, 97%, 70:30b
N
O
Ph
106, 80%, 93:7b
O
107, 74%, >95:5b
Scale-up:[b] 2.87 g, 76%, >95:5
MeO
MeO
OMe
O
OMe
OMe
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that CPME and 2-methyl THF were superior to toluene. The advantage of using PMHS was 
clearly evident – by stirring the crude reaction mixture in EtOAc the siloxane precipitated 
and could be removed by filtration. A quick purification step was performed by column 
chromatography to isolate the pure compound. A substrate study was undertaken whereby 
several aryl, heteroaryl and aliphatic aldehydes were coupled with ester, ketone and cyano 
activated halides (table 9). 2-Methyl THF proved essential as the solvent when using cyano-
containing substrates. Yields ranged from good to excellent, while the E/Z ratio was 
typically in the region of 66:34, similar to the selectivity obtained using diphenylsilane. Of 
particular interest is compound 107, a somewhat resveratrol-like structure. Synthesis of 107 
proceeded well on multigram scale (2.87 g, 7.7 mmol, 76%) and yielded only the E-isomer. 
Isolation of 107 was trivial in comparison to previous protocols, filtration and 
recrystallization steps were sufficient to purify the compound.  
3.2 PMHS in the CWR of Semi-Stabilised Ylides 
Adoption of PMHS into the CWR of semi-stabilised ylides would be a further improvement 
of the overall process, allowing two ylide classes to be facilitated using green conditions. 
Section 3.1 showed that PCb is reduced efficiently by PMHS at 100 °C. It was therefore 
expected that semi-stabilised ylides could be accomodated using PCb, PMHS and 54. At 
110 °C, the synthesis of 55 proceeded in good yield. Notably, toluene functioned well as the 
solvent, providing similar yields to reactions in CPME and 2-methyl THF. 
 
Graph 2: Reduction of PCd by PMHS at 150 °C. 
Conversions were determined by 31P NMR spectroscopy. 
An interesting prospect would be to merge the PMHS conditions with the DIPEA conditions 
which rely on the ylide-tuning concept. A CWR employing semi-stabilised, a cheap, green 
silane and a mild base is an attractive option. The principle issue lies with the reduction of 
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an electron-poor phosphine oxide. Pleasingly, at 150 °C the reduction of PCd by PMHS 
proceeded efficiently (graph 2). The new conditions were tested using the synthesis of 55 as 
a model reaction. Initially low yields were obtained; this was found to be due to the reaction 
concentration. It became apparent that a more concentrated reaction mixture is necessary for 
an efficient rate of ylide formation. Reducing the equivalents of PMHS from 5.0 to 3.5 
resulted in increased reaction yields. The lower equivalents of reducing agent did not have 
any significant impact on phosphine oxide reduction during the reaction. In comparison to 
toluene, the other green solvents screened provided no significant yield increase. A brief 
substrate study was undertaken to demonstrate the scope of the PMHS protocol (table 10). 
Table 10: Substrate study of semi-stabilised ylides using PMHS 
 
  
[a] E/Z ratio was determined by1H NMR spectroscopy of the unpurified reaction mixture. 
[b] Conditions A: PCb (10-20 mol %), 2.0 equiv 54, 110 °C; B: PCd (10 mol %), 1.2 equiv 
DIPEA, 150 °C.  
 
Aliphatic and heteroaryl aldehydes were tolerated, although in certain cases increasing the 
catalyst loading to 15 or 20 mol % was necessary to obtain acceptable yields. Using portion-
wise addition of halide was again the key to employing allylic and secondary benzylic 
halides as substrates. Using PCd and DIPEA was also effective in the CWR using PMHS. 
As with the reactions of stabilised ylides using PMHS, purification was vastly improved by 
the ease of siloxane removal.  
 
+
R1 H
O
Yield %, E/Z,[a] 
Conditions A or B[b], X
1.0 equiv
toluene, 110 - 150 °C, 24 h
1.2 equiv
3.5 - 5.0 equiv PMHS R1
R2
R3
X
R3
R2
Conditions A or B
sealed tube
72%, 80:20, A, Br 56, 78%, 66:34, A, Br
Br
O
108, 65%, 80:20, A, Br 57, 67%, 70:30, A, Br
109, 64%, >95:5, A, Br 63, 59%, 75:25, A, Br
MeO
110, 73%, 80:20, A, Cl62, 47%, 70:30, A, Br
71%, 80:20, B, Br
68, 74%, 70:30, B, Br
F
F
O
O
78, 73%, 85:15, A, Br 73, 70%, 45:55, B, Br
Br
O
O NO2
55
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4 E/Z Selectivity: Probing the Phosphine Structure 
4.1 Properties of the 1-Substituent 
The CWR was developed in the hope of creating a broad-scope organocatalytic olefination 
process with minimal waste. Advances have been made in substrate expansion and waste 
removal in the CWR. The only central issue which remains is the relatively poor E/Z 
selectivity of the reaction. Upon analysis of the crude reaction mixture, the E/Z observed 
ratio typically ranges from 45:55 to 70:30. Some exceptions do exist, such as certain 
reactions involving ketone or ester stabilised ylides which undergo phosphine-mediated 
isomerisation resulting in a final E/Z ratio of >95:5. From an industrial viewpoint this, on 
occasion, is not detrimental to the process. In several cases the isomeric olefin mixture can 
be isomerised to the thermodynamically favoured E-olefin using UV light, heat or in 
conjunction with a catalytic amount of iodine, acid or a metal-based catalyst. If 
isomerisation can be performed easily with no significant loss in yield, the intrinsic E/Z 
selectivity holds no great value.  
 
Figure 13: Pre-catalysts based on 53 used for selectivity studies 
 
Alternatively, if both the E- and Z-olefin are useful products/intermediates and can be 
readily separated via chromatography, a non-selective olefination process can be useful in 
preparing two compounds in one synthetic step. However, often only one isomer is desired 
and application of isomerisation techniques is limited, so it would therefore be beneficial to 
develop a selective CWR method. From the literature it is evident that the substituents at the 
phosphorus centre, and thus reactivity of the ylide, are critical in determining the E/Z ratio 
of the olefin.[53] This accounts for the general trends associated with the varying selectivity 
between the three ylide classes. Varying the substituents of the phosphine becomes 
economically viable in the CWR. This was observed in section 2 when the phosphine was 
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tuned to lower the pKa of the ylide-forming proton. In this section the effect of substituent 
variation on the E/Z selectivity will be examined. Previous studies demonstrated that the 5-
membered cyclic ring facilitates easier reduction of the phosphine oxide so for the E/Z study 
this fragment will remain intact. A library of phosphines based on structure 53 was chosen 
with various P-substituents in the 1-position (figure 13). PCa-c and PCg-h contain 
substituents with varying electronic properties, while PCi-k possess substituents which may 
impart a steric influence. The effect, if any, of the electronic or steric nature of the 
substituent on the selectivity will provide information on how to approach the design of a 
new catalyst. 
Each pre-catalyst was screened in three key protocols:  
! Standard conditions for stabilised ylides at 110 °C 
! Acid-catalysed room temperature conditions for stabilised ylides 
! Standard conditions for semi-stabilised ylides at 110 °C  
The synthesis of 95 was chosen as a model reaction for stabilised ylides, as no post-reaction 
phosphine-mediated Z to E isomerisation occurs for this compound. The synthesis of 55 was 
chosen as a model reaction for semi-stabilised ylides. 
Table 11: Phosphine oxide screening for stabilised ylides at 110 °C  
 
Entry Pre-catalyst E/Z 
1 PCa 60:40 
2 PCb 63:37 
3 PCg 62:38 
4 PCc 58:42 
5 PCh 59:41 
6 PCi 58:42 
7 PCj 56:44 
8 PCk 55:45 
9 PCl 72:28 
10 PCm 80:20 
 
Ph H
O
Br CN+
PCa-k (10 mol %)
toluene, 110 °C, 24 h
CN
Ph
1.2 equiv Ph2SiH2
1.1 equiv DIPEA
1.0 equiv 1.1 equiv
95
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Table 12: Phosphine oxide screening for stabilised ylides at RT 
 
Entry Pre-catalyst E/Z 
1 PCa 67:33 
2 PCb 71:29 
3 PCg 71:29 
4 PCc 64:35 
5 PCh 60:40 
6 PCi 66:34 
7 PCj 60:40 
8 PCk 54:46 
9[a] PCl 62:38 
10 PCm 93:7 
[a]Conversion for this reaction was 16% 
 
Table 13: Phosphine oxide screening for semi-stabilised ylides 
 
Entry Pre-catalyst E/Z 
1 PCa 66:34 
2 PCb 78:22 
3 PCg 76:24 
4 PCc 70:30 
5 PCh 63:37 
6 PCi 68:32 
7 PCj 62:38 
8 PCk 60:40 
9 PCl 91:9 
10 PCm 96:4 
Ph H
O
Br CN+
PCa-k (10 mol %)
EtOAc, RT, 24 h
1.4 equiv PhSiH3
1.4 equiv DIPEA1.0 equiv 1.3 equiv
4-NO2C6H4CO2H (10 mol %) CN
Ph
95
Ph H
O
Br Ph+
PCa-k (10 mol %)
toluene, 110 °C, 24 h
Ph
Ph
1.2 equiv Ph2SiH2
2.0 equiv 54
1.2 equiv 1.0 equiv
55
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For PCa-k no significant leap in E/Z selectivity was observed. Addition of a strong EWG 
failed to impact the selectivity (tables 11-13, entry 4), as did the addition of a strong EDG 
(entry 5). No great change was observed for PCi-k, however their use did appear to favour 
the Z-olefin slightly more. This increased preference for Z-selectivity is marginal, but could 
suggest that the potential for creating a Z-selective CWR lies with varying the sterics of this 
P-substituent. The only improvement observed is entries 2 and 3, which highlights the 
greater selectivity when using an alkyl substituent in place of an aryl one. In terms of 
selectivity no phosphine appeared particularly suited to either ylide class. 
4.2 An Alternative Approach 
The next structural adjustment with the potential to impart selectivity into the CWR is to 
alter the cyclic component of the phosphine. Potential candidates include PCl and PCm, 
whose corresponding phosphines have been used in conventional Wittig reactions resulting 
in high E-selectivity (figure 14).[93]  
 
Figure 14: Alternate cyclic phosphine oxide pre-catalysts 
 
The core 5-membered ring is still present in both PCl and PCm so reduction of the 
phosphine oxide should not be hindered. Employment of PCl and PCm in the three CWR 
protocols produced interesting results. For the high temperature stabilised ylide reaction a 
significant increase in selectivity was observed (table 11, entries 9 and 10), while an E/Z 
ratio of 93:7 was obtained using PCm at room temperature (table 2, entry 10). Conversions 
using PCl were lower than for PCm, particularly at RT where only 16% conversion of 
aldehyde to olefin was obtained (table 12, entry 9). This is likely caused by the ring system 
of PCl adding increased stability to the ylide which significantly lowers its reactivity. A 
similar effect was observed with a previous reaction using an ester-activated bromide, where 
olefin yields using PCl were significantly lower than those using PCa. PCl and PCm 
performed remarkably in the semi-stabilised ylide conditions with both pre-catalysts 
imparting high E/Z ratios (table 14, entries 9 and 10). From these results it is clear that both 
PCl and PCm are far superior to PCa-k for obtaining high E-selectivity in the CWR.  
 
P
OPh
P
PhO
PCl PCm
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Table 14: Substrate study using PCm 
 
 
[a] E/Z ratio was determined by1H NMR spectroscopy of the unpurified reaction mixture. 
 
While PCl gave lower conversions for stabilised ylides, particularly in the room temperature 
conditions, PCm performed superbly for all protocols. A quick substrate study of semi-
stabilised ylides using PCm showed that for all substrates a significant increase in 
selectivity was observed (table 14). Substrates were chosen for which iodine-mediated 
isomerisation of the olefin mixture was unsuccessful. A ketone was facilitated for 
preparation of 87, and even 88 was prepared from a non-stabilised ylide in moderate yield 
with a reasonable increase in the E/Z ratio. This study illustrates that varying the P-
substituent at the 1-position provided minimal influence on the selectivity. Use of PCm 
resulted in a CWR favouring formation of the E-olefin. The next stage of optimisation will 
focus on the development of a new catalyst based on PCm to impart high E-selectivity into 
the existing CWR protocols. 
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O
Br R3
+
PCm (10-20 mol %)
toluene, 110-150 °C, 24-48 h
R3
R1
Yield, E/Z[a]
1.2 equiv Ph2SiH2
2.0-3.5 equiv 54
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5 Conclusions  
This work has outlined the steps taken to eradicate the issues associated with the CWR. 
Substrate scope was a major issue with only stabilised ylides tolerated in the original CWR. 
Expansion to semi-stabilised and non-stabilised ylides required efficient ylide formation via 
deprotonation of the phosphonium salt. Using strong bases such as NaOtBu was shown to 
be incompatible with the CWR due to unwanted reaction with the silane. 54, described as a 
masked form of NaOtBu, enabled semi-stabilised ylides to be used in the CWR, thus 
tolerating primary and secondary benzylic and allylic bromides and chlorides as substrates. 
The concept of ylide tuning was explored as an alternative method for ylide formation. By 
drawing electron density away from the phosphorus the pKa of the ylide-forming proton was 
lowered. By using an electron-deficient phosphine PCd, formation of semi-stabilised ylides 
could be achieved using a mild, commercially available base (DIPEA). An alternative route 
to tri-substituted olefins was obtained by using ketones in place of aldehydes. The key to 
successful reactions of ketones was the limiting of the amount of halide in solution. This 
was achieved by developing a pseudo-catalytic pulse olefination technique, which ensured 
that the halide component was converted to phosphonium salt before any side-reaction or 
decomposition could occur. Substrate studies illustrated the wide application of the CWR, 
with a considerable amount of alkyl, aryl and heteroaryl aldehydes, ketones and 
organohalides utilised as substrates. The E/Z selectivity ranged from 45:55 to 80:20. For 
several examples, a post-reaction iodine-mediated isomerisation technique allowed full 
conversion to the E-olefin, minimising the significance of the poor E/Z selectivity. Non-
stabilised ylides were facilitated using a combination of masked base 54 and ylide tuning. 
Use of organoiodides as substrates was critical to achieve phosphonium salt formation using 
an electron-deficient phosphine. These developments ensure that the CWR can now tolerate 
all three ylide classes as well as ketones. The protocols also transferred efficiently to 
multigram scale reactions. Siloxane removal was another significant drawback of the CWR, 
so the use of polymeric silane PMHS as an alternative reducing agent was investigated. 
While not as efficient as diphenylsilane for phosphine oxide reduction, PMHS was used 
successfully as a replacement in the CWR using stabilised and semi-stabilised ylides. 
Various primary and secondary cyano, ketone and ester-activated halides were utilised as 
substrates. Purification was improved considerably; the siloxane could be removed by 
simple filtration. Multigram synthesis of 108 proceeded in good yield and required only 
filtration and recrystallization steps to obtain the pure olefin. PMHS was successfully 
incorporated into the two CWR protocols for semi-stabilised ylides, using either PCb and 
54 or PCd and DIPEA. Moderate to good yields were obtained using benzylic and allylic 
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halides. The use of PMHS in the CWR has eased the purification process immensely, while 
also reducing reagent cost, energy demand and greenhouse emissions. The final aspect of 
the CWR to be examined was the E/Z selectivity. With the exception of ketone or ester-
substituted olefins which undergo phosphine-mediated isomerisation to E/Z >95:5, the 
selectivity of the CWR was typically 80:20 at best. To combat this issue the phosphine 
oxide pre-catalyst structure was probed to determine which structural properties influenced 
the E/Z ratio of the olefin. Initially, the substituent in the 1-position was varied to determine 
the effect of EWGs, EDGs and steric effect of bulky substituents.  
 
Figure 15: Potential targets for second-generation CWR pre-catalysts 
 
Aside from a slight increase in selectivity obtained using an alkyl substituent in place of an 
aryl group, no great improvements were observed. A second approach was taken whereby 
two phosphines known to give high E-selectivity in conventional Wittig reactions were 
tested in the CWR. The chosen candidates possessed a 5-membered cyclic structure which 
would ensure phosphine oxide reduction would not be hindered. PCl gave high E/Z ratios at 
high temperatures, albeit at lower conversions than pre-catalysts PCa-k. However, at room 
temperature only 16% conversion was obtained, likely due to the lower nucleophilicity of 
the phosphine. Pleasingly, PCm exhibited significantly increased E-selectivity and 
consistent yields for all CWR protocols. Future explorations will focus on designing a pre-
catalyst using the core structure of PCm (figure 15, PCm1 and PCm2). The ylide tuning 
concept explored in section 2 may be applied to PCm. Addition of EWGs should facilitate 
easier ylide formation, resulting in an E-selective phosphine which can be used in 
conjunction with DIPEA for semi-stabilised ylides or with 54 for non-stabilised ylides. 
Alternatively, adding an alkyl group in the 1-position instead of the phenyl group may 
increase selectivity as was observed for pre-catalysts PCb and PCa. The alkyl substituent 
may also increase the nucleophilicity of the phosphine to increase the rates of phosphine 
oxide reduction and phosphonium salt formation, two important factors for reactions 
involving ketone substrates. The final investigation will focus on combining these selective 
pre-catalysts based with PMHS as the reducing agent. If achieved, this would result in a 
cheap, green, selective organocatalytic olefination – a process which would be of substantial 
benefit to research and industrial synthetic chemists. 
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Appendix A: Experimental 
General Experimental 
All reagents were purchased from commercial sources and were used without further 
purification, unless otherwise stated. Polymethylhydrosiloxane (PMHS) average Mn 1700-
3200 amu was purchased from Sigma Aldrich or Gelest Inc. Dry solvents were purchased 
from Sigma Aldrich and Fisher (Acros Organics) and handled under argon. Toluene was 
freshly distilled from calcium hydride and handled under argon. Tetrahydrofuran (THF) was 
freshly distilled from sodium/benzophenone and handled under argon. Deuterated solvents 
were purchased from Fluorochem. Thin Layer Chromatography (TLC) was performed on 
Macherey-Nagel ALUGRAM® Xtra SIL G/UV254 aluminum-backed plates, and spots were 
visualized using UV light (254 nm), KMnO4, or PMA stains. Column chromatography 
purifications were carried out using the flash technique on DAVISIL LC60A (35-70 µm) or 
using the dry flash technique on Fluka TLC Grade silica gel.[1] NMR spectra were recorded 
on Bruker Avance 400 and Bruker Avance Ultrashield 600 spectrometers. The chemical 
shifts (δ) for 1H and 13C are given in ppm and referenced to the residual proton signal of the 
deuterated solvent (CHCl3 at δ 7.26 ppm, 77.16 ppm, respectively), (H2O at δ 4.79 ppm); 
coupling constants are expressed in Hz. Melting points were recorded on a Stuart Scientific 
SMP1 melting point apparatus and are uncorrected. All experiments were conducted under 
an atmosphere of dry argon or nitrogen, unless otherwise noted, using Schlenk technique.[1]  
Reaction vessels were sealed with a septum and purged with inert gas using the needle line 
from a Schlenk manifold and silicone oil bubbler. E and Z refer to the stereochemistry of the 
bond formed during the reaction (colored dark blue in tables 1-14). Compounds were named 
using ACD IUPAC naming tools. Phosphine oxides PCa-m were prepared by Dr Florie 
Lavigne, Dr Emma E. Coyle and Bryan J. Doonan. 
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Synthetic Procedures 
1-Phenyl-3-phospholene-1-oxide:[2] A flame-dried sealed tube was charged 
with 2,6-di-t-butyl-4-methylphenol (110 mg, 0.5 mmol, 0.5 mol %) under 
nitrogen. 1,3-Butadiene (14.0 mL, 0.3 mol, 3.0 equiv.) was introduced by condensation at -
78 °C in a liquid nitrogen/acetone bath, after which P,P-dichlorophenylphosphine (13.6 mL, 
0.1 mol, 1.0 equiv.) was added. The tube was sealed and allowed to stand in darkness at RT 
for 15 days. After removal of excess 1,3-butadiene, ice water (30 mL) was added to the 
remaining red-brown viscous oil, which was stirred vigorously until residues dissolved 
fully. The solution was extracted in dichloromethane (3 x 30 mL) and the combined organic 
layers were neutralized using sodium carbonate (effervescence observed). The resultant 
solution was filtered, dried with magnesium sulfate, filtered and the solvent removed in 
vacuo to give a yellow-orange oil. Purification by dry flash column chromatography 
(methanol/dichloromethane, gradient 4-8%) yielded 1-phenyl-3-phospholene-1-oxide as a 
pale green solid (5.2 g, 30%). 1H and 31P NMR spectra are consistent with literature. 
1-Chloro-3-phospholene-1-oxide:[3] A flame-dried sealed tube (100 mL 
ChemGlass CG-1880-25 or 125 mL AceGlass 8648-96) equipped with a stir-bar 
was charged with 2,6-di-t-butyl-4-methylphenol (55 mg, 0.25 mmol, 0.5 mol %) under 
nitrogen. 1,3-Butadiene (6.8 mL, 0.15 mol, 3.0 equiv.) was introduced by condensation at -
78 °C in a liquid nitrogen/acetone bath, after which phosphorus trichloride (4.4 mL, 0.05 
mol, 1.0 equiv.) and tris(2-chloroethyl) phosphite (6.0 mL, 0.03 mol, 0.6 equiv.) were 
introduced via syringe. The tube was sealed under nitrogen using a front-sealing bushing 
(back sealing bushings are unsuitable, as contact with hot reaction vapors causes swelling, 
resulting in loss of seal). The solution was stirred at 105 °C for 48 hours. A blast shield was 
placed around the reaction vessel for the duration of the reaction. A cloudy yellow solution 
resulted, which was filtered via needle cannula.[1] 1,2-Dichloroethane was removed in vacuo 
and the resultant pale yellow solid was shown to consist of 1-chloro-3-phospholene-1-oxide 
P
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and 1-hydroxy-3-phospholene-1-oxide (90:10). 1H and 31P NMR spectra are consistent with 
literature. Product was used without further purification. 
General procedure for 3-phospholene-1-oxide preparation: A round-bottom flask 
equipped with a stir-bar and reflux condenser was charged with magnesium turnings (1.2 
equiv.), then flame dried in vacuo. Iodine (one crystal) and THF (1.0 mL) were introduced. 
A solution of organohalide (1.0 equiv) in THF was added dropwise until the brown color 
dissipated and the reaction was initiated by heating. The remaining organohalide solution 
was added slowly, maintaining reflux, and the resultant solution was stirred at reflux for a 
further 1 h. To a portion of this Grignard reagent (1.0 equiv.) at 0 °C was added 1-chloro-3-
phospholene-1-oxide solution dropwise (1.0 equiv., 1 M in THF. Introduction of THF to 
crude 1-chloro-3-phospholene-1-oxide led to precipitation of the 1-hydroxy-3-phospholene 
by-product. 1-Chloro-3-phospholene-1-oxide solution was obtained following needle 
cannulation). The resultant solution was allowed to warm to RT and stirred for 16 h. The 
reaction mixture was quenched with water and the aqueous layer was extracted with diethyl 
ether (3 x 20 mL). The combined organic layers were dried over magnesium sulfate, filtered 
and solvent removed in vacuo to give the crude 3-phospholene-1-oxide. Purification by 
flash column chromatography yielded pure 3-phospholene-1-oxide. 
General procedure for preparation of phospholane-1-oxides via hydrogenation of 3-
phospholene-1-oxides: Pd/C (10% w/w, 6-10 mol %) was transferred to a round-bottom 
flask containing a magnetic stir-bar and sealed under nitrogen. Dichloromethane (1 mL) was 
added, followed by 3-phospholene-1-oxide dissolved in methanol (0.35 M). The vessel was 
purged with hydrogen using a balloon and silicon oil bubbler. The bubbler was removed and 
the mixture was stirred under hydrogen at room temperature for 24 h. The crude mixture 
was filtered through a plug of Celite® and the filtrate treated with activated charcoal to 
remove any residual dissolved palladium. After stirring for 1 h the solution was filtered 
through Celite® and solvent removed in vacuo. 
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1-Phenylphospholane-1-oxide[4] (PCa) was prepared in accordance with the 
general procedure for hydrogenation from the reaction of 1-phenyl-3-
phospholene-1-oxide (1.79 g, 10.0 mmol, 1.0 equiv.) with an excess of H2 
using Pd/C (10 % w/w; 1.10 g, 1.0 mmol, 10 mol %) in methanol/dichloromethane solution 
(30:1 mL) at room temperature for 24 h. PCa was obtained as a pale yellow, viscous oil 
(1.80 g, 99%). 1H and 31P NMR spectra are consistent with literature. 
1-n-Octyl-3-phospholane-1-oxide (PCb) was prepared according to the 
general procedure from the reaction of magnesium turnings (0.29 g, 12.0 
mmol, 1.2 equiv.), 1-bromooctane (1.7 mL, 10.0 mmol, 1.0 equiv., 1 M in 
THF) and 1-chloro-3-phospholene-1-oxide (0.98 g, 7.1 mmol, 1.0 equiv.). Purification by 
flash column chromatography (methanol/dichloromethane, gradient 1-3%) gave 1-n-octyl-3-
phospholene-1-oxide as a yellow oil (0.93 g, 61%). Hydrogenation in accordance with the 
general procedure, from the reaction of 1-n-octyl-3-phospholene-1-oxide (0.93 g, 4.3 mmol, 
1.0 equiv.) with an excess of H2 using Pd/C (10% w/w; 0.42 g, 0.4 mmol, 10 mol %) in a 
methanol/dichloromethane solution (4:1 mL) at room temperature for 24 h yielded PCb as a 
colorless oil (0.90 g, 97%). 1H NMR (400 MHz, CDCl3) δ: 0.69 (t, J = 7.2 Hz, 3H), 1.08-
1.10 (m, 8H), 1.20-1.27 (m, 2H), 1.42-1.69 (m, 10H), 1.78-1.88 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ: 13.8, 21.9 (d, JCP = 4.4 Hz), 22.3, 24.3 (d, JCP = 8.0 Hz), 26.3, 26.6 (d, JCP 
= 64.9 Hz), 28.8 (d, JCP = 10.9 Hz), 30.6 (d, JCP = 61.8 Hz), 30.8 (d, JCP = 13.1 Hz), 31.5; 
31P NMR (162 MHz, CDCl3) δ: 71.4; HRMS [M+H]+ m/z calcd. 217.1721, found 217.1717.  
1-(4-(Trifluoromethyl)phenyl)phospholane-1-oxide (PCc) was 
prepared according to the general procedure from the reaction of 
magnesium turnings (0.72 g, 36.0 mmol, 1.2 equiv.), 4-
bromobenzotrifluoride (4.2 mL, 30.0 mmol, 1.0 equiv., 1 M in THF) 
and 1-chloro-3-phospholene-1-oxide (3.60 g, 26.3 mmol, 1.0 equiv.). Purification by flash 
column chromatography (methanol/dichloromethane, gradient 0.5-1.0%) gave 1-(4-
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(trifluoromethyl)phenyl)-3-phospholene-1-oxide as a white solid (3.21 g, 49%). 
Hydrogenation in accordance with the general procedure, from the reaction of 1-(4-
(trifluoromethyl)phenyl)-3-phospholene-1-oxide (2.36 g, 9.6 mmol, 1.0 equiv.) with an 
excess of H2 using Pd/C (10% w/w; 0.96 g, 0.9 mmol, 9 mol %) in a 
methanol/dichloromethane solution (11:1 mL) at room temperature for 24 h yielded PCc as 
a white solid (2.21 g, 93%). 1H NMR (400 MHz, CDCl3) δ: 1.88-2.22 (m, 8H), 7.88 (dd, J = 
8.4, 2.0 Hz, 2H), 7.82 (dd, J = 10.8, 8.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ: 25.3 (d, 
JCP = 8.7 Hz), 29.7 (d, JCP = 67.6 Hz), 123.6 (q, JCF = 270.8 Hz), 125.5 (dq, JCP = 3.6 Hz, JCF 
= 11.6 Hz), 130.5 (d, JCP = 10.2 Hz), 133.6 (qd, JCP = 3.0 Hz, JCF = 29.8 Hz), 138.9 (d, JCP = 
85.9 Hz); 31P NMR (162 MHz, CDCl3) δ: 57.2; 19F NMR (376 MHz, CDCl3) δ: -63.2; mp 
59-61 °C; HRMS [M+H]+ m/z calcd. 249.0656, found 249.0658. 
1-(3,5-Bis(trifluoromethyl)phenyl)phospholane-1-oxide (PCd) was 
prepared according to the general procedure from the reaction of 
magnesium turnings (0.69 g, 28.8 mmol, 1.2 equiv.), 1,3-
bis(trifluoromethyl)-5-bromobenzene (4.1 mL, 24.0 mmol, 1.0 equiv., 
0.5 M in THF) and 1-chloro-3-phospholene-1-oxide (3.00 g, 21.9 
mmol, 1.0 equiv.). Purification by flash column chromatography 
(methanol/dichloromethane, gradient 0.5-1.0%) gave 1-(3,5-bis(trifluoromethyl)phenyl)-3-
phospholene-1-oxide as a white solid (3.51 g, 51%). Hydrogenation in accordance with the 
general procedure, from the reaction of 1-(3,5-bis(trifluoromethyl)phenyl)-3-phospholene-1-
oxide (3.50 g, 11.1 mmol, 1.0 equiv.) with an excess of H2 using Pd/C (10% w/w; 1.08 g, 
1.0 mmol, 10 mol %) in a methanol/dichloromethane solution (30:1 mL) at room 
temperature for 24 h yielded PCd as a yellow solid (3.42 g, 97%). 1H NMR (400 MHz, 
CDCl3) δ: 1.87-2.19 (m, 8H), 7.89 (s, 1H), 8.07 (d, J = 10.8 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ: 25.2 (d, JCP = 34.8 Hz), 29.6 (d, JCP = 68.4 Hz), 122.8 (q, JCF = 271.4 Hz), 125.3 
(m), 130.1 (dd, JCP = 2.9 Hz, JCF = 9.5 Hz), 132.1 (qd, JCP = 10.9 Hz, JCF = 33.4 Hz), 138.1 
P
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(d, JCP = 83.7 Hz); 31P NMR (162 MHz, CDCl3) δ: 54.98; 19F NMR (376 MHz, CDCl3) δ: -
63.17; mp 82-85 °C; HRMS [M+H]+ m/z calcd. 317.0530, found 317.0530. 
4-Bromo-2,6-bis(trifluoromethyl)benzoic acid:[5] 1,3-Dibromo-5,5-
dimethylhydantoin (5.48 g, 19.2 mmol, 1.0 equiv) was dissolved at RT 
in conc. sulfuric acid (20 mL). The solution was cooled to 0 °C and 
2,6-bis(trifluoromethyl)benzoic acid (5.00 g, 19.2 mmol, 1.0 equiv.) was added. The slurry 
was stirred at 0 °C for 2 h followed by stirring overnight at RT after which time it was 
poured into ice water (250 mL). The white precipitate was isolated by filtration and dried in 
vacuo to give 4-bromo-2,6-bis(trifluoromethyl)benzoic acid as a white solid (4.91 g, 77%). 
1H NMR spectrum is consistent with literature. 
Methyl-4-bromo-2,6-bis(trifluoromethyl)benzoate:[6] To a solution 
of 4-bromo-2,6-bis(trifluoromethyl) benzoic acid (5.00 g, 14.8 
mmol) in acetonitrile (56 mL) were added iodomethane (4.6 mL, 
75.9 mmol) and K2CO3 (5.11 g, 37.0 mmol) at RT under N2 atmosphere. After being stirred 
for 6 h at RT, the reaction mixture was quenched with sat. aq. Na2S2O3, diluted with EtOAc, 
washed with water and brine, dried over magnesium sulfate, filtered and concentrated in 
vacuo. Purification by flash column chromatography (1% ethyl acetate in hexane) gave 
methyl-4-bromo-2,6-bis(trifluoromethyl)benzoate as a white solid (4.21 g, 85%). 1H NMR 
spectrum is consistent with literature. 
1-(Methyl-2,6-bis(trifluoromethyl)benzoate)phospholane-1-oxide 
(PCe): A 50 mL round-bottom flask equipped with a stir-bar and 
reflux condenser was charged with magnesium turnings (0.43 g, 18.0 
mmol, 1.2 equiv.), then flame dried in vacuo. Iodine (one crystal) and 
THF (1.0 mL) were introduced. A solution of 2-chloropropane (1.4 
mL, 15.0 mmol, 1.0 equiv.) in THF (15.0 mL) was added dropwise until the brown color 
dissipated and the reaction was initiated by heating. The remaining halide solution was 
added slowly, maintaining reflux, and the resultant solution was stirred at reflux for a 
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further 3 h. In a 100 mL round-bottom flask, methyl-4-bromo-2,6-
bis(trifluoromethyl)benzoate (3.90 g, 11.0 mmol, 1.0 equiv.) was dissolved in THF (22 mL) 
under argon. The reaction mixture was cooled to –40 °C and charged slowly with a portion 
of the Grignard reagent (12.0 mL, 12.0 mmol, 1.1 equiv.). The reaction mixture was 
maintained at this temperature for 3 h, then 1-chloro-3-phospholene-1-oxide solution was 
added dropwise (1.50 g, 11.0 mmol, 1.0 equiv.). The resultant solution was stirred at –40 °C 
for 2 h, then warmed to RT and stirred for 16 h, resulting in a yellow solution. The reaction 
mixture was quenched with water and the aqueous layer was extracted with diethyl ether (3 
x 20 mL). The combined organic layers were dried over magnesium sulfate, filtered and 
solvent removed in vacuo to give a yellow oil. Purification by flash column chromatography 
(methanol/dichloromethane, gradient 0.5-1.0%) gave 1-(methyl-2,6-
bis(trifluoromethyl)benzoate)-3-phospholene-1-oxide as a white solid (2.73 g, 67%). 
Hydrogenation in accordance with the general procedure, from the reaction of 1-(methyl-
2,6-bis(trifluoromethyl) benzoate)-3-phospholene-1-oxide (2.63 g, 7.1 mmol, 1.0 equiv.) 
with an excess of H2 using Pd/C (10% w/w; 675 mg, 0.6 mmol, 8 mol %) in a 
methanol/dichloromethane solution (23:1 mL) at room temperature for 14 h yielded PCe as 
an off-white solid (2.58 g, 97%). 1H NMR (400 MHz, CDCl3) δ: 1.88-2.30 (m, 8H), 3.90 (s, 
3H), 8.18 (d, J = 10.9 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ: 25.3 (d, JCP = 8.7 Hz), 29.7 
(d, JCP = 68.4 Hz), 53.6, 122.4 (q, JCF = 273.5 Hz), 129.6 (dq, JCP = 10.9 Hz, JCF = 32.7 Hz), 
131.4 (m), 133.2 (m), 138.8 (d, JCP = 82.9 Hz); 31P NMR (162 MHz, CDCl3) δ: 55.8; 19F 
NMR (376 MHz, CDCl3) δ: -60.1; mp 141-143 °C; HRMS [M+H]+ m/z calcd. 375.0585, 
found 375.0585. 
1-(3,4,5-Tris(trifluoromethyl)phenyl)phospholane-1-oxide (PCf) 
was prepared using the same procedure as 1-(methyl-2,6-
bis(trifluoromethyl)benzoate)-3-phospholene-1-oxide by the reaction of 
magnesium turnings (260 mg, 11.0 mmol, 1.1 equiv.), 2-chloropropane 
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(910 mL, 10.0 mmol, 1.0 equiv.), 1-bromo-3,4,5-tris(trifluoromethyl)benzene (1.30 g, 3.7 
mmol, 1.0 equiv.) and 1-chloro-3-phospholene-1-oxide (510 mg, 3.7 mmol, 1.0 equiv.). 
Purification by flash column chromatography (methanol/dichloromethane, gradient 0.5-
1.0%) to give 1-(3,4,5-tris(trifluoromethyl)phenyl)-3-phospholene-1-oxide as a white solid 
(655 mg, 46%). Hydrogenation in accordance with the general procedure, from the reaction 
of 1-(3,4,5-tris(trifluoromethyl)phenyl)-3-phospholene-1-oxide (653 mg, 1.7 mmol, 1.0 
equiv.) with an excess of H2 using Pd/C (10% w/w; 138 mg, 0.1 mmol, 6 mol %) in a 
methanol/dichloromethane solution (5:1 mL) at room temperature for 24 h yielded PCf as 
an off-white solid (645 mg, 99%). 1H NMR (400 MHz, CDCl3) δ: 1.84-2.37 (m, 8H), 8.32 
(d, J = 10.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ: 25.3 (d, JCP = 8.7 Hz), 29.6 (d, JCP = 
68.4 Hz), 121.2 (q, JCF = 274.2 Hz), 122.1 (q, JCF = 273.5 Hz), 130.4 (q, JCF = 36.4 Hz),  
125.3 (m), 131.4 (qd, JCP = 10.9 Hz, JCF = 33.5 Hz), 133.0 (m), 141.2 (d, JCP = 81.5 Hz); 31P 
NMR (162 MHz, CDCl3) δ: 58.1; 19F NMR (376 MHz, CDCl3) δ: -55.3, -57.9; mp 103-105 
°C; HRMS [M+H]+ m/z calcd. 385.0404, found 385.0421. 
1-n-Butyl-3-phospholane-1-oxide (PCg)[7] was prepared according to the 
general procedure from the reaction of magnesium turnings (0.43 g, 18.0 
mmol, 1.2 equiv.), 1-bromobutane (1.6 mL, 15.0 mmol, 1.0 equiv., 1 M in 
THF) and 1-chloro-3-phospholene-1-oxide (1.66 g, 12.0 mmol, 1.0 equiv.). Purification by 
flash column chromatography (methanol/dichloromethane, gradient 1-3%) gave 1-n-butyl-
3-phospholene-1-oxide as a yellow oil (1.05 g, 55%). Hydrogenation in accordance with the 
general procedure, from the reaction of 1-n-butyl-3-phospholene-1-oxide (0.60 g, 3.8 mmol, 
1.0 equiv.) with an excess of H2 using Pd/C (10% w/w; 0.31 g, 0.4 mmol, 10 mol %) in a 
methanol/dichloromethane solution (9:1 mL) at room temperature for 48 h yielded PCg as a 
yellow oil (0.58 g, 96%). 1H NMR (400 MHz, CDCl3) δ: 0.93 (t, J = 7.4 Hz, 3H), 1.45 (m, 
2H), 1.58-1.84 (m, 10H), 1.93-2.07 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 13.7, 24.2 (d, 
JCP = 13.8 Hz), 24.3 (d, JCP = 4.4 Hz), 24.6 (d, JCP = 8 Hz), 27.0 (d, JCP = 64.7 Hz), 30.6 (d, 
P
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JCP = 61.8 Hz); 31P NMR (162 MHz, CDCl3) δ: 69.0; HRMS [M+H]+: m/z calcd. 161.1095, 
found 161.1093. 
1-(4-Methoxyphenyl)phospholane-1-oxide (PCh) was prepared 
according to the general procedure from the reaction of magnesium 
turnings (0.18 g, 7.3 mmol, 1.2 equiv.), 4-bromoanisole (0.77 mL, 6.1 
mmol, 1.0 equiv., 1 M in THF) and 1-chloro-3-phospholene-1-oxide 
(0.76 g, 5.5 mmol, 1.0 equiv.). Purification by flash column chromatography 
(methanol/dichloromethane, gradient 0-1%) gave 1-(4-methoxyphenyl)-3-phospholene-1-
oxide as a colorless oil (0.58 g, 51%). Hydrogenation in accordance with the general 
procedure, from the reaction of 1-(4-methoxyphenyl)-3-phospholene-1-oxide (1.02 g, 4.9 
mmol, 1.0 equiv.) with an excess of H2 using Pd/C (10% w/w; 0.52 g, 0.5 mmol, 10 mol %) 
in a methanol/dichloromethane solution (4:1 mL) at room temperature for 48 h yielded PCh 
as a white solid (0.27 g, 26%). 1H NMR (400 MHz, CDCl3) δ: 1.84-2.20 (m, 8H), 3.82 (s, 
3H), 6.97 (dd, J = 8.8, 2.0 Hz, 2H), 7.63 (dd, J = 11.2, 8.8 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ: 25.3 (d, JCP = 8.1 Hz), 29.9 (d, JCP = 68.4 Hz), 55.4, 114.3 (d, JCP = 12.5 Hz), 
125.4 (d, JCP = 96.2 Hz), 131.8 (d, JCP = 11.0 Hz), 162.4 (d, JCP = 2.9 Hz); 31P NMR (162 
MHz, CDCl3) δ: 60.0. 
1-(Naphthalene-2-yl)phospholane-1-oxide (PCi) was prepared 
according to the general procedure from the reaction of magnesium 
turnings (0.13 g, 5.5 mmol, 1.1 equiv.), 2-bromonaphthalene (1.04 g, 5.0 
mmol, 1.0 equiv., 1 M in THF) and 1-chloro-3-phospholene-1-oxide 
(0.61 g, 4.4 mmol, 1.0 equiv.). Purification by flash column chromatography 
(methanol/dichloromethane, gradient 0-2%) gave 1-(2-naphthyl)-3-phospholene-1-oxide as 
a green solid (0.49 g, 50%). Hydrogenation in accordance with the general procedure, from 
the reaction of 1-(naphthalene-2-yl)-3-phospholene-1-oxide (0.49 g, 2.2 mmol, 1.0 equiv.) 
with an excess of H2 using Pd/C (10% w/w; 0.21 g, 0.2 mmol, 10 mol %) in a 
methanol/dichloromethane solution (4:1 mL) at room temperature for 48 h yielded PCi as 
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an off-white solid (0.39 g, 77%). 1H NMR (400 MHz, CDCl3) δ: 1.88-2.20 (m, 8H), 7.47-
7.57 (m, 3H), 7.78-7.89 (m, 3H), 8.34 (d, J = 12.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 
25.4 (d, JCP = 8.1 Hz), 29.7 (d, JCP = 67.6 Hz), 124.5 (d, JCP = 11.0 Hz), 127.0, 127.7, 128.0, 
128.6 (d, JCP = 11.7 Hz), 128.7, 131.1 (d, JCP = 90.4 Hz), 132.0 (d, JCP = 8.9 Hz), 132.4 (d, 
JCP = 12.4 Hz), 134.5 (d, JCP = 2.2 Hz); 31P NMR (162 MHz, CDCl3) δ: 60.4. 
1-(Naphthalene-1-yl)phospholane-1-oxide (PCj) was prepared according to 
the general procedure from the reaction of magnesium turnings (0.13 g, 5.5 
mmol, 1.1 equiv.), 1-bromonaphthalene (1.04 g, 5.0 mmol, 1.0 equiv., 1 M in 
THF) and 1-chloro-3-phospholene-1-oxide (0.78 g, 5.6 mmol, 1.1 equiv.). 
Purification by flash column chromatography (methanol/dichloromethane, 
gradient 0-3%) gave 1-naphthalene-1-yl)-3-phospholene-1-oxide as a white solid (0.89 g, 
78%). Hydrogenation in accordance with the general procedure, from the reaction of 1-
(naphthalene-1-yl)-3-phospholene-1-oxide (0.28 g, 1.2 mmol, 1.0 equiv.) with an excess of 
H2 using Pd/C (10% w/w; 0.13 g, 0.1 mmol, 10 mol %) in a methanol/dichloromethane 
solution (4:1 mL) at room temperature for 48 h yielded PCj as a viscous oil (0.26 g, 94%). 
1H NMR (400 MHz, CDCl3) δ: 1.82-1.96 (m, 2H), 2.13-2.26 (m, 4H), 2.29-2.37 (m, 2H), 
7.47-7.63 (m, 3H), 7.83 (ddd, J = 14.4, 7.2, 1.2 Hz, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.99 (d, J 
= 8.4 Hz, 1H), 8.54 (d, J = 8.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 24.6 (d, JCP = 8.8 
Hz), 28.8 (d, JCP = 70.0 Hz), 124.6 (d, JCP = 13.2 Hz), 126.3 (d, JCP = 5.2 Hz), 126.6, 127.6, 
129.2, 129.8 (d, JCP = 9.6 Hz), 130.1 (d, JCP = 88.2 Hz), 132.9 (d, JCP = 3.0 Hz), 133.0, 
133.9 (d, JCP = 8.1 Hz); 31P NMR (162 MHz, CDCl3) δ: 63.1. 
1-(Biphenyl-3-yl)phospholane-1-oxide (PCk) was prepared 
according to the general procedure from the reaction of magnesium 
turnings (0.13 g, 5.5 mmol, 1.1 equiv.), 2-bromobiphenyl (1.66 g, 
5.0 mmol, 1.0 equiv., 1 M in THF) and 1-chloro-3-phospholene-1-
oxide (0.73 g, 5.3 mmol, 1.1 equiv.). Purification by flash column chromatography 
(methanol/dichloromethane, gradient 0-2%) gave 1-(biphenyl-3-yl)-3-phospholene-1-oxide 
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as a green oil (0.88 g, 69%). Hydrogenation in accordance with the general procedure, from 
the reaction of 1-(biphenyl-3-yl)-3-phospholene-1-oxide (0.75 g, 2.9 mmol, 1.0 equiv.) with 
an excess of H2 using Pd/C (10% w/w; 0.31 g, 0.3 mmol, 10 mol %) in a 
methanol/dichloromethane solution (4:1 mL) at room temperature for 48 h yielded PCk as a 
white solid (0.66 g, 89%). 1H NMR (400 MHz, CDCl3) δ: 1.40-1.52 (m, 2H), 1.65-1.71 (m, 
4H), 1.81-1.95 (m, 2H), 7.35-7.48 (m, 5H), 7.51-7.57 (m, 3H), 7.91 (ddd, J = 12.4, 7.6, 1.2 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 24.1 (d, JCP = 8.1 Hz), 29.0 (d, JCP = 69.8 Hz), 
127.3 (d, JCP = 11.0 Hz), 128.2, 128.5, 129.7, 131.2 (d, JCP = 8.8 Hz), 131.5 (d, JCP = 2.1 
Hz), 132.1 (d, JCP = 9.5 Hz), 132.9 (d, JCP = 88.9 Hz), 141.2 (d, JCP = 3.6 Hz), 145.3 (d, JCP 
= 8.1 Hz); 31P NMR (162 MHz, CDCl3) δ: 64.1. 
5-Phenyl-5H-benzo[b]phosphindole:[8] To a stirring solution of 
triphenylphosphine oxide (2.0 g, 7.2 mmol, 1.0 equiv.) in dry THF (52 
mL) at 0 °C was added dropwise 2.0 M phenyllithium (7.22 mL, 14.4 
mmol, 2.0 equiv.). The mixture was heated to reflux overnight. The solvent was removed in 
vacuo, water (70 mL) was added and the mixture was neutralised with 1 M aqueous HCl. 
The aqueous layer was extracted with dichloromethane (3 x 70 mL), dried over MgSO4 and 
the solvent was removed in vacuo. Purification by flash column chromatography (ethyl 
acetate/hexane, gradient 20-30%) yielded 5-phenyl-5H-benzo[b]phosphindole as a white 
solid (1.06 g, 56%). 1H NMR (400 MHz, CDCl3) δ: 7.23-7.29 (m, 3H), 7.31-7.38 (m, 4H), 
7.49 (t, J = 7.6 Hz, 2H), 7.73 (t, J = 6.0 Hz, 2H), 7.98 (d, J = 8.0 Hz, 2H); 31P NMR (162 
MHz, CDCl3) δ: -10.2. 
5-Phenyl-5H-benzo[b]phosphindole 5-oxide (PCl):[8] To a stirring 
solution of x (200 mg, 0.77 mmol, 1.0 equiv.) in diethyl ether (3.80 mL) 
was added dropwise hydrogen peroxide (30% wt/wt in water, 0.35 mL, 
3.1 mmol, 4.0 equiv.). After stirring at room temperature for 0.5 h the 
reaction was filtered and washed with diethyl ether to yield pure PCl as a white solid (189 
mg, 89%). 1H NMR (400 MHz, CDCl3) δ: 7.36-7.40 (m, 4H), 7.49 (td, J = 7.6, 1.2 Hz, 1H), 
PCl 
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7.59 (t, J = 7.6 Hz, 2H), 7.62-7.67 (m, 2H), 7.70-7.74 (m, 2H), 7.82 (dd, J = 8.0, 2.8 Hz, 
2H). 31P NMR (162 MHz, CDCl3) δ: 34.4. 
9-Phenyl-9-phosphabicyclo[4.2.1]nonatriene:[9] To a flame dried 2-neck 
round-bottom flask, equipped with a reflex condenser, argon inlet and 
connected to an oil bubbler, was added lithium (25% in mineral oil; 1.01 g, 
36.4 mmol, 2.1 equiv.). The mineral oil was removed by washing with dry pentane (5 x 10 
mL) and the lithium dried under a flow of argon. Anhydrous diethyl ether (54 mL) was 
introduced, followed by cyclooctatetraene (2.0 mL, 17.3 mmol, 1.0 equiv.). The resulting 
mixture was stirred at RT for 16 h, during which time the color changed from yellow to 
deep brown, with a large quantity of solid evident. A flame dried 2-neck round-bottom flask 
was charged with dichlorophenylphosphine (5.1 mL, 37.7 mmol, 2.2 equiv) and diethyl 
ether (27 mL) at 0 °C. The lithium cyclooctatetraene dianion solution was transferred via 
syringe to this flask over a 15 min period, and additional residues were transferred in diethyl 
ether washes (4 x 5 mL). The resultant yellow mixture was stirred at 0 °C for 1 h. The 
reaction was quenched using water (10 mL) and neutralized using saturated sodium 
carbonate solution (23 mL), then filtered through Celite®. The filter cake was washed 
repeatedly with diethyl ether. The resulting yellow biphasic solution was extracted and the 
aqueous layer washed with diethyl ether (2 x 50 mL). The combined organic layers were 
dried over magnesium sulfate, toluene (54 mL) was added and the ether removed in vacuo. 
The residual yellow solution was refluxed for 2 h, until the solution was deep brown in 
color. The solvent was removed in vacuo to yield a brown solid, which was purified via 
flash column chromatography (2% diethyl ether in pentane, Rf = 0.33) to yield 9-phenyl-9-
phosphabicyclo[4.2.1]nonatriene as a pale brown solid (1.99 g, 54%). 
9-Phenyl-9-phosphabicyclo[4.2.1]nonatriene oxide:[9] To a stirring 
solution of 9-phenyl-9-phosphabicyclo[4.2.1]nonatriene (987 mg, 4.7 mmol, 
1.0 equiv.) in chloroform (10 mL) at 0 °C was added hydrogen peroxide (35% w/w; 1.2 mL, 
13.5 mmol, 2.9 equiv.). The resultant biphasic solution was stirred vigorously for 1.5 h. 
P
Ph
P
PhO
 
 
 
 
A-13 
Additional water (5 mL) was added and the layers separated. The aqueous layer was washed 
with chloroform (3 x 5 mL) and the combined organic layers dried over magnesium sulfate, 
filtered and dried in vacuo. 9-Phenyl-9-phosphabicyclo[4.2.1]nonatriene oxide was obtained 
as a pale yellow solid (1.04 g, 98%). 
9-Phenyl-9-phosphabicyclo[4.2.1]nonane oxide[9] (PCm) was obtained in 
accordance with the general hydrogenation procedure, from the reaction of 9-
phenyl-9-phosphabicyclo[4.2.1]nonatriene oxide (615 mg, 2.7 mmol), 1.0 
equiv.) with an excess of H2 using Pd/C (10% w/w; 860 mg, 0.8 mmol, 30 
mol %) in a methanol/dichloromethane solution (10:1 mL) at room temperature for 24 h. 
PCm was obtained as an off-white solid (610 mg, 96%). 1H NMR (400 MHz, CDCl3) δ: 
1.02-1.12 (m, 2H), 1.36-1.45 (m, 2H), 1.50-1.67 (m, 2H), 1.77-1.86 (m, 4H), 2.68-2.82 (m, 
4H), 7.46-7.54 (m, 3H), 7.66-7.72 (m, 2H); 31P NMR (162 MHz, CDCl3) δ: 67.9. 
Sodium tert-butyl carbonate (54):[10] To a flame-dried 500 mL round-
bottom flask equipped with a stir-bar was added NaOtBu (8.46 g, 88.0 
mmol) and dry THF (250 mL). The vessel was sealed with a rubber 
septum and purged with argon using a silicon oil bubbler. The solution was stirred 
vigorously until all of the alkoxide was dissolved. Solid CO2 (dry ice) was added gradually 
in small portions (~20 g) until approximately 250 g was added in total. The turbid solution 
was stirred for 1 h under a flow of argon. The THF was removed in vacuo yielding a white 
solid. The solid was stirred in dry toluene (30 mL) for 15 min after which drying in vacuo 
yielded 54 as a white solid (11.20 g, 79.9 mmol, 91%). A 50 mg/mL solution of the 54 in 
water gave a pH of 9-10 on universal indicator paper. 1H NMR (400 MHz, D2O) δ: 1.19 (s, 
9H); 13C NMR (100 MHz, D2O) δ: 29.6, 69.7, 161.8.  
2-(Chloromethyl)thiophene:[11] To a stirring solution of 2-
thiophenemethanol (470 µL, 5.0 mmol, 1.0 equiv.) in dry THF (5.0 mL) was 
added thionyl chloride (800 µL, 11.0 mmol, 2.2 equiv.) dropwise over 5 min at 0 °C. The 
solution was slowly warmed to RT and stirred for a further 30 min. The reaction was 
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quenched with aq. NaHCO3 and the aqueous phase was extracted with dichloromethane (3 x 
6 mL). The combined organic layers were dried over magnesium sulfate and dried in vacuo 
to yield 2-(chloromethyl)thiophene as a pale yellow oil (491 mg, 86%) which was used 
immediately for the synthesis of 76. 1H NMR (400 MHz, CDCl3) δ: 4.82 (s, 2H), 6.96 (t, J = 
4.4 Hz, 1H), 7.09 (d, J = 3.2 Hz, 1H), 7.32 (d, J = 4.8 Hz, 1H). 
 8-Iodo-2,6-dimethyloct-2-ene:[12] To a stirring solution of 
citronellol (8.7 g, 55.6 mmol 1.0 equiv.) in THF (150 mL) was 
added triphenylphosphine (16.0 g, 61.2 mmol, 1.1 equiv.), imidazole (4.16 g, 61.2 mmol, 
1.1 equiv.) and iodine (15.5 g, 61.2 mmol, 1.1 equiv.). The mixture was stirred at room 
temperature for 24 h and then concentrated in vacuo. Purification via dry flash 
chromatography (hexane, Rf = 0.61) afforded  8-iodo-2,6-dimethyloct-2-ene as a colourless 
liquid (10.6 g, 72%). 1H NMR (400 MHz, CDCl3) δ: 0.88 (d, J = 6.8 Hz, 3H), 1.12-1.21 (m, 
1H), 1.25-1.38 (m, 1H), 1.53-1.71 (m, 1H), 1.61 (s, 3H), 1.68 (d, J = 1.2 Hz, 3H), 1.83-2.05 
(m, 3H), 3.13-3.28 (m, 2H), 5.06-5.11 (m, 1H). 
Optimization studies 
General procedure for solvent study using 54: In air, a 1-dram vial equipped with a stir-
bar was charged with PCb (18 mg, 0.1 mmol, 10 mol %) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.). The vial was then sealed with a rubber septum and purged with argon via needle 
inlet. Solvent (1.0 mL), benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), benzyl bromide (120 
µL, 1.0 mmol, 1.0 equiv.) and diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) were 
introduced, the septum was replaced with a PTFE-lined screw cap under an inert 
atmosphere,[1] and the reaction was heated at 100 °C for 24 h. The crude reaction mixture 
was filtered through Celite®, concentrated in vacuo, and purified via flash column 
chromatography to afford pure 55, as detailed in table 1. 
General procedure for phosphine oxide screening using DIPEA: In air, a 4 mL pressure 
vessel equipped with a stir-bar was charged with phosphine oxide PCa-f (0.10 mmol, 10 
I
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mol %). The vessel was then sealed with a rubber septum and purged with argon via needle 
inlet. Toluene (0.33 mL), benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), benzyl bromide 
(120 µL, 1.0 mmol, 1.0 equiv.), DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) and diphenylsilane 
(223 µL, 1.2 mmol, 1.2 equiv.) were introduced, the septum was replaced with a PTFE-lined 
screw cap under an inert atmosphere,[1] and the reaction was heated at 100 or 140 °C for 24 
h. The crude reaction mixture was filtered through Celite®, concentrated in vacuo and 
purified via flash column chromatography to afford pure 55, as detailed in table 3. 
General procedure for solvent study using DIPEA: In air, a 4 mL pressure vessel 
equipped with a stir-bar was charged with PCd (32 mg, 0.10 mmol, 10 mol %). The vessel 
was then sealed with a rubber septum and purged with argon via needle inlet. Solvent (0.33 
mL), benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 
equiv.), DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) and diphenylsilane (223 µL, 1.2 mmol, 1.2 
equiv.) were introduced, the septum was replaced with a PTFE-lined screw cap under an 
inert atmosphere,[1] and the reaction was heated at 140 °C for 24 h. The crude reaction 
mixture was filtered through Celite®, concentrated in vacuo and 1H NMR spectroscopy 
analysis was used to determine conversion and E/Z ratio, as shown in table 4. 
Development of the pulse olefination protocol: In air, a 1-dram vial equipped with a stir-
bar was charged with PCb (0.15 mmol, 15 mol %) and 54 (0.5-1.0 equiv.). The vial was 
then sealed with a rubber septum and purged with argon via needle inlet. Toluene (1.0 mL), 
acetophenone (117 µL, 1.2 mmol, 1.2 equiv.) and diphenylsilane (1.2 mmol, 1.2 equiv.) 
were introduced at this time. Addition of 54 and benzyl bromide (1.0-1.35 equiv.) was 
varied as detailed in table 6. The reactions were conducted at 110 °C unless otherwise 
stated. The crude reaction mixture was filtered through Celite®, concentrated in vacuo and 
1H NMR spectroscopy analysis was used to determine conversion and E/Z ratio, as shown in 
table 6. 
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General procedure A1: (table 2, conditions A) preparation of compounds 55-58, 60 and 
61 via catalytic Wittig reaction using 54.  
In air, a 1-dram vial equipped with a stir-bar was charged with PCb (0.10-0.20 mmol, 10-20 
mol %) and 54 (2.0 mmol, 2.0 equiv.). Any other solid reagents were also added at this 
point, in the following quantities: aldehyde (1.1-1.2 mmol, 1.1-1.2 equiv.) and organohalide 
(1.0 mmol, 1.0 equiv.). The vial was then sealed with a rubber septum and purged with 
argon via needle inlet. Toluene (1.0 mL) and liquid reagents were introduced in the 
following quantities: aldehyde (1.1-1.2 mmol, 1.1-1.2 equiv.), organohalide (1.0 mmol, 1.0 
equiv.). Diphenylsilane (1.1-1.4 mmol, 1.1-1.4 equiv.) was introduced and the septum was 
replaced with a PTFE-lined screw cap under an inert atmosphere,[1] and the reaction was 
heated at 110 °C for 24 h. The crude reaction mixture was filtered through Celite®, 
concentrated in vacuo, and purified via flash column chromatography.  
General procedure A2: (table 2, conditions B) preparation of compounds 59 and 62-66 via 
catalytic Wittig reaction using 54 with portion-wise addition. 
In air, a 1-dram vial equipped with a stir-bar was charged with PCb (0.15 mmol, 15 mol %) 
and 54 (0.66 mmol, 0.66 equiv.). The vial was then sealed with a rubber septum and purged 
with argon via needle inlet. Toluene (1.0 mL) and diphenylsilane (0.9 mmol, 0.9 equiv.) 
were introduced and the septum was replaced with a PTFE-lined screw cap under an inert 
atmosphere.[1] The reaction solution was heated at 110 °C for 45 min, then aldehyde (0.33 
mmol, 0.33 equiv.) and organohalide (0.15 mmol, 0.15 equiv.) were introduced and the 
reaction solution stirred at RT for 5-10 min, before returning to 110 °C for a further hour. 
Additional halide (0.15 mmol, 0.15 equiv.) was added hourly (total of 7 additions) and 
additional 54 (2 x 0.66 mmol, 0.66 equiv.) and aldehyde (2 x 0.33 mmol, 0.33 equiv.) were 
added after 2 h and 5 h. Diphenylsilane (0.3 mmol, 0.3 equiv.) was added after 5 h. After all 
additions were complete the reaction solution was stirred at 110 °C for a total time of 24 h. 
The crude reaction mixture was filtered through Celite®, concentrated in vacuo, and 
purified via flash column chromatography. 
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General procedure B: (table 5) preparation of compounds 55, 58 and 67-77 via catalytic 
Wittig reaction using DIPEA.  
In air, a 4 mL pressure vessel equipped with a stir-bar was charged with phosphine oxide 
PCd (0.10 mmol, 10 mol %). Any other solid reagents were also added at this point, in the 
following quantities: aldehyde (1.2 mmol, 1.2 equiv.) and organohalide (1.0 mmol, 1.0 
equiv.). The vessel was then sealed with a rubber septum and purged with argon via needle 
inlet. Toluene (0.33 mL) and liquid reagents were introduced in the following quantities: 
aldehyde (1.2 mmol, 1.2 equiv.), organohalide (1.0 mmol, 1.0 equiv.), DIPEA (1.2 mmol, 
1.2 equiv.). Diphenylsilane (1.2 mmol, 1.2 equiv.) was introduced and the septum was 
replaced with a PTFE-lined screw cap under an inert atmosphere,[1] and the reaction was 
heated at 140 °C for 24 h. The crude reaction mixture was concentrated in vacuo, and 
purified via flash column chromatography.  
General procedure C: (table 7) preparation of compounds 78-87 via catalytic Wittig 
reaction using pulse olefination.  
In air, a 1-dram vial equipped with a stir-bar was charged with PCb (0.15 mmol, 15 mol %) 
and 54 (1.0 mmol, 1.0 equiv.). If solid, ketone (1.0 mmol, 1.0 equiv.) was also added at this 
point. The vial was then sealed with a rubber septum and purged with argon via needle inlet. 
Toluene (1.0 mL) and ketone (1.0 mmol, 1.0 equiv.), if liquid, were added via syringe. 
Diphenylsilane (1.2 mmol, 1.2 equiv.) was introduced and the septum was replaced with a 
PTFE-lined screw cap under an inert atmosphere,[1] and the reaction was heated at 110 °C 
for 30 min. The reaction was cooled to RT and organohalide (0.15 mmol, 0.15 equiv.) was 
added. The reaction was stirred at RT for 30 min, then returned to 110 °C for 2 h. This 
process was repeated until 9 additions of halide were carried out. Additional base was 
introduced after the 3rd (1.0 mmol, 1.0 equiv.), 6th (1.0 mmol, 1.0 equiv.) and 8th (0.5 mmol, 
0.5 equiv.) additions. If required, the reaction was allowed to stir at 110 °C overnight (10 h) 
between the 5th and 6th addition. The crude reaction mixture was filtered through Celite®, 
concentrated in vacuo, and purified via flash column chromatography. 
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General procedure D: (table 8) preparation of compounds 88-93 via catalytic Wittig 
reaction.  
In air, a 1-dram vial equipped with a stir-bar was charged with PCd (0.2 mmol, 20 mol %) 
and 54 (2.0-3.5 mmol, 2.0-3.5 equiv.). If solid, aldehyde (1.0-1.2 mmol, 1.0-1.2 equiv.) was 
also added at this point. The vial was then sealed with a rubber septum and purged with 
argon via needle inlet. Toluene (1.4 mL) and liquid reagents were introduced in the 
following quantities: aldehyde (1.2 mmol, 1.2 equiv.) and organohalide (1.0 mmol, 1.0 
equiv.). Diphenylsilane (1.2 mmol, 1.2 equiv.) was introduced and the septum was replaced 
with a PTFE-lined screw cap under an inert atmosphere.[1] The reaction was heated at 140 
°C or 150 °C for 24-48 h. Additional portions of base and halide were added at 24 h for 48 h 
reactions. The crude reaction mixture was filtered through Celite®, concentrated in vacuo, 
and purified via flash column chromatography. 
General procedure E1: (table 10, conditions A) preparation of compounds 55-57 and 108-
110 using PMHS and 54 
In air, a 1-dram vial equipped with a stir-bar was charged with PCb (0.10-0.20 mmol, 10-20 
mol %) Any solid reagents were also added at this point, in the following quantities: 54 (2.0 
mmol, 2.0 equiv.), aldehyde (1.0-1.2 mmol, 1.0-1.2 equiv.) and organohalide (1.0-1.3 mmol, 
1.0-1.3 equiv.). The vial was then sealed with a rubber septum and purged with argon via 
needle inlet. Solvent (0.4 -1.0 mL) and liquid reagents were introduced in the following 
quantities: aldehyde (1.0-1.2 mmol, 1.0-1.2 equiv.), organohalide (1.0-1.3 mmol, 1.0-1.3 
equiv.). PMHS (3.5-5.0 mmol, 3.5-5.0 equiv.) was introduced and the septum was replaced 
with a PTFE-lined screw cap under an inert atmosphere,[1] and the reaction was heated at 
110 °C for 24 h. The crude reaction mixture was stirred in ethyl acetate, filtered through 
Celite®, concentrated in vacuo, and purified via flash column chromatography.  
General procedure E2: (table 10, conditions A) preparation of compounds 62, 63 and 78 
using PMHS and 54 with portion-wise addition 
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In air, a 1-dram vial equipped with a stir-bar was charged with PCb (0.15 mmol, 15 mol %) 
and 54 (0.66 mmol, 0.66 equiv.). The vial was then sealed with a rubber septum and purged 
with argon via needle inlet. Toluene (1.0 mL) and PMHS (5.0 mmol, 5.0 equiv.) were 
introduced and the septum was replaced with a PTFE-lined screw cap under an inert 
atmosphere.1 The reaction solution was heated at 110 °C for 45 min, then aldehyde (0.33 
mmol, 0.33 equiv.) and organohalide (0.15 mmol, 0.15 equiv.) were introduced and the 
reaction solution stirred at RT for 5-10 min, before returning to 110 °C for a further hour. 
Additional halide (0.15 mmol, 0.15 equiv.) was added hourly (total of 7 additions) and 
additional 54 (2 x 0.66 mmol, 0.66 equiv.) and aldehyde (2 x 0.33 mmol, 0.33 equiv.) were 
added after 2 h and 5 h. After all additions were complete the reaction solution was stirred at 
110 °C for a total time of 24 h. The crude reaction mixture was filtered through Celite®, 
concentrated in vacuo, and purified via flash column chromatography.  
General procedure F: (table 9 and table 10, conditions B) preparation of compounds 55, 
68, 73 and 94-107 using PMHS and DIPEA 
In air, a 1-dram vial (or 4 mL pressure vessel for reactions at 150 °C) equipped with a stir-
bar was charged with PCb or PCd (0.10 mmol, 10 mol %) Any solid reagents were also 
added at this point, in the following quantities: aldehyde (1.0-1.2 mmol, 1.0-1.2 equiv.) and 
organohalide (1.0-1.3 mmol, 1.0-1.3 equiv.). The vial was then sealed with a rubber septum 
and purged with argon via needle inlet. Solvent (0.4 -1.0 mL) and liquid reagents were 
introduced in the following quantities: aldehyde (1.0-1.2 mmol, 1.0-1.2 equiv.), 
organohalide (1.0-1.3 mmol, 1.0-1.3 equiv.) and DIPEA (1.1-1.3 mmol, 1.1-1.3 equiv.). 
PMHS (3.5-5.0 mmol, 3.5-5.0 equiv.) was introduced and the septum was replaced with a 
PTFE-lined screw cap under an inert atmosphere,[1] and the reaction was heated at 110 °C or 
150 °C for 24 h. The crude reaction mixture was stirred in ethyl acetate, filtered through 
Celite®, concentrated in vacuo, and purified via flash column chromatography.  
General procedure for iodine-catalyzed olefin isomerization: In air, a 1-dram vial 
equipped with a stir-bar was charged with the pure E/Z olefin mixture obtained via catalytic 
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Wittig reaction (1.0 mmol) and iodine (1 crystal). The vial was then sealed with a rubber 
septum and purged with argon via needle inlet, before introduction of toluene (1.0 mL). The 
septum was replaced with a PTFE-lined screw cap under an inert atmosphere,[1] and the 
reaction was heated at 110 °C for 5 h. The mixture was diluted with diethyl ether (5 mL) 
and washed with saturated aq. NaHSO3 and brine. The diethyl ether layer was dried over 
magnesium sulfate and the solvent was removed in vacuo to yield pure E-olefin in 
quantitative yield.  
1,2-Diphenylethene[13] (55) was obtained in accordance with 
general procedure A1 from the reaction of benzaldehyde (122 µL, 
1.2 mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCb (22 mg, 0.1 mmol, 10 mol %) in toluene (1.0 mL) at 110 °C for 24 h. The 
crude product was purified via flash column chromatography (hexane, E-55: Rf = 0.44, Z-
55: Rf = 0.52) to afford E-55 as a white solid and Z-55 as a colorless oil (128 mg, 71%, E/Z 
80:20). E-55: 1H NMR (400 MHz, CDCl3) δ: 7.12 (s, 2H), 7.25-7.29 (m, 2H), 7.37 (t, J = 
7.6 Hz, 4H), 7.53 (d, J = 7.6 Hz, 4H). Z-55: 1H NMR (400 MHz, CDCl3) δ: 6.62 (s, 2H), 
7.19-7.29 (m, 10H). 
When 55 was prepared in accordance with general procedure A1 from the reaction of 
benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCm (23 mg, 0.1 mmol, 10 mol %) in toluene (1.0 mL) at 110 °C for 24 h, 
yield was 82% (148 mg, E/Z 95:5). 
When 55 was prepared in accordance with general procedure B from the reaction of 
benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 
equiv.) using PCd (32 mg, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h, yield was 
72% (129 mg, E/Z 80:20). 
55 
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When 55 was prepared in accordance with general procedure E1 from the reaction of 
benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 
equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using 
PCb (23 mg, 0.1 mmol, 10 mol %) in in toluene (1.0 mL) at 110 °C for 24 h, yield was 72% 
(130 mg, E/Z 80:20). 
When 55 was prepared in accordance with general procedure F from the reaction of 
benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 
equiv.), PMHS (217 µL, 3.5 mmol, 3.5 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) 
using PCd (32 mg, 10 mol %) in toluene (0.40 mL) at 150 °C for 24 h, yield was 71% (128 
mg, E/Z 80:20). 
Isomerization of 55 (126 mg, 0.7 mmol) using iodine (one crystal) was carried out in 
accordance with the general procedure, and E-55 was obtained in 99% yield. 
 
2-(4-Bromophenyl)-1-(2-furyl)ethene (56) was obtained in 
accordance with general procedure A1 from the reaction of 
furfural (100 µL, 1.2 mmol, 1.2 equiv.), 4-bromobenzyl 
bromide (250 mg, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 
54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (22 mg, 0.1 mmol, 10 mol %) in toluene (1.0 
mL) at 110 °C for 24 h. The crude product was purified via flash column chromatography 
(hexane, Rf = 0.33) to afford an isomeric mixture of 56 as a white solid (185 mg, 74%, E/Z 
66:34). E-56: 1H NMR (600 MHz, CDCl3) δ: 6.39-6.40 (m, 1H), 6.46 (dd, J = 3.6 Hz, 1.8 
Hz, 1H), 6.89 (d, J = 16.2 Hz, 1H), 6.99 (d, J = 16.2 Hz, 1H), 7.31-7.37 (m, 2H), 7.44 (d, J 
= 1.8 Hz, 1H), 7.47-7.50 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 109.3, 111.8, 117.2, 
121.3, 125.8, 127.8, 131.8, 136.0, 142.5, 153.0. Z-56: 1H NMR (600 MHz, CDCl3) δ: 6.31 
(d, J = 3.6 Hz, 1H), 6.37 (dd, J = 3.6 Hz, 1.8 Hz, 1H), 6.38 (d, J = 12.0 Hz, 1H), 6.41 (d, J = 
12.6 Hz, 1H), 7.31-7.37 (m, 2H), 7.34 (d, J = 1.2 Hz, 1H), 7.47-7.50 (m, 2H); 13C NMR 
O
Br
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(100 MHz, CDCl3) δ: 110.7, 111.4, 118.5, 121.3, 126.5, 130.5, 131.3, 136.3, 141.9, 151.9. 
HRMS [M]+ m/z calcd. 247.9837, found 247.9835. 
When 56 was prepared in accordance with general procedure A1 from the reaction of 
furfural (100 µL, 1.2 mmol, 1.2 equiv.), 4-bromobenzyl bromide (250 mg, 1.0 mmol, 1.0 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCm (23 mg, 0.1 mmol, 10 mol %) in toluene (1.0 mL) at 110 °C for 24 h, 
yield was 64% (159 mg, E/Z 85:15). 
When 56 was prepared in accordance with general procedure E1 from the reaction of 
furfural (100 µL, 1.2 mmol, 1.2 equiv.), 4-bromobenzyl bromide (250 mg, 1.0 mmol, 1.0 
equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using 
PCb (42 mg, 0.2 mmol, 20 mol %) in in toluene (1.0 mL) at 110 °C for 24 h, yield was 78% 
(195 mg, E/Z 66:34). 
 
 (1E)-1,4-Diphenylbuta-1,3-diene[14] (57) was obtained in 
accordance with general procedure A1 from the reaction of 
benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), 3-bromo-1-
phenyl-1-propene (197 mg, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 
equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (22 mg, 0.1 mmol, 10 mol %) in 
toluene (1.0 mL) at 110 °C for 24 h. The crude product was purified via flash column 
chromatography (hexane, E-57: Rf = 0.26, Z-57: Rf = 0.36) to afford both E-57 and Z-57 as 
white solids (152 mg, 74%, E/Z 70:30). E-57 1H NMR (400 MHz, CDCl3) δ: 6.65-6.73 (m, 
2H), 6.94-7.01 (m, 2H), 7.25 (t, J = 7.6 Hz, 2H), 7.48 (t, J = 7.6 Hz, 4H), 7.46 (d, J = 7.6 
Hz, 4H). Z-57 1H NMR (400 MHz, CDCl3) δ: 6.45 (t, J = 11.6 Hz, 1H), 6.55 (d, J = 11.6 
Hz, 1H), 6.74 (d, J = 15.6 Hz, 1H), 7.22-7.43 (m, 11H). 
When 57 was prepared in accordance with general procedure E1 from the reaction of 
benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), 3-bromo-1-phenyl-1-propene (197 mg, 1.0 
mmol, 1.0 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
57 
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equiv.) using PCb (21 mg, 0.1 mmol, 10 mol %) in in toluene (1.0 mL) at 110 °C for 24 h, 
yield was 67% (139 mg, E/Z 70:30). 
Isomerization of 57 (134 mg, 0.65 mmol) using iodine (one crystal) was carried out in 
accordance with the general procedure, and E-57 was obtained in 98% yield. 
1-(2-Furyl)-2-(2-naphthyl)ethene[15] (58) was obtained in 
accordance with general procedure A1 from the reaction of 
furfural (100 µL, 1.2 mmol, 1.2 equiv.), 2-
(bromomethyl)naphthalene (221 mg, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 
mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (22 mg, 0.1 mmol, 10 
mol %) in toluene (1.0 mL) at 110 °C for 24 h. The crude product was purified via flash 
column chromatography (hexane, Rf = 0.31) to afford 58 as a white solid (181 mg, 82%, E/Z 
66:34). E-58: 1H NMR (400 MHz, CDCl3) δ: 6.47 (d, J = 3.2 Hz, 1H), 6.52 (dd, J = 3.2 Hz, 
1.6 Hz, 1H), 7.10 (d, J = 16.4 Hz, 1H), 7.31 (d, J = 16.4 Hz, 1H), 7.50-7.56 (m, 3H), 7.74 
(dd, J = 8.4 Hz, 1.2 Hz, 1H), 7.86-7.92 (m, 4H); Z-58: 1H NMR (400 MHz, CDCl3) δ: 6.39 
(d, J = 0.8 Hz, 2H), 6.58 (d, J = 12.8 Hz, 1H), 6.71 (d, J = 12.8 Hz, 1H), 7.39 (br. s, 1H), 
7.50-7.56 (m, 2H), 7.69 (dd, J = 8.4 Hz, 1.2 Hz, 1H), 7.86-7.92 (m, 3H), 8.00 (br. s, 1H). 
When 58 was prepared in accordance with general procedure A1 from the reaction of 
furfural (100 µL, 1.2 mmol, 1.2 equiv.), 2-(bromomethyl)naphthalene (221 mg, 1.0 mmol, 
1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCm (23 mg, 0.1 mmol, 10 mol %) in toluene (1.0 mL) at 110 °C for 24 h, 
yield was 65% (143 mg, E/Z 90:10). 
When 58 was obtained in accordance with general procedure B from the reaction of 
furfural (100 µL, 1.2 mmol, 1.2 equiv.), 2-(bromomethyl)naphthalene (221 mg, 1.0 mmol, 
1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 
1.2 equiv.) using PCd (32 mg, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h, yield was 
72% (160 mg, E/Z 70:30).  
O
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1-Cyclohexyl-2-phenylprop-1-ene[16] (59) was obtained in 
accordance with general procedure A2 using a portion-wise 
addition of organohalide (7 x 0.14 mmol portions added at 1 h 
intervals) from the reaction of cyclohexanecarboxaldehyde (145 µL, 1.2 mmol, 1.2 equiv.), 
(1-bromoethyl)benzene (136 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 
1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (22 mg, 10 mol %) in toluene 
(1.0 mL) at 110 °C for 24 h. The crude product was purified via flash column 
chromatography (hexane, Rf = 0.69) to afford an isomeric mixture of 59 as a colorless liquid 
(141 mg, 79%, E/Z 70:30). E-59: 1H NMR (400 MHz, CDCl3) δ: 1.05-1.41 (m, 5H), 1.60-
1.79 (m, 5H), 2.07 (d, J = 1.2 Hz, 3H), 2.32-2.42 (m, 1H), 5.65 (dd, J = 8.8 Hz, 1.2 Hz, 1H), 
7.18-7.42 (m, 5H). Z-59: 1H NMR (400 MHz, CDCl3) δ: 1.05-1.41 (m, 6H), 1.60-1.79 (m, 
5H), 2.02 (d, J = 1.2 Hz, 3H), 5.29 (dd, J = 10.0 Hz, 1.2 Hz, 1H), 7.18-7.42 (m, 5H).  
1,4-Diphenylpenta-1,3-diene[17] (60) was obtained in 
accordance with general procedure A1 from the reaction of 
trans-cinnamaldehyde (150 µL, 1.2 mmol, 1.2 equiv.), (1-
bromoethyl)benzene (136 µL, 1.0 mmol, 1.0 equiv.), 
diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using 
PCb (22 mg, 0.1 mmol, 10 mol %) in toluene (1.0 mL) at 110 °C for 24 h. The crude 
product was purified via flash column chromatography (hexane, Rf = 0.29) to afford an 
isomeric mixture of 60 as a white solid (174 mg, 79%, E/Z 70:30). E-60: 1H NMR (400 
MHz, CDCl3) δ: 2.31 (s, 3H), 6.68 (d, J = 10.8 Hz, 1H), 6.70 (d, J = 15.2 Hz, 1H), 7.16-7.44 
(m, 7H), 7.48-7.54 (m, 4H). Z-60: 1H NMR (400 MHz, CDCl3) δ: 2.22 (s, 3H), 6.34 (d, J = 
11.2 Hz, 1H), 6.57 (d, J = 15.6 Hz, 1H), 6.89 (dd, J = 15.6 Hz, 11.2 Hz, 1H), 7.16-7.44 (m, 
10H). 
2-Phenyl-1-(2-thienyl)-prop-1-ene[18] (61) was obtained in 
accordance with general procedure A1 from the reaction of 2-
59 
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thiophenecarboxaldehyde (112 µL, 1.2 mmol, 1.2 equiv.), (1-bromoethyl)benzene (136 µL, 
1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 
mmol, 2.0 equiv.) using PCb (22 mg, 0.1 mmol, 10 mol %) in toluene (1.0 mL) at 110 °C 
for 24 h. The crude product was purified via flash column chromatography (hexane, Rf = 
0.26) to afford an isomeric mixture of 61 as a pale yellow oil (154 mg, 77%, E/Z 80:20). E-
61: 1H NMR (400 MHz, CDCl3) δ: 2.54 (d, J = 1.2 Hz, 3H), 7.09 (br. s, 1H), 7.17 (dd, J = 
4.8 Hz, 3.6 Hz, 1H), 7.21 (br. d, J = 3.6 Hz, 1H), 7.36-7.62 (m, 6H). Z-61: 1H NMR (400 
MHz, CDCl3) δ: 2.29 (d, J = 1.2 Hz, 3H), 6.74 (d, J = 1.2 Hz, 1H), 6.85 (br. d, J = 3.6 Hz, 
1H), 6.92 (dd, J = 4.8 Hz, 3.6 Hz, 1H), 7.04 (br. d, J = 5.2 Hz, 1H), 7.36-7.62 (m, 5H). 
4-Methyl-1-phenylpenta-1,3-diene[19] (62) was obtained in 
accordance with general procedure A2 from the reaction of 
benzaldehyde (100 µL, 1.0 mmol, 1.0 equiv.), 3,3-dimethylallyl 
bromide (140 µL, 1.2 mmol, 1.2 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 
54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol %) in toluene (1.0 
mL) at 110 °C for 24 h using a portion-wise addition process. The crude product was 
purified via flash column chromatography (hexane, Rf = 0.38) to afford an isomeric mixture 
of 62 as a colorless liquid (112 mg, 71%, E/Z 66:34). E-62: 1H NMR (400 MHz, CDCl3) δ: 
1.90 (s, 3H), 1.92 (s, 3H), 6.06 (d, J = 10.8 Hz, 1H), 6.48 (d, J = 15.6 Hz, 1H), 7.05 (dd, J = 
15.6 Hz, 10.8 Hz, 1H), 7.21-7.45 (m, 5H). Z-62: 1H NMR (400 MHz, CDCl3) δ: 1.88 (s, 
3H), 1.89 (s, 3H), 6.36-6.51 (m, 3H), 7.21-7.45 (m, 5H). 
1H), 7.16-7.44 (m, 10H). 
1-(9-Anthryl)-4-methylpenta-1,3-diene (63) was obtained in 
accordance with general procedure A2 from the reaction of 9-
anthracenecarboxaldehyde (206 mg, 1.0 mmol, 1. 0 equiv.), 3,3-
dimethylallyl bromide (140 µL, 1.2 mmol, 1.2 equiv.), 
diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using 
PCb (32 mg, 0.15 mmol, 15 mol %) in toluene (1.0 mL) at 110 °C for 24 h using a portion-
62 
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wise addition process. The crude product was purified via flash column chromatography 
(hexane, Rf = 0.38) to afford an isomeric mixture of 63 as a bright yellow oil (188 mg, 73%, 
E/Z 80:20). E-63: 1H NMR (400 MHz, CDCl3) δ: 1.86 (s, 3H), 1.98 (s, 3H), 6.37 (d, J = 
10.8 Hz, 1H), 6.85-6.94 (m, 1H), 7.27 (d, J = 15.6 Hz, 1H), 7.48-7.50 (m, 4H), 8.01-8.06 
(m, 2H), 8.36-8.38 (m, 3H). Z-63: 1H NMR (400 MHz, CDCl3) δ: 1.57 (s, 3H), 1.92 (s, 3H), 
5.48 (d, J = 10.8 Hz, 1H), 6.85-6.94 (m, 1H), 7.05 (t, J = 11.2 Hz, 1H), 7.48-7.50 (m, 4H), 
8.01-8.06 (m, 2H), 8.19-8.22 (m, 2H), 8.44 (br. s, 1H). E+Z-63: 13C NMR (100 MHz, 
CDCl3) δ: 18.6, 18.7, 26.3, 26.4, 122.2, 123.6, 125.2, 125.2, 125.3, 125.4, 125.8, 126.1, 
126.2, 126.3, 126.8, 128.7, 128.7, 129.7, 130.3, 131.5, 131.6, 132.6, 133.7, 134.6, 137.1, 
138.1. HRMS [M]+ m/z calcd. 258.1409, found 258.1403. 
 (3E)-1-(2-Furyl)-4,8-dimethylnona-1,3,7-triene (64) 
was obtained in accordance with general procedure A2 
from the reaction of furfural (83 µL, 1.0 mmol, 1.0 
equiv.), geranyl bromide (238 µL, 1.2 mmol, 1.2 equiv.), diphenylsilane (223 µL, 1.2 mmol, 
1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol 
%) in toluene (1.0 mL) at 110 °C for 24 h using a portion-wise addition process. The crude 
product was purified via flash column chromatography (hexane, Rf = 0.42) to afford an 
isomeric mixture of 64 as a pale yellow liquid (139 mg, 64%, E/Z 66:34). E-64: 1H NMR 
(400 MHz, CDCl3) δ: 1.64 (s, 3H), 1.71 (s, 3H), 1.86 (s, 3H), 2.00-2.31 (m, 4H), 5.11-5.19 
(m, 1H), 5.96 (d, J = 11.2 Hz, 1H), 6.21 (d, J = 3.2 Hz, 1H), 6.26 (d, J = 15.6 Hz, 1H), 6.40 
(br. d, J = 11.6 Hz, 1H), 6.93 (dd, J = 15.2 Hz, 11.6 Hz, 1H), 7.35 (br. s, 1H). Z-64: 1H 
NMR (400 MHz, CDCl3) δ: 1.65 (s, 3H), 1.71 (s, 3H), 1.85 (s, 3H), 2.00-2.31 (m, 4H), 5.11-
5.19 (m, 1H), 6.06 (d, J = 12.0 Hz, 1H), 6.28 (d, J = 11.6 Hz, 1H), 6.32 (d, J = 2.8 Hz, 1H), 
6.40 (br. d, J = 11.6 Hz, 1H), 6.79 (d, J = 11.2 Hz, 1H), 7.43 (br. s, 1H). E+Z-64: 13C NMR 
(100 MHz, CDCl3) δ: 16.8, 17.1, 17.9, 18.0, 25.9, 26.7, 26.8, 27.1, 40.3, 40.6, 107.3, 109.8, 
111.4, 111.6, 114.6, 117.8, 122.2, 123.8, 124.0, 124.1, 124.6, 132.0, 140.7, 141.7, 142.0, 
142.7, 154.0, 154.1. HRMS [M]+ m/z calcd. 216.1514, found 216.1507.  
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 (6E)-2,6,11,15-Tetramethylhexadeca-
2,6,8,14-tetraene (65) was obtained in 
accordance with general procedure A2 from 
the reaction of (±)-citronellal (180 µL, 1.0 mmol, 1.0 equiv.), geranyl bromide (238 µL, 1.2 
mmol, 1.2 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 
mmol, 2.0 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol %) in toluene (1.0 mL) at 110 °C 
for 24 h using a portion-wise addition process. The crude product was purified via flash 
column chromatography (hexane, Rf = 0.71) to afford an isomeric mixture of 65 as a clear 
liquid (203 mg, 74%, E/Z 70:30). E-65: 1H NMR (400 MHz, CDCl3) δ: 0.90 (d, J = 6.8 Hz, 
3H), 1.12-1.22 (m, 1H), 1.34-1.44 (m, 1H), 1.47-1.57 (m, 1H), 1.62 (br. s, 6H), 1.70 (br. s, 
6H), 1.76 (s, 3H), 1.92-2.23 (m, 8H), 5.10-5.15 (m, 2H), 5.58 (dt, J = 15.2 Hz, 7.2 Hz, 1H), 
5.83 (br. d, J = 10.8 Hz, 1H), 6.21-6.28 (m, 1H). Z-65: 1H NMR (400 MHz, CDCl3) δ: 0.92 
(d, J = 6.8 Hz, 3H), 1.12-1.22 (m, 1H), 1.34-1.44 (m, 1H), 1.47-1.57 (m, 1H), 1.62 (br. s, 
6H), 1.70 (br. s, 6H), 1.76 (s, 3H), 1.92-2.23 (m, 8H), 5.10-5.15 (m, 2H), 5.38 (dt, J = 10.8 
Hz, 7.6 Hz, 1H), 6.09 (br. d, J = 11.6 Hz, 1H), 6.21-6.28 (m, 1H). E+Z-65: 13C NMR (100 
MHz, CDCl3) δ: 16.6, 16.7, 17.8, 17.8, 17.8, 19.6, 19.7, 25.8, 25.8, 25.8, 25.9, 26.8, 33.1, 
33.3, 34.8, 36.8, 36.9, 40.0, 40.4, 40.6, 120.3, 124.3, 124.3, 124.9, 125.0, 125.6, 128.0, 
128.7, 131.1, 131.2, 131.6, 136.3, 138.4; HRMS [M]+ m/z calcd. 274.2661, found 274.2666. 
When 65 was prepared in accordance with general procedure A2 from the reaction of (±)-
citronellal (180 µL, 1.0 mmol, 1.0 equiv.), geranyl bromide (238 µL, 1.2 mmol, 1.2 equiv.), 
diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using 
PCm (35 mg, 0.15 mmol, 15 mol %) in toluene (1.0 mL) at 110 °C for 24 h, yield was 63% 
(173 mg, E/Z 85:15). 
65 was obtained on a 28.0 mmol scale in accordance with general procedure A2 from the 
reaction of (±)-citronellal (5.3 mL, 28.0 mmol, 1.0 equiv.), geranyl bromide (7.0 mL, 33.6 
mmol, 1.2 equiv.), diphenylsilane (6.2 mL, 33.6 mmol, 1.2 equiv.) and 54 (7.85 g, 56.0 
mmol, 2.0 equiv.) using PCb (908 mg, 4.2 mmol, 15 mol %) in toluene (28 mL). The 
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reaction was prepared in a 100 mL pressure vessel under an inert atmosphere and run at .110 
°C for 24 h to afford 65 in 84% yield (6.42 g, E/Z 70:30).  
3-Benzylidenecyclohex-2-ene[20] (66) was obtained in accordance with 
general procedure A2 from the reaction of benzaldehyde (100 µL, 1.0 
mmol, 1.0 equiv.), 3-bromocyclohexene (138 µL, 1.2 mmol, 1.2 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCb (32 mg, 0.15 mmol, 15 mol %) in toluene (1.0 mL) at 110 °C for 24 h 
using a portion-wise addition process. The crude product was purified via flash column 
chromatography (hexane, Rf = 0.59) to afford an isomeric mixture of 66 as a colorless liquid 
(116 mg, 68%, E/Z 55:45). E-66: 1H NMR (400 MHz, CDCl3) δ: 1.76 (qn, J = 6.0 Hz, 1H), 
1.87 (qn, J = 6.0 Hz, 1H), 2.21-2.27 (m, 2H), 2.49 (dt, J = 6.0 Hz, 1.2 Hz, 1H), 2.70 (dt, J = 
6.0 Hz, 1.6 Hz, 1H), 5.93-6.00 (m, 1H), 6.25-6.32 (m, 2H), 7.22-7.39 (m, 5H). Z-66: 1H 
NMR (400 MHz, CDCl3) δ: 1.76 (qn, J = 6.0 Hz, 1H), 1.87 (qn, J = 6.0 Hz, 1H), 2.21-2.27 
(m, 2H), 2.49 (dt, J = 6.0 Hz, 1.2 Hz, 1H), 2.70 (dt, J = 6.0 Hz, 1.6 Hz, 1H), 5.93-6.00 (m, 
1H), 6.28 (s, 1H), 6.68 (d, J = 10.4 Hz, 1H), 7.22-7.39 (m, 5H). 
1-(6-Bromo-1,3-dioxa-5-indanyl)-2-phenylethene[21] (67) was 
obtained in accordance with general procedure B from the 
reaction of benzaldehyde (122 µL, 1.2 mmol, 1.2 equiv.), 5-bromo-6-bromomethyl-1,3-
benzodioxole (294 mg, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 
equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) using PCd (32 mg, 0.1 mmol, 10 mol %) 
in toluene (0.33 mL) at 140 °C for 24 h. The crude product was purified via flash column 
chromatography (hexane, E-67: Rf = 0.15, Z-67: Rf = 0.24) to afford both E-67 and Z-67 as 
white solids (239 mg, 79%, E/Z 70:30). E-67: 1H NMR (400 MHz, CDCl3) δ: 5.99 (s, 2H), 
6.90 (d, J = 16.4 Hz, 1H), 7.05 (s, 1H), 7.16 (s, 1H), 7.29 (t, J = 7.2 Hz, 1H), 7.38 (t, J = 8.0 
Hz, 2H), 7.42 (d, J = 16.0 Hz, 1H), 7.54 (d, J = 7.6 Hz, 2H). Z-67: 1H NMR (400 MHz, 
CDCl3) δ: 5.92 (s, 2H), 6.54 (d, J = 11.6 Hz, 1H), 6.63 (d, J = 11.2 Hz, 1H), 6.64 (s, 1H), 
7.07 (s, 1H), 7.17-7.26 (m, 5H).  
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Isomerization of 67 (172 mg, 0.65 mmol) using iodine (one crystal) was carried out in 
accordance with the general procedure, and E-67 was obtained in 97% yield. 
5-(2-(2,4-Difluorophenyl)ethenyl)-1,3-benzodioxole (68) 
was obtained in accordance with general procedure B from 
the reaction of piperonal (180 mg, 1.2 mmol, 1.2 equiv.), 
2,5-difluorobenzyl bromide (128 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 
mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) using PCd (32 mg, 0.1 mmol, 
10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude product was purified via flash 
column chromatography (benzene/hexane, 10:90, E-68: Rf = 0.32, Z-68: Rf = 0.36) to afford 
both E-68 and Z-68 as white solids (222 mg, 85%, E/Z 70:30, Z-68 inseparable from E-68). 
E-68: 1H NMR (400 MHz, CDCl3) δ: 5.98 (s, 2H), 6.79-6.90 (m, 2H), 6.80 (d, J = 8.0 Hz, 
1H), 6.94 (dd, J = 8.0 Hz, 1.6 Hz, 1H), 7.01 (s, 2H), 7.07 (d, J = 1.6 Hz, 1H), 7.52 (dt, J = 
8.8 Hz, 6.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 101.3, 104.2 (t, JCF = 25.8 Hz), 105.6, 
108.5, 111.6 (dd, JCF = 21.3 Hz, 3.6 Hz), 118.2 (dd, JCF = 2.9 Hz, 1.5 Hz), 121.7-121.9 (m), 
121.8, 127.6 (dd, JCF = 9.6 Hz, 5.1 Hz), 130.3 (dd, JCF = 5.1 Hz, 2.9 Hz), 131.7, 147.7, 
148.3, 159.9 (dd, JCF = 178.2 Hz, 11.7 Hz), 162.4 (dd, JCF = 177.7 Hz, 11.7 Hz); 19F NMR 
(376 MHz, CDCl3) δ: -114.0 (d, J = 7.1 Hz, 1F), -111.3 (d, J = 7.1 Hz, 1F); mp 84-85 °C. Z-
68: 1H NMR (400 MHz, CDCl3) δ: 5.92 (s, 2H), 6.45 (d, J = 12.0 Hz, 1H), 6.62 (d, J = 12.0 
Hz, 1H), 6.70-6.76 (m, 4H), 6.80-6.90 (m, 1H), 7.24 (dt, J = 8.8 Hz, 6.4 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ: 101.1, 104.1 (t, JCF = 25.8 Hz), 108.3, 108.6, 111.2 (dd, JCF = 21.3 Hz, 
3.6 Hz), 120.5 (d, JCF = 2.2 Hz), 121.2 (dd, JCF = 14.6 Hz, 3.6 Hz), 123.1, 130.7, 131.3 (dd, 
JCF = 9.5 Hz, 5.1 Hz), 132.0, 147.0, 147.6, 160.0 (dd, JCF = 183.6 Hz, 11.7 Hz), 162.6 (dd, 
JCF = 181.5 Hz, 11.7 Hz); 19F NMR (376 MHz, CDCl3) δ: -110.8 (d, J = 7.1 Hz, 1F), -110.4 
(d, J = 7.1 Hz, 1F). HRMS [M]+ m/z calcd. 260.0649, found 260.0645.  
When 68 was prepared in accordance with general procedure F from the reaction of 
piperonal (180 mg, 1.2 mmol, 1.2 equiv.), 2,5-difluorobenzyl bromide (128 µL, 1.0 mmol, 
1.0 equiv.), PMHS (217 µL, 3.5 mmol, 3.5 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 
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equiv.) using PCd (32 mg, 10 mol %) in toluene (0.40 mL) at 150 °C for 24 h, yield was 
74% (193 mg, E/Z 70:30). 
Isomerization of 68 (182 mg, 0.7 mmol) using iodine (one crystal) was carried out in 
accordance with the general procedure, and E-68 was obtained in 98% yield. 
5-(2-(1,3-Benzodioxol-5-yl)ethenyl)-6-bromo-1,3-
benzodioxole (69) was obtained in accordance with 
general procedure B from the reaction of piperonal (180 
mg, 1.2 mmol, 1.2 equiv.), 5-bromo-6-bromomethyl-1,3-benzodioxole (294 mg, 1.0 mmol, 
1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 
1.2 equiv.) using PCd (32 mg, 0.1 mmol, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 
h. The crude product was purified via flash column chromatography (benzene/hexane, 
20:80, Rf = 0.32) to afford both E-69 and Z-69 as white solids (243 mg, 70%, E/Z 66:34, Z-
69 inseparable from E-69). E-69: 1H NMR (400 MHz, CDCl3) δ: 5.98 (s, 4H), 6.79 (d, J = 
16.4 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 6.93 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 7.02 (s, 1H), 7.08 
(d, J = 1.6 Hz, 1H), 7.10 (s, 1H), 7.21 (d, J = 16.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 
101.3, 101.9, 105.7, 105.8, 108.5, 112.9, 115.2, 121.8, 125.7, 129.5, 130.7, 131.8, 147.6, 
147.8, 147.9, 148.3. Z-69: 1H NMR (400 MHz, CDCl3) δ: 5.91 (s, 2H), 5.93 (s, 2H), 6.40 (d, 
J = 12.0 Hz, 1H), 6.50 (d, J = 12.0 Hz, 1H), 6.64-6.69 (m, 4H), 7.04 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ: 101.1, 101.8, 108.3, 108.9, 110.2, 112.7, 114.8, 123.4, 128.1, 130.4, 130.4, 
130.9, 146.9, 147.1, 147.5, 147.7. HRMS [M]+ m/z calcd. 345.9841, found 345.9832. 
Isomerization of 69 (208 mg, 0.6 mmol) using iodine (one crystal) was carried out in 
accordance with the general procedure, and E-69 was obtained in 99% yield. 
1-(2-Bromo-3-thienyl)-2-(4-bromo-2-thienyl)ethene (70) was 
obtained in accordance with general procedure B from the 
reaction of 4-bromo-2-thiophenecarboxaldehyde (229 mg, 1.2 
mmol, 1.2 equiv.), 2-bromo-3-(bromomethyl)thiophene (130 µL, 1.0 mmol, 1.0 equiv.), 
diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) 
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using PCd (32 mg, 0.1 mmol, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude 
product was purified via flash column chromatography (hexane, E-70: Rf = 0.44, Z-70: Rf = 
0.66) to afford both E-70 and Z-70 as pale yellow oils (312 mg, 89%, E/Z 75:25). E-70: 1H 
NMR (400 MHz, CDCl3) δ: 6.91 (d, J = 16.0 Hz, 1H), 7.00 (d, J = 16.0 Hz, 1H), 7.00 (d, J 
= 1.2 Hz, 1H), 7.11 (d, J = 1.2 Hz, 1H), 7.15 (d, J = 6.0 Hz, 1H), 7.27 (d, J = 6.0 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ: 110.5, 112.3, 121.8, 121.9, 122.3, 124.5, 126.5, 128.3, 
137.4, 143.4. Z-70: 1H NMR (400 MHz, CDCl3) δ: 6.33 (d, J = 12.0 Hz, 1H), 6.68 (d, 12.0 
Hz, 1H), 6.88 (d, J = 5.6 Hz, 1H), 6.90 (br. s, 1H), 7.08 (d, J = 1.2 Hz, 1H), 7.25 (d, J = 5.6 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 109.7, 113.2, 123.3, 123.6, 124.1, 126.4, 127.9, 
130.4, 136.9, 140.6. HRMS [M]+ m/z calcd. 347.8278, found 347.8282. 
6-(2-Phenylethenyl)-2H-chromen-2-one (71) was obtained 
in accordance with general procedure B from the reaction 
of 2-oxo-2H-chromene-6-carbaldehyde (209 mg, 1.2 mmol, 
1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 
mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) using PCd (32 mg, 0.1 mmol, 
10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude product was purified via flash 
column chromatography (ethyl acetate/benzene/hexane, 7:30:63, E-71: Rf = 0.20, Z-71: Rf = 
0.29) to afford E-71 as a white solid and Z-71 as a pale yellow oil (228 mg, 92%, E/Z 
70:30). E-71: 1H NMR (400 MHz, CDCl3) δ: 6.44 (d, J = 9.6 Hz, 1H), 7.10 (s, 2H), 7.27-
7.33 (m, 2H), 7.38 (br. t, J = 8.0 Hz, 2H), 7.52 (d, J = 9.2 Hz, 2H), 7.57 (d, J = 2.0 Hz, 1H), 
7.70 (t, J = 9.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ: 117.1, 117.3, 119.1, 125.6, 126.7, 
126.7, 128.1, 128.9, 129.8, 129.8, 134.1, 136.8, 143.4, 153.4, 160.7; mp 136-138 °C. Z-71: 
1H NMR (400 MHz, CDCl3) δ: 6.39 (d, J = 9.6 Hz, 1H), 6.59 (d, J = 12.4 Hz, 1H), 6.69 (d, 
J = 12.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.22-7.28 (m, 5H), 7.34 (d, J = 2.0 Hz, 1H), 7.40 
(dd, J = 8.4 Hz, 2.0 Hz, 1H), 7.56 (d, J = 9.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 
116.8, 116.8, 118.8, 127.6, 128.0, 128.3, 128.6, 128.9, 131.5, 132.7, 133.8, 136.7, 143.5, 
153.0, 160.8. HRMS [M+H]+ m/z calcd. 249.0916, found 249.0911.  
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Isomerization of 71 (199 mg, 0.8 mmol) using iodine (one crystal) was carried out in 
accordance with the general procedure, and E-71 was obtained in 98% yield. 
1-(5-Methyl-3-phenyl-4-isoxazolyl)-2-phenylethene (72) was 
obtained in accordance with general procedure B from the reaction 
of 5-methyl-3-phenylisoxazole-4-carboxaldehyde (225 mg, 1.2 
mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 
1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) using PCd (32 mg, 0.1 
mmol, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude product was purified 
via flash column chromatography (benzene/hexane, 50:50, E-72: Rf = 0.17, Z-72: Rf = 0.31) 
to afford both E-72 and Z-72 as pale yellow oils (211 mg, 81%, E/Z 70:30). E-72: 1H NMR 
(400 MHz, CDCl3) δ: 2.51 (s, 3H), 6.60 (d, J = 16.4 Hz, 1H), 6.71 (d, J = 16.4 Hz, 1H), 
7.15-7.20 (m, 1H), 7.25 (br. t, J = 7.2 Hz, 2H), 7.30-7.32 (m, 2H), 7.37-7.40 (m, 3H), 7.57-
7.61 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 12.5, 112.7, 116.7, 126.3, 128.0, 128.7, 
128.8, 128.9, 129.5, 129.7, 132.3, 137.0, 161.7, 166.3. Z-72: 1H NMR (400 MHz, CDCl3) δ: 
1.95 (d, J = 0.8 Hz, 3H), 6.28 (dd, J = 12.0 Hz, 0.8 Hz, 1H), 6.79 (d, J = 12.0 Hz, 1H), 7.18-
7.29 (m, 5H), 7.44-7.47 (m, 3H), 7.81-7.86 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 11.0, 
111.5, 118.1, 127.6, 127.9, 128.4, 128.7, 128.8, 129.6, 129.8, 134.1, 136.8, 161.7, 166.3. 
HRMS [M+H]+ m/z calcd 262.1232, found 262.1228. 
5-(2-(4-bromophenyl)ethenyl)-6-nitro-1,3-benzodioxole 
(73) was obtained in accordance with general procedure B 
from the reaction of 6-nitropiperonal (234 mg, 1.2 mmol, 
1.2 equiv.), 4-bromobenzyl bromide (250 mg, 1.0 mmol, 1.0 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 
equiv.) using PCd (32 mg, 0.1 mmol, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. 
The crude product was purified via flash column chromatography (benzene/hexane, 40:60, 
Rf = 0.30) to afford an inseparable mixture of 73 as a bright yellow solid (302 mg, 87%, E/Z 
45:55). E-73: 1H NMR (400 MHz, CDCl3) δ: 6.13 (s, 2H), 6.87 (d, J = 16.0 Hz, 1H), 7.09 
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(s, 1H), 7.37 (br. d, J = 8.4 Hz, 2H), 7.49 (br. d, J = 8.4 Hz, 2H), 7.51 (s, 1H), 7.63 (d, J = 
16.0 Hz, 1H). Z-73: 1H NMR (400 MHz, CDCl3) δ: 6.08 (s, 2H), 6.54 (s, 1H), 6.62 (d, J = 
12.0 Hz, 1H), 6.87 (d, J = 12.0 Hz, 1H), 6.95 (br. d, J = 8.4 Hz, 2H), 7.32 (br. d, J = 8.4 Hz, 
2H), 7.63 (s, 1H). E+Z-73: 13C NMR (100 MHz, CDCl3) δ: 103.1, 103.2, 105.6, 105.7, 
106.7, 110.5, 121.6, 122.4, 125.2, 128.3, 128.5, 129.7, 130.2, 130.4, 130.8, 131.6, 132.0; mp 
143-152 °C; HRMS [M]+ m/z calcd. 346.9793, found 346.9782.  
When 73 was prepared in accordance with general procedure F from the reaction of 6-
nitropiperonal (234 mg, 1.2 mmol, 1.2 equiv.), 4-bromobenzyl bromide (250 mg, 1.0 mmol, 
1.0 equiv.), PMHS (217 µL, 3.5 mmol, 3.5 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 
equiv.) using PCd (32 mg, 10 mol %) in toluene (0.40 mL) at 150 °C for 24 h, yield was 
70% (244 mg, E/Z 45:55). 
6-(2-(2-bromothiophen-3-yl)ethenyl)-2H-chromen-2-one 
(74) was obtained in accordance with general procedure B 
from the reaction of coumarin-6-carboxaldehyde (209 mg, 
1.2 mmol, 1.2 equiv.), 2-bromo-3-(bromomethyl)thiophene (130 µL, 1.0 mmol, 1.0 equiv.), 
diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) 
using PCd (32 mg, 0.1 mmol, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude 
product was purified via flash column chromatography (ethyl acetate/benzene/hexane, 
7:30:63, E-74: Rf = 0.20, Z-74: Rf = 0.30) to afford E-74 as a pale green solid and Z-74 as a 
white solid (303 mg, 91%, E/Z 66:34). E-74: 1H NMR (400 MHz, CDCl3) δ: 6.46 (d, J = 9.6 
Hz, 1H), 6.98 (d, J = 16.4 Hz, 1H), 7.10 (d, J = 16.4 Hz, 1H), 7.23 (d, J = 5.6 Hz, 1H), 7.29 
(dd, J = 5.6 Hz, 0.8 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 
8.4 Hz, 2.0 Hz, 1H), 7.73 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 112.3, 117.2, 
117.5, 119.2, 122.0, 124.6, 125.6, 126.5, 128.5, 129.9, 133.8, 137.8, 143.4, 153.7, 160.7; mp 
195-200 °C. Z-74: 1H NMR (400 MHz, CDCl3) δ: 6.29 (d, J = 9.6 Hz, 1H), 6.38 (d, J = 12.4 
Hz, 1H), 6.48 (d, J = 6.0 Hz, 1H), 6.56 (d, J = 12.0 Hz, 1H), 6.98 (d, J = 5.2 Hz, 1H), 7.11 
(d, J = 8.4 Hz, 1H), 7.25 (d, J = 1.6 Hz, 1H), 7.29 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 7.50 (d, J = 
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9.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 113.2, 116.8, 116.9, 118.7, 123.8, 125.8, 
127.4, 127.9, 129.4, 132.4, 133.5, 136.9, 143.3, 153.2, 160.5; mp 101-105 °C. HRMS [M]+ 
m/z calcd. 331.9507, found 331.9514. 
Isomerization of 74 (233 mg, 0.7 mmol) using iodine (one crystal) was carried out in 
accordance with the general procedure, and E-74 was obtained in 99% yield. 
1-Fluoro-4-(2-(4-(methylsulfonyl)phenyl)ethenyl) 
benzene[22] (75) was obtained in accordance with general 
procedure B from the reaction of 4-(methylsulfonyl) 
benzaldehyde (221 mg, 1.2 mmol, 1.2 equiv.), 4-
fluorobenzyl bromide (125 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 
1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) using PCd (32 mg, 0.1 mmol, 10 
mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude product was purified via flash 
column chromatography (0.5% ethyl acetate in benzene, Rf = 0.28) to afford an isomeric 
mixture of 75 as a white solid (240 mg, 87%, E/Z 66:34). E-75: 1H NMR (400 MHz, CDCl3) 
δ: 3.07 (s, 3H), 7.04 (d, J = 16.4 Hz, 1H), 7.07 (t, J = 8.8 Hz, 2H), 7.20 (d, J = 16.4 Hz, 1H), 
7.51 (dd, J = 8.8 Hz, 5.6 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.91 (d, J = 8.4 Hz, 2H). Z-75: 
1H NMR (400 MHz, CDCl3) δ: 3.05 (s, 3H), 6.58 (d, J = 12.0 Hz, 1H), 6.72 (d, J = 12.0 Hz, 
1H), 6.94 (t, J = 8.4 Hz, 2H), 7.17 (dd, J = 8.4 Hz, 5.6 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 
7.79 (d, J = 8.4 Hz, 2H). 
1-(2-Thienyl)-2-(3,4,5-trimethoxyphenyl)ethene[23] (76) 
was obtained in accordance with general procedure B from 
the reaction of 3,4,5-trimethoxybenzaldehyde (235 mg, 1.2 
mmol, 1.2 equiv.), 2-(chloromethyl)thiophene (133 mg, 1.0 mmol, 1.0 equiv.), 
diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) 
using PCd (32 mg, 0.1 mmol, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude 
product was purified via flash column chromatography (80:20 benzene/hexane, E-76: Rf = 
0.22, Z-76: Rf = 0.32) to afford both E-76 and Z-76 as pale yellow oils (213 mg, 77%, E/Z 
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50:50). E-76: 1H NMR (400 MHz, CDCl3) δ: 3.88 (s, 3H), 3.90 (s, 3H), 3.91 (s, 3H), 6.69 
(d, J = 8.4 Hz, 1H), 7.00 (dd, J = 4.8 Hz, 3.6 Hz, 1H), 7.05 (d, J = 3.6 Hz, 1H), 7.12 (d, J = 
16.0 Hz, 1H), 7.17-7.18 (m, 1H), 7.19 (d, J = 16.4 Hz, 1H), 7.25 (d, J = 9.6 Hz, 1H). Z-76: 
1H NMR (400 MHz, CDCl3) δ: 3.83 (s, 3H), 3.89 (s, 3H), 3.91 (s, 3H), 6.50 (d, J = 11.6 Hz, 
1H), 6.64 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 11.6 Hz, 1H), 6.89 (dd, J = 4.8 Hz, 3.2 Hz, 1H), 
6.98 (d, J = 3.2 Hz, 1H), 7.05-7.08 (m, 2H). 
1,2,3-Trimethoxy-5-(2-(4-
methoxyphenyl)ethenyl)benzene[24] (77) was obtained 
in accordance with general procedure B from the 
reaction of 3,4,5-trimethoxybenzaldehyde (235 mg, 1.2 
mmol, 1.2 equiv.), 4-methoxybenzyl chloride (136 µL, 1.0 mmol, 1.0 equiv.), 
diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and DIPEA (210 µL, 1.2 mmol, 1.2 equiv.) 
using PCd (32 mg, 0.1 mmol, 10 mol %) in toluene (0.33 mL) at 140 °C for 24 h. The crude 
product was purified via flash column chromatography (ethyl acetate/benzene, gradient 0-
2%, E-77: Rf = 0.34, Z-77: Rf = 0.31) to afford E-77 as a light yellow solid and Z-77 as a 
pale yellow oil (225 mg, 75%, E/Z 75:25). E-77: 1H NMR (400 MHz, CDCl3) δ: 3.83 (s, 
3H), 3.87 (s, 3H), 3.91 (s, 6H), 6.72 (s, 2H), 6.90 (br. d, J = 8.8 Hz, 2H), 6.91 (d, J = 16.0 
Hz, 1H), 6.98 (d, J = 16.0 Hz, 1H), 7.45 (br. d, J = 8.8 Hz, 1H). Z-77: 1H NMR (400 MHz, 
CDCl3) δ: 3.69 (s, 6H), 3.79 (s, 3H), 3.85 (s, 3H), 6.42 (d, J = 12.0 Hz, 1H), 6.51 (s, 2H), 
6.52 (d, J = 12.0 Hz, 1H), 6.79 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 8.8 Hz, 2H). 
77 was obtained on a 25.0 mmol scale in accordance with general procedure B from the 
reaction of 3,4,5-trimethoxybenzaldehyde (5.90 g, 30.0 mmol, 1.2 equiv.), 4-methoxybenzyl 
chloride (3.5 mL, 25.0 mmol, 1.0 equiv.), diphenylsilane (5.7 mL, 30.0 mmol, 1.2 equiv.) 
and DIPEA (5.3 mL, 30.0 mmol, 1.2 equiv.) using PCd (790 mg, 0.1 mmol, 10 mol %) in 
toluene (8.30 mL). The reaction was prepared in a 100 mL pressure vessel under an inert 
atmosphere and run at .140 °C for 24 h before purification by dry flash chromatography 
(ethyl acetate/benzene, gradient 0-2%) to afford 77 in 81% yield (6.42 g, E/Z 75:25). 
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Isomerization in accordance with the general procedure produced E-77 in 77% yield (5.78 g, 
19.0 mmol). 
1,2-Diphenylprop-1-ene[25] (78) was obtained in accordance with 
general procedure C from the reaction of acetophenone (117 µL, 
1.0 mmol, 1.0 equiv.), benzyl bromide (160 µL, 1.3 mmol, 1.3 
equiv.), diphenylsilane (279 µL, 1.2 mmol, 1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 
equiv.) using PCb (32 mg, 0.15 mmol, 15 mol %) in toluene (1.0 mL) using the pulse 
olefination technique. The crude product was purified via flash column chromatography 
(hexane, Rf = 0.28) to afford an isomeric mixture of 78 as a white solid (168 mg, 86%, E/Z 
65:35). E-78: 1H NMR (400 MHz, CDCl3) δ: 2.18 (d, J = 1.5 Hz, 3H), 6.74 (br. d, J = 1.2 
Hz, 1H), 6.83-7.44 (m, 5H). Z-78: 1H NMR (400 MHz, CDCl3) δ: 2.10 (d, J = 1.5 Hz, 3H), 
6.37 (br. d, J = 1.3 Hz, 1H), 6.83-7.44 (m, 5H). 
When 78 was prepared in accordance with general procedure E2 using a portion-wise 
addition of organohalide (7 x 0.17 mmol portions added at 1 h intervals) from the reaction 
of benzaldehyde (101 µL, 1.0 mmol, 1.0 equiv.), (1-bromoethyl)benzene (177 µL, 1.3 
mmol, 1.3 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 
mmol, 2.0 equiv.) using PCb (32 mg, 15 mol %) in toluene (1.0 mL) at 110 °C for 24 h the 
yield was 73% (141 mg, E/Z 85:15) 
4-Benzylidenetetrahydro-2H-pyran[26] (79) was obtained in 
accordance with general procedure C from the reaction of tetrahydro-
4H-pyran-4-one (92 µL, 1.0 mmol, 1.0 equiv.), benzyl bromide (160 
µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 1.2 mmol, 1.2 equiv.) and 54 (490 mg, 
3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol %) in toluene (1.0 mL) using 
the pulse olefination technique. The crude product was purified via flash column 
chromatography (benzene/hexane gradient 5-100%, Rf (benzene) = 0.36) to afford 79 as a 
yellow oil (105 mg, 60%). 1H NMR (400 MHz, CDCl3) δ: 2.41 (td, J = 5.6 Hz, 1.3 Hz, 2H), 
2.54 (td, J = 5.6 Hz, 1.3 Hz, 2H), 3.67 (t, J = 5.6 Hz, 2H), 3.80 (t, J = 5.6 Hz, 2H), 6.35 (s, 
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1H), 7.19-7.23 (m, 3H), 7.31-7.35 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 30.7, 37.3, 68.6, 
69.5, 124.0, 126.3, 128.3, 128.9, 137.5, 137.8. 
1-Methoxy-5-methyl-2-phenylhexa-2,4-diene (80) was obtained in 
accordance with general procedure C from the reaction of 2-
methoxyacetophenone (138 µL, 1.0 mmol, 1.0 equiv.), 3,3-
dimethylallyl bromide (150 µL, 1.3 mmol, 1.3 equiv.), 
diphenylsilane (279 µL, 1.2 mmol, 1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using 
PCb (32 mg, 0.15 mmol, 15 mol %) in toluene (1.0 mL) using the pulse olefination 
technique. The crude product was purified via flash column chromatography (benzene in 
hexane, gradient 5-50%, Rf (50% benzene in hexane) = 0.32) to afford an isomeric mixture 
of 80 as a colorless oil (121 mg, 60%, E/Z 60:40). E-80: 1H NMR (600 MHz, CDCl3) δ: 
1.70 (s, 3H), 1.80 (s, 3H), 3.31 (s, 3H), 4.18 (s, 2H), 5.86-5.90 (m, 1H), 6.49 (d, J = 11.3 
Hz, 1H), 7.17-7.48 (m, 5H); 13C NMR (151 MHz, CDCl3) δ: 18.6, 26.5, 57.8, 77.8, 121.7, 
126.2, 127.1, 128.2, 129.0, 135.7, 137.7, 139.1. Z-80: 1H NMR (600 MHz, CDCl3) δ: 1.83 
(s, 3H), 1.86 (s, 3H), 3.33 (s, 3H), 4.42 (s, 2H), 6.26-6.30 (m, 1H), 6.76 (d, J = 11.3 Hz, 
1H), 7.17-7.48 (m, 5H); 13C NMR (151 MHz, CDCl3) δ: 18.6, 26.9, 58.0, 69.2, 121.1, 125.6, 
127.0, 128.2, 128.5, 133.6, 139.4, 142.1. HRMS [M]+ m/z calcd. 202.1358, found 202.1351. 
1-(2,4-Difluorophenyl)-2-(5-methyl-2-furyl)prop-1-ene (81) 
was obtained in accordance with general procedure C from 
the reaction of 2-acetyl-5-methylfuran (116 µL, 1.0 mmol, 1.0 
equiv.), 2,4-difluorobenzyl bromide (167 µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 
1.2 mmol, 1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 
mmol, 15 mol %) in toluene (1.0 mL) using the pulse olefination technique. The crude 
product was purified via flash column chromatography (pentane, Rf = 0.30) to afford an 
isomeric mixture of 81 as a colorless oil (162 mg, 69%, E/Z 55:45). E-81: 1H NMR (600 
MHz, CDCl3) δ: 2.06 (br. t, J = 1.1 Hz, 3H), 2.36 (s, 3H), 6.02-6.04 (m, 1H), 6.31 (d, J = 
3.4 Hz, 1H), 6.82-6.90 (m, 2H), 6.97 (br. s, 1H), 7.28-7.33 (m, 1H); 13C NMR (151 MHz, 
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CDCl3) δ: 13.8, 14.9, 103.9 (t, JCF = 25.9 Hz), 107.6, 108.2, 110.9 (dd, JCF = 20.9 Hz, 4.4 
Hz), 114.4 (d, JCF = 2.2 Hz), 121.8 (dd, JCF = 14.3 Hz, 4.4 Hz), 128.4, 131.4 (dd, JCF = 8.8 
Hz, 5.5 Hz), 152.4, 154.1, 160.4 (dd, JCF = 220.2 Hz, 12.1 Hz), 161.9 (dd, JCF = 216.8, 11.0 
Hz); 19F NMR (376 MHz, CDCl3) δ: -109.8 (d, J = 8.0 Hz, 1F), -110.7 (d, J = 8.0 Hz, 1F). 
Z-81: 1H NMR (600 MHz, CDCl3) δ: 2.16 (s, 3H), 2.18 (s, 3H), 5.91-5.93 (m, 1H), 6.10 (d, 
J = 3.4 Hz, 1H), 6.18 (br. s, 1H), 6.76-6.80 (m, 2H), 7.22-7.27 (m, 1H); 13C NMR (151 
MHz, CDCl3) δ: 13.5, 22.3, 103.4 (t, JCF = 25.9 Hz), 107.2, 110.4, 110.5 (dd, JCF = 20.9 Hz, 
3.3 Hz), 116.5 (d, JCF = 2.2 Hz), 122.5 (dd, JCF = 15.4 Hz, 4.4 Hz), 128.6, 131.8 (dd, JCF = 
9.9 Hz, 5.5 Hz), 151.8, 152.0, 160.3 (dd, JCF = 218.0 Hz, 12.1 Hz), 162.0 (dd, JCF = 216.9 
Hz, 12.1 Hz); 19F NMR (376 MHz, CDCl3) δ: -112.0 (d, J = 6.8 Hz, 1F), -112.3 (d, J = 6.8 
Hz, 1F). HRMS [M]+ m/z calcd. 234.0856, found 234.0865. 
1-(2,4-Difluorophenyl)-2-methylhexa-1,5-diene (82) was 
obtained in accordance with general procedure C from the 
reaction of 5-hexen-2-one (116 µL, 1.0 mmol, 1.0 equiv.), 2,4-
difluorobenzyl bromide (167 µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 1.2 mmol, 
1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol 
%) in toluene (1.0 mL) using the pulse olefination technique. The crude product was 
purified via flash column chromatography (hexane, Rf = 0.36) to afford an isomeric mixture 
of 82 as a colorless oil (133 mg, 64%, E/Z 68:32). E-82: 1H NMR (400 MHz, CDCl3) δ: 
1.76 (br. t, J = 1.3 Hz, 3H), 2.27-2.31 (m, 4H), 4.97-5.11 (m, 2H), 5.79-5.93 (m, 1H), 6.16 
(s, 1H), 6.75-6.85 (m, 2H), 7.10-7.22 (m, 1H); 13C NMR (100 MHz, CDCl3) δ: 18.0, 32.3, 
39.6, 103.7 (t, JCF = 25.9 Hz), 110.7 (dd, JCF = 20.9, 4.4 Hz), 114.9, 117.0 (d, JCF = 2.2 Hz), 
122.4 (dd, JCF = 15.4 Hz, 4.4 Hz), 131.5 (dd, JCF = 8.8, 5.5 Hz), 138.2, 141.1, 160.2 (dd, JCF 
= 248.8, 12.1 Hz), 161.6 (dd, JCF = 247.6, 12.1 Hz); 19F NMR (376 MHz, CDCl3) δ: -110.9 
(d, J = 6.9 Hz, 1F), -112.8 (d, J = 6.8 Hz, 1F). Z-82: 1H NMR (400 MHz, CDCl3) δ: 1.91 (d, 
J = 1.5 Hz, 3H), 2.20-2.22 (m, 4H), 4.93-5.06 (m, 2H), 5.71-5.81 (m, 1H), 6.16 (s, 1H), 
6.75-6.85 (m, 2H), 7.10-7.22 (m, 1H); 13C NMR (100 MHz, CDCl3) δ: 23.6, 32.0, 32.2, 
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103.8 (t, JCF = 25.3 Hz), 110.8 (dd, JCF = 20.9 Hz, 3.3 Hz), 114.9, 117.8 (d, JCF = 2.2 Hz), 
122.2 (dd, JCF = 15.4 Hz, 4.4 Hz), 131.3 (dd, JCF = 8.8 Hz, 5.5 Hz), 138.1, 141.4, 160.2 (dd, 
JCF = 246.6 Hz, 12.1 Hz), 161.7 (dd, JCF = 247.6 Hz, 12.1 Hz); 19F NMR (376 MHz, CDCl3) 
δ: -111.0 (d, J = 6.9 Hz, 1F), -112.9 (d, J = 6.9 Hz, 1F). HRMS [M]+ m/z calcd. 208.1064, 
found 208.1063.  
5,9-Dimethyl-2-(1,3-thiazol-2-yl)-deca-2,4,8-triene (83) 
was obtained in accordance with general procedure C 
from the reaction of 2-acetylthiazole (104 µL, 1.0 mmol, 
1.0 equiv.), geranyl bromide (258 µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 1.2 
mmol, 1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 mmol, 15 
mol %) in toluene (1.0 mL) using the pulse olefination technique. The crude product was 
purified via flash column chromatography (benzene/hexane, gradient 5-50%, Rf (50% 
benzene in hexane) = 0.23) to afford an isomeric mixture of 83 as a yellow oil (178 mg, 
72%, E/Z 63:37). E-83: 1H NMR (600 MHz, CDCl3) δ: 1.63 (s, 3H), 1.71 (s, 3H), 1.91 (br. 
d, J = 0.8 Hz, 3H), 2.16-2.21 (m, 4H), 2.26 (br. d, J = 0.7 Hz, 3H), 5.10-5.15 (m, 1H), 6.23 
(dd, J = 11.3 Hz, 1.1 Hz, 1H), 7.16 (d, J = 3.4 Hz, 1H), 7.28 (dd, J = 11.7 Hz, 1.5 Hz, 1H), 
7.75 (d, J = 3.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 15.1, 17.2, 17.8, 25.7, 26.6, 40.7, 
117.3, 120.8, 123.8, 126.8, 127.7, 131.9, 143.1, 144.1, 172.3. Z-83: 1H NMR (600 MHz, 
CDCl3) δ: 1.62 (s, 3H), 1.69 (s, 3H), 1.86 (s, 3H), 2.10-2.37 (m, 4H), 2.31 (s, 3H), 5.12-5.19 
(m, 1H), 6.58 (dd, J = 11.7 Hz, 1.1 Hz, 1H), 6.96 (d, J = 11.6 Hz, 1H), 7.29 (d, J = 3.4 Hz, 
1H), 7.85 (d, J = 3.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 17.0, 17.8, 24.5, 25.8, 26.7, 
40.6, 118.3, 122.0, 124.0, 126.0, 128.4, 131.8, 142.8, 143.9, 167.9. HRMS [M+H]+ m/z 
calcd. 248.1473, found 248.1469. 
83 was obtained on a 25.0 mmol scale according to general procedure C from the reaction 
of 2-acetylthiazole (3.7 mL, 35.0 mmol, 1.0 equiv.), geranyl bromide (9.9 mL, 47.3 mmol 
1.35 equiv.), diphenylsilane (9.8 mL, 51.2 mmol, 1.5 equiv.) and 54 (17.20 g, 122.5 mmol, 
3.5 equiv.) using PCb (1.14 g, 5.3 mmol, 15 mol %) in toluene (35 mL). The reaction was 
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prepared in a 100 mL pressure vessel under an inert atmosphere and run at 110 °C for 24 h 
before purification by dry flash chromatography (benzene/hexane, gradient 10-100%) to 
afford 83 in 68% yield (5.89 g, E/Z 75:25).  
2-(2-Chlorophenyl)-5-methylhexa-2,4-diene (84) was obtained in 
accordance with general procedure C from the reaction of 2’-
chloroacetophenone (130 µL, 1.0 mmol, 1.0 equiv.), 3,3-
dimethylallyl bromide (150 µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 1.2 mmol, 
1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol 
%) in toluene (1.0 mL) using the pulse olefination technique. The crude product was 
purified via flash column chromatography (hexane, Rf = 0.38) to afford an isomeric mixture 
of 84 as a yellow oil (143 mg, 69%, E/Z 70:30). E-84: 1H NMR (400 MHz, CDCl3) δ: 1.81 
(s, 3H), 1.91 (s, 3H), 2.14 (s, 3H), 6.16-6.21 (m, 1H), 6.27 (br. dq, J = 11.4 Hz, 1.3 Hz, 1H), 
7.13-7.29 (m, 3H), 7.36-7.39 (m, 1H); 13C NMR (100 MHz, CDCl3) δ: 17.8, 18.5, 26.7, 
121.3, 126.6, 126.7, 127.9, 129.7, 130.2, 132.5, 133.7, 136.8, 144.7. Z-84: 1H NMR (400 
MHz, CDCl3) δ: 1.69 (s, 3H), 1.82 (s, 3H), 2.11 (s, 3H), 5.42-5.47 (m, 1H), 6.40 (br. dq, J = 
11.4 Hz, 1.3 Hz, 1H), 7.13-7.29 (m, 3H), 7.41-7.44 (m, 1H); 13C NMR (100 MHz, CDCl3) 
δ: 18.4, 24.8, 26.3, 122.0, 125.0, 126.8, 128.2, 129.6, 130.7, 132.7, 134.0, 134.7, 141.1. 
HRMS [M]+ m/z calcd. 206.0862, found 206.0867. 
5,9-Dimethyl-2-phenyldeca-2,4,8-triene[27] (85) was 
obtained in accordance with general procedure C from 
the reaction of acetophenone (117 µL, 1.0 mmol,  1.0 
equiv.), geranyl bromide (258 µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 1.2 mmol, 
1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol 
%) in toluene (1.0 mL) using the pulse olefination technique. The crude product was 
purified via flash column chromatography (hexane, Rf = 0.34) to afford an isomeric mixture 
of 85 as a colorless oil (195 mg, 81%, E/Z 55:45). E-85: 1H NMR (400 MHz, CDCl3) δ: 
1.63 (s, 3H), 1.70 (s, 3H), 1.84 (s, 3H), 1.95-2.20 (m, 4H), 2.15 (s, 3H), 5.14 (m, 1H), 6.21 
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(dd, J = 7.5 Hz, 0.8 Hz, 1H), 6.63 (dd, J = 7.5 Hz, 0.8 Hz, 1H), 7.20-7.50 (m, 5H). Z-85: 1H 
NMR (400 MHz, CDCl3) δ: 1.54 (s, 3H), 1.66 (s, 3H), 1.79 (s, 3H), 1.95-2.20 (m, 4H), 2.13 
(s, 3H), 5.04 (tt, J = 4.2 Hz, 0.8 Hz, 1H), 6.21 (dd, J = 7.5 Hz, 0.8 Hz, 1H), 6.63 (dd, J = 7.5 
Hz, 0.8, 1H), 7.20-7.50 (m, 5H). 
Benzyl 4-(2,4-difluorobenzylidene) piperidine-1-
carboxylate (86) was obtained in accordance with 
general procedure C from the reaction of 2-acetyl-5-
methylfuran (116 µL, 1.0 mmol, 1.0 equiv.), 2,4-
difluorobenzyl bromide (167 µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 1.2 mmol, 
1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 mmol, 15 mol 
%) in toluene (1.0 mL) using the pulse olefination technique. The crude product was 
purified via flash column chromatography (benzene, Rf = 0.30) to afford 86 as a colorless 
oil (299 mg, 87%). 1H NMR (400 MHz, CDCl3) δ: 2.25-2.45 (m, 4H), 3.51 (t, J = 5.8 Hz, 
2H), 3.61 (t, J = 5.8 Hz, 2H), 5.17 (s, 2H), 6.22 (s, 1H), 6.76-6.88 (m, 2H), 7.12 (q, J = 7.8 
Hz, 1H), 7.29-7.41 (m, 5H); 13C NMR (100 MHz, CDCl3) δ: 44.7, 45.6, 67.2, 103.9 (t, JCF = 
25.5 Hz), 110.9 (dd, JCF = 21.1 Hz, 3.6 Hz), 116.6 (d, JCF = 1.5 Hz), 121.0 (dd, JCF = 15.3 
Hz, 3.6 Hz), 128.0, 128.1, 128.6, 131.5 (dd, JCF = 9.5 Hz, 5.1 Hz), 134.3-134.7 (m, 2C), 
136.8, 140.6, 155.3, 160.1 (dd, JCF = 247.3 Hz, 11.6 Hz), 161.8 (dd, JCF = 247.3 Hz, 11.6 
Hz); 19F NMR (376 MHz, CDCl3) δ: -110.3 (d, J = 43.5 Hz, 1F), -110.7 (br. s, 1F). HRMS 
[M+H]+ m/z calcd. 344.1462, found 344.1457. 
2-(1-(3-Methoxyphenyl)prop-1-en-2-yl]-1,3-thiazole (87) 
was obtained in accordance with general procedure C from 
the reaction of 2-acetylthiazole (104 µL, 1.0 mmol, 1. 0 
equiv.), 3-methoxybenzyl bromide (182 µL, 1.3 mmol, 1.3 equiv.), diphenylsilane (279 µL, 
1.2 mmol, 1.2 equiv.) and 54 (490 mg, 3.5 mmol, 3.5 equiv.) using PCb (32 mg, 0.15 
mmol, 15 mol %) in toluene (1.0 mL) using the pulse olefination technique. The crude 
product was purified via flash column chromatography (benzene, Rf = 0.26) to afford an 
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isomeric mixture of 87 as a yellow oil (178 mg, 77%, E/Z 65:35). E-87: 1H NMR (600 
MHz, CDCl3) δ: 2.44 (s, 3H), 3.83 (s, 3H), 6.85 (dd, J = 8.6 Hz, 2.6 Hz, 1H), 6.96 (br. s, 
1H), 7.02 (d, J = 7.5 Hz, 1H), 7.25 (br. s, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.48 (br. s, 1H), 7.81 
(d, J = 3.4 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ: 16.8, 55.3, 113.2, 115.0, 118.4, 122.0, 
129.4, 130.8, 131.9, 138.0, 143.3, 159.6, 171.9. Z-87: 1H NMR (600 MHz, CDCl3) δ: 2.37 
(s, 3H), 3.71 (s, 3H), 6.71 (br. s, 1H), 6.76 (d, J = 7.5 Hz, 1H), 6.82 (dd, J = 8.3 Hz, 2.6 Hz, 
1H), 6.84 (br. s, 1H), 7.48 (br. d, J = 2.6 Hz, 1H), 7.21 (t, J = 7.9 Hz, 1H), 7.75 (d, J = 3.4 
Hz, 1H); 13C NMR (151 MHz, CDCl3) δ: 24.4, 55.2, 113.7, 114.1, 119.9, 121.5, 129.7, 
131.5, 132.0, 138.3, 142.0, 159.8, 167.0. HRMS [M+H]+ m/z calcd. 232.0796, found 
232.0804. 
1-(4-Chlorophenyl)-3-phenylprop-1-ene[28] (88) was 
obtained in accordance with general procedure D from the 
reaction of 4-chlorobenzaldehyde (169 mg, 1.2 mmol, 1.2 
equiv.), (2-iodoethyl)benzene (145 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 
mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCd (63 mg, 20 mol %) in 
toluene (1.4 mL) at 140 °C for 48 h. An additional portion of 54 (210 mg, 1.5 mmol, 1.5 
equiv.) was added at 24 h. The crude product was purified via flash column chromatography 
(hexane, Rf = 0.45) to afford an isomeric mixture of 88 as a colorless liquid (166 mg, 73%, 
E/Z 55:45). E-88: 1H NMR (400 MHz, CDCl3) δ: 3.54 (d, J = 6.0 Hz, 2H), 6.33 (dt, J = 16.0 
Hz, 6.0 Hz, 1H), 6.40 (d, J = 16.0 Hz, 1H), 7.21-7.34 (m, 9H). Z-88: 1H NMR (400 MHz, 
CDCl3) δ: 3.64 (d, J = 7.6 Hz, 2H), 5.89 (dt, J = 11.6 Hz, 7.6 Hz, 1H), 6.54 (d, J = 11.6 Hz, 
1H), 7.18-7.34 (m, 9H).  
When 88 was prepared in accordance with general procedure D from the reaction of 4-
chlorobenzaldehyde (169 mg, 1.2 mmol, 1.2 equiv.), (2-iodoethyl)benzene (145 µL, 1.0 
mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (490 mg, 3.5 
mmol, 3.5 equiv.) using PCm (47 mg, 20 mol %) in toluene (1.4 mL) at 140 °C for 48 h, 
yield was 63% (144 mg, E/Z 75:25). 
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5-(4,8-Dimethylnona-1,7-dien-1-yl)-1,3-
benzodioxole (89) was obtained in accordance with 
general procedure D from the reaction of piperonal 
(180 mg, 1.2 mmol, 1.2 equiv.), 8-iodo-2,6-dimethyl-oct-2-ene (266 mg, 1.0 mmol, 1.0 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCd (63 mg, 20 mol %) in toluene (1.4 mL) at 140 °C for 48 h. An additional 
portion of 54 (210 mg, 1.5 mmol, 1.5 equiv.) was added at 24 h. The crude product was 
purified via flash column chromatography (8% benzene in hexane, Rf = 0.34) to afford an 
isomeric mixture of 89 as a colorless liquid (144 mg, 53%, E/Z 55:45). E-89: 1H NMR (400 
MHz, CDCl3) δ: 0.97 (d, J = 6.8 Hz, 3H), 1.18-1.51 (m, 3H), 1.66 (s, 3H), 1.76 (s, 3H), 
1.98-2.40 (m, 4H), 4.71-4.74 (m, 1H), 5.94 (s, 2H), 6.08 (dt, J = 15.6 Hz, 7.2 Hz, 1H), 6.32 
(d, J = 15.6 Hz, 1H), 6.75-7.00 (m, 3H); 13C NMR (100 MHz, CDCl3) δ: 17.7, 19.6, 25.7, 
25.8, 33.1, 36.8, 40.5, 101.0, 105.5, 108.2, 121.1, 124.9, 127.9, 130.6, 131.2, 132.6, 146.6, 
148.0. Z-89: 1H NMR (400 MHz, CDCl3) δ: 0.97 (d, J = 6.8 Hz, 3H), 1.18-1.51 (m, 3H), 
1.64 (s, 3H), 1.73 (s, 3H), 1.98-2.40 (m, 4H), 5.14-5.16 (m, 1H), 5.63 (dt, J = 11.6 Hz, 7.2 
Hz, 1H), 5.96 (s, 2H), 6.39 (d, J = 11.6 Hz, 1H), 6.75-7.00 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ: 17.7, 19.7, 25.7, 25.8, 33.5, 35.8, 36.9, 100.9, 108.1, 109.1, 120.3, 122.6, 124.9, 
129.1, 130.8, 132.1, 146.1, 147.5. HRMS [M]+ m/z calcd. 272.1776, found 272.1770. 
1-Methoxy-4-(prop-1-en-1-yl)benzene[29] (90) was obtained in 
accordance with general procedure D from the reaction of 4-
anisaldehyde (122 µL, 1.0 mmol, 1.0 equiv.), iodoethane (80 µL, 
1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 
mmol, 2.0 equiv.) using PCd (63 mg, 20 mol %) in toluene (1.4 mL) at 150 °C for 48 h. 
Additional portions of 54 (210 mg, 1.5 mmol, 1.5 equiv.) and iodoethane (80 µL, 1.0 mmol, 
1.0 equiv.) were added at 24 h. The crude product was purified via flash column 
chromatography (gradient 5-10% benzene in hexane, Rf (7% benzene in hexane) = 0.31) to 
afford an isomeric mixture of 90 as a colorless liquid (94 mg, 63%, E/Z 55:45). E-90: 1H 
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NMR (400 MHz, CDCl3) δ: 1.90 (dd, J = 6.4 Hz, 1.6 Hz, 3H), 3.83 (s, 3H), 6.14 (dq, J = 
15.6 Hz, 6.8 Hz, 1H), 6.37-6.43 (m, 1H), 6.88 (d, J = 8.4 Hz, 2H), 7.27-7.31 (m, 2H). Z-90: 
1H NMR (400 MHz, CDCl3) δ: 1.94 (dd, J = 7.2 Hz, 1.6 Hz, 3H), 3.85 (s, 3H), 5.75 (dq, J = 
11.6 Hz, 6.8 Hz, 1H), 6.37-6.43 (m, 1H), 6.93 (d, J = 8.4 Hz, 2H), 7.27-7.31 (m, 2H). 
5,9-Dimethyl-1-phenyl-2,8-decadiene (91) was 
obtained in accordance with general procedure D 
from the reaction of (±)-citronellal (216 µL, 1.2 mmol, 
1.2 equiv.), (2-iodoethyl)benzene (145 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 
1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCd (63 mg, 20 mol %) 
in toluene (1.4 mL) at 140 °C for 48 h. An additional portion of 54 (210 mg, 1.5 mmol, 1.5 
equiv.) was added at 24 h. The crude product was purified via flash column chromatography 
(hexane, Rf = 0.82) to afford an isomeric mixture of 91 as a colorless liquid (121 mg, 50%, 
E/Z 60:40). E-91: 1H NMR (400 MHz, CDCl3) δ: 0.96 (d, J = 6.8 Hz, 3H), 1.19-1.61 (m, 
3H), 1.65 (s, 3H), 1.73 (s, 3H), 1.88-2.24 (m, 4H), 3.44 (d, J = 7.2 Hz, 2H), 5.13-5.17 (m, 
1H), 5.53-5.68 (m, 2H), 7.20-7.36 (m, 5H); 13C NMR (100 MHz, CDCl3) δ: 17.8, 19.7, 25.8, 
25.9, 33.2, 33.7, 34.6, 37.0, 125.0, 125.9, 128.5, 128.5, 129.0, 129.7, 131.3, 141.4. Z-91: 1H 
NMR (400 MHz, CDCl3) δ: 0.92 (d, J = 6.4 Hz, 3H), 1.19-1.61 (m, 3H), 1.64 (s, 3H), 1.73 
(s, 3H), 1.88-2.24 (m, 4H), 3.39 (d, J = 7.2 Hz, 2H), 5.13-5.17 (m, 1H), 5.58-5.68 (m, 2H), 
7.20-7.36 (m, 5H); 13C NMR (100 MHz, CDCl3) δ: 17.8, 19.6, 25.7, 25.9, 32.9, 33.5, 34.7, 
36.8, 125.0, 126.0, 127.0, 128.5, 130.1, 130.7, 131.2, 141.2. HRMS [M]+ m/z calcd. 
242.2035, found 242.2033. 
5-(Prop-1-en-1-yl)-1,3-benzodioxole[30] (92) was obtained in 
accordance with general procedure D from the reaction of piperonal 
(150 mg, 1.0 mmol, 1.0 equiv.), iodoethane (80 µL, 1.0 mmol, 1.0 
equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCd (63 mg, 20 mol %) in toluene (1.4 mL) at 150 °C for 48 h. Additional 
portions of 54 (210 mg, 1.5 mmol, 1.5 equiv.) and iodoethane (80 µL, 1.0 mmol, 1.0 equiv.) 
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were added at 24 h. The crude product was purified via flash column chromatography (5% 
benzene in hexane, Rf = 0.34) to afford an isomeric mixture of 92 as a colorless liquid (111 
mg, 68%, E/Z 60:40). E-92: 1H NMR (400 MHz, CDCl3) δ: 1.86 (dd, J = 6.8 Hz, 1.6 Hz, 
3H), 5.94 (s, 2H), 6.07 (dq, J = 16.0 Hz, 6.8 Hz, 1H), 6.23-6.36 (m, 1H), 6.73-6.89 (m, 3H). 
Z-92: 1H NMR (400 MHz, CDCl3) δ: 1.89 (dd, J = 7.2 Hz, 2.0 Hz, 3H), 5.71 (dq, J = 11.6 
Hz, 7.2 Hz, 1H), 5.96 (s, 2H), 6.23-6.36 (m, 1H), 6.73-6.89 (m, 3H).  
5-(3-phenylprop-1-en-1-yl)-1,3-benzodioxole (93) was 
obtained in accordance with general procedure D from the 
reaction of piperonal (180 mg, 1.2 mmol, 1.2 equiv.), (2-
iodoethyl)benzene (145 µL, 1.0 mmol, 1.0 equiv.), diphenylsilane (223 µL, 1.2 mmol, 1.2 
equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCd (63 mg, 20 mol %) in toluene (1.4 
mL) at 140 °C for 48 h. An additional portion of 54 (210 mg, 1.5 mmol, 1.5 equiv.) was 
added at 24 h. The crude product was purified via flash column chromatography 
(hexane/benzene, 80:20, Rf = 0.33) to afford an isomeric mixture of 93 as a pale yellow 
liquid (179 mg, 75%, E/Z 60:40). E-93: 1H NMR (400 MHz, CDCl3) δ: 3.57 (d, J = 6.8 Hz, 
2H), 5.96 (s, 2H), 6.24 (dt, J = 16.0 Hz, 6.8 Hz, 1H), 6.42 (d, J = 16.0 Hz, 1H), 6.78-6.86 
(m, 2H), 6.97 (br. s, 1H), 7.25-7.39 (m, 5H); 13C NMR (100 MHz, CDCl3) δ: 39.3, 101.0, 
108.3, 120.7, 126.3, 127.6, 128.6, 128.7, 130.7, 132.1, 134.4, 140.4, 146.9, 148.9. Z-93: 1H 
NMR (400 MHz, CDCl3) δ: 3.72 (d, J = 7.6 Hz, 2H), 5.84 (dt, J = 11.6 Hz, 7.6 Hz, 1H), 
5.98 (s, 2H), 6.55 (d, J = 11.6 Hz, 1H), 6.78-6.86 (m, 2H), 6.90 (br. s, 1H), 7.25-7.39 (m, 
5H); 13C NMR (100 MHz, CDCl3) δ: 34.8, 108.3, 109.0, 122.5, 126.2, 128.4, 128.6, 129.6, 
129.8, 130.2, 131.4, 140.9, 146.5, 147.6. HRMS [M]+ m/z calcd. 238.0994, found 238.0997. 
Methyl (2E)-3-phenylprop-2-enoate[31] (94) was obtained in 
accordance with general procedure F from the reaction of 
benzaldehyde (100 µL, 1.0 mmol, 1.0 equiv.), methyl bromoacetate (105 µL, 1.1 mmol, 1.1 
equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) 
using PCb (21 mg, 0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. The crude 
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product was purified via flash column chromatography (6% diethyl ether/hexane, Rf = 0.31) 
to afford 94 as a white solid (140 mg, 86%, E/Z >95:5). 1H NMR (400 MHz, CDCl3) δ: 3.75 
(s, 3H), 6.41 (d, J = 16.0 Hz, 1H), 7.32-7.33 (m, 3H), 7.45-7.47 (m, 2H), 7.66 (d, J = 16.0 
Hz, 1H). 
3-Phenylprop-2-enenitrile[32]  (95) was obtained in accordance with 
general procedure F from the reaction of benzaldehyde (100 µL, 1.0 
mmol, 1.0 equiv.), bromoacetonitrile (86 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 µL, 5.0 
mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCb (21 mg, 0.1 mmol, 
10 mol %) in 2-methyl THF (1.0 mL) at 100 °C for 24 h. The crude product was purified via 
flash column chromatography (6% diethyl ether/hexane, E-95: Rf = 0.23, Z-95: Rf = 0.26) to 
afford both E-95 and Z-95 as colorless oils (97 mg, 75%, E/Z 70:30). E-95: 1H NMR (500 
MHz, CDCl3) δ: 5.88 (d, J = 16.7 Hz, 1H), 7.39-7.46 (m, 6H). Z-95: 1H NMR (500 MHz, 
CDCl3) δ: 5.45 (d, J = 12.4 Hz, 1H), 7.13 (d, J = 12.4 Hz, 1H), 7.44-7.45 (m, 3H), 7.80-7.81 
(m, 2H). 
 3-(4-Chlorophenyl)acrylate[32] (96) was obtained in accordance 
with general procedure F from the reaction of 4-
chlorobenzaldehyde (141 mg, 1.0 mmol, 1.0 equiv.), 
bromoacetonitrile (86 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and 
DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCg (16 mg, 0.1 mmol, 10 mol %) in 2-
methyl THF (1.0 mL) at 100 °C for 24 h. The crude product was purified via flash column 
chromatography (6% diethyl ether/hexane, Rf = 0.28) to afford an isomeric mixture of 96 as 
a colorless oil (138 mg, 70%, E/Z 80:20). E-96: 1H NMR (400 MHz, CDCl3) δ: 5.86 (d, J = 
16.8 Hz, 1H), 7.33-7.41 (m, 5H). Z-96: 1H NMR (400 MHz, CDCl3) δ: 5.47 (d, J = 12.0 Hz, 
1H), 7.08 (d, J = 12.0 Hz, 1H), 7.33-7.41 (m, 2H), 7.74 (d, J = 8.8 Hz, 2H). 
 Methyl (2E)-3-(4-chlorophenyl)-2-methylprop-2-
enoate[33] (97) was obtained in accordance with general 
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procedure F from the reaction of 4-chlorobenzaldehyde (141 mg, 1.0 mmol, 1.0 equiv.), 
methyl 2-bromopropionate (145 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 
equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCg (16 mg, 0.1 mmol,10 mol %) 
in CPME (1.0 mL) at 100 °C for 24 h. The crude product was purified via flash column 
chromatography (5% ethyl acetate in hexane, Rf = 0.33) to afford an isomeric mixture of 97 
as a colorless liquid (188 mg, 89%, E/Z 88:12). E-97: 1H NMR (400 MHz, CDCl3) δ: 2.08 
(d, J = 1.5 Hz, 3H), 3.80 (s, 3H), 7.29-7.35 (m, 4H), 7.61 (br. s, 1H). Z-97: 1H NMR (400 
MHz, CDCl3) δ: 2.10 (s, 3H), 3.66 (s, 3H), 6.65 (br s, 1H), 7.16 (d, J = 8.8 Hz, 2H), 7.27 (d, 
J = 8.8 Hz, 2H). 
Methyl (2E)-5,9-dimethyldeca-2,8-dienoate[34] (98) 
was obtained in accordance with general procedure F 
from the reaction of (±)-citronellal (180 µL, 1.0 mmol, 
1.0 equiv.), methyl bromoacetate (125 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 µL, 5.0 
mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCb (21 mg, 0.1 mmol, 
10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. The crude product was purified via flash 
column chromatography (pentane/benzene, 70:30, Rf = 0.17) to afford 98 as a colorless oil 
(189 mg, 90%, E/Z 92:8). E-98: 1H NMR (400 MHz, CDCl3) δ: 0.90 (d, J = 6.9 Hz, 3H), 
1.14-1.21 (m, 1H), 1.31-1.38 (m, 1H), 1.56-1.70 (m, 1H), 1.59 (s, 3H), 1.67 (s, 3H), 1.90-
2.06 (m, 3H), 2.18-2.23 (m, 1H), 3.72 (s, 3H), 5.07 (t, J = 7.1 Hz, 1H), 5.81 (d, J = 15.6 Hz, 
1H), 6.91-6.97 (m, 1H).  
 Methyl 2-benzylidenebutanoate[35] (99) was obtained in 
accordance with general procedure F from the reaction of 
benzaldehyde (100 µL, 1.0 mmol, 1.0 equiv.), methyl 2-
bromobutyrate (150 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and 
DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCb (21 mg, 0.1 mmol, 10 mol %) in CPME 
(1.0 mL) at 100 °C for 24 h. The crude product was purified via flash column 
chromatography (5% diethyl ether/hexane, Rf = 0.33) to afford an isomeric mixture of 99 as 
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a colorless oil (188 mg, 99%, E/Z 75:25). E-99: 1H NMR (400 MHz, CDCl3) δ: 1.20 (t, J = 
7.6 Hz, 3H), 2.57 (q, J = 7.6 Hz, 2H), 3.82 (s, 3H), 7.23-7.42 (m, 5H), 7.68 (s, 1H). Z-99:  
1H NMR (400 MHz, CDCl3) δ: 1.16 (t, J = 7.6 Hz, 3H), 2.47 (qd, J = 7.6, 1.6 Hz, 2H), 3.66 
(s, 3H), 6.63 (br s, 1H), 7.23-7.42 (m, 5H). 
 (3E, 5E)-3-Methyl-6-phenylhexa-3,5-dien-2-one (100) was 
obtained in accordance with general procedure F from the 
reaction of trans-cinnamaldehyde (126 µL, 1.0 mmol, 1.0 
equiv.), 3-bromobutan-2-one (138 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 
equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCg (16 mg, 0.1 mmol, 10 mol %) 
in CPME (1.0 mL) at 100 °C for 24 h. The crude product was purified via flash column 
chromatography (pentane/benzene/diethyl ether, 63:30:7, Rf = 0.31) to afford 100 as a pale 
yellow solid (157 mg, 84%, E/Z >95:5). 1H NMR (600 MHz, CDCl3) δ: 1.99 (d, J = 1.2 Hz, 
3H), 2.39 (s, 3H), 6.91 (d, J = 15.0 Hz, 1H), 7.11-7.16 (m, 1H), 7.20 (dd, J = 11.4 Hz, 1.2 
Hz, 1H), 7.30-7.32 (m, 1H), 7.35-7.38 (br. t, J = 7.2 Hz, 2H), 7.50 (br. d, J = 7.2 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ: 11.7, 25.6, 124.4, 127.1, 128.8, 128.9, 136.3, 136.4, 139.3, 
139.6, 199.4; HRMS [M]+: m/z calcd. 186.1045, found 186.1043. 
Methyl 3-(4-bromo-2-thienyl)-2-methylprop-2-enoate (101) 
was obtained in accordance with general procedure F from the 
reaction of 4-bromothiophene-2-carboxaldehyde (212 mg, 1.0 
mmol, 1.0 equiv.), methyl 2-bromopropionate (145 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 
µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCb (21 mg, 
0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. The crude product was purified 
via flash column chromatography (pentane/benzene, 60:40, E-101: Rf = 0.37, Z-101: Rf = 
0.26) to afford E-101 and Z-101 as yellow solids (259 mg, 99%, E/Z 75:25). E-101: 1H 
NMR (400 MHz, CDCl3) δ: 2.16 (d, J = 0.8 Hz, 3H), 3.79 (s, 3H), 7.14 (s, 1H), 7.34 (s, 1H), 
7.69 (br. s, 1H); 13C NMR (100 MHz, CDCl3) δ: 14.4, 52.4, 110.9, 126.0, 126.6, 130.2, 
133.2, 140.2, 168.5. Z-101: 1H NMR (400 MHz, CDCl3) δ: 2.02 (d, J = 1.2 Hz, 3H), 3.74 (s, 
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3H), 6.75 (s, 1H), 7.04 (s, 1H), 7.18 (br. d, J = 1.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 
21.8, 52.0, 109.4, 125.4, 126.6, 130.3, 134.4, 139.2, 168.2; HRMS [M]+: m/z calcd. 
259.9507, found 259.9513. 
  
Methyl 3-(2-furyl)-2-methylprop-2-enoate[36] (102) was obtained 
in accordance with general procedure F from the reaction of 
furfural (83 µL, 1.0 mmol, 1.0 equiv.), methyl 2-bromopropionate 
(145 µL, 1.3 mmol, 1.3 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 
1.3 mmol, 1.3 equiv.) using PCg (16 mg, 0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 
°C for 24 h. The crude product was purified via flash column chromatography (5% diethyl 
ether/hexane, Rf = 0.33) to afford an isomeric mixture of 102 as a brown oil (158 mg, 95%, 
E/Z 75:25). E-102: 1H NMR (400 MHz, CDCl3) δ: 2.20 (s, 3H), 3.76 (s, 3H), 6.45 (dd, J = 
3.4, 1.8 Hz, 1H), 6.57 (d, J = 3.6 Hz, 1H), 7.42 (br. s, 1H), 7.49 (d, J = 1.2 Hz, 1H). Z-102: 
1H NMR (400 MHz, CDCl3) δ: 2.05 (d, J = 0.8 Hz, 3H), 3.77 (s, 3H), 6.38 (dd, J = 3.6, 1.8 
Hz, 1H), 6.49 (br. s, 1H), 6.90 (d, J = 3.6 Hz, 1H), 7.35 (d, J = 1.2 Hz, 1H). 
tert-Butyl 2-(3-methoxy-3-oxoprop-1-en-1-yl)-1H-pyrrole-1-
carboxylate[37] (103) was obtained in accordance with general 
procedure F from the reaction of tert-butyl 2-formyl-1H-pyrrole-1-
carboxylate (195 mg, 1.0 mmol, 1.0 equiv.), methyl bromoacetate (123 µL, 1.3 mmol, 1.3 
equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) 
using PCg (16 mg, 0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. The crude 
product was purified via flash column chromatography (benzene/diethyl ether, 80:20, E-
103: Rf = 0.33, Z-103: Rf = 0.31) to afford both E-103 and Z-103 as brown oils (177 mg, 
70%, E/Z 42:58). E-103: 1H NMR (400 MHz, CDCl3) δ: 1.62 (s, 9H), 3.76 (s, 3H), 6.20 (t, J 
= 3.2 Hz, 1H), 6.21 (d, J = 16.0 Hz, 1H), 6.69 (br. d, J = 3.2 Hz, 1H), 7.38 (dd, J = 3.6, 2.0 
Hz, 1H), 8.30 (d, J = 16.0 Hz, 1H). Z-103: 1H NMR (400 MHz, CDCl3) δ: 1.59 (s, 9H), 3.71 
CO2MeO
102 
CO2MeN
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(s, 3H), 5.78 (d, J = 12.8 Hz, 1H), 6.23 (dd, J = 6.8, 3.6 Hz, 1H), 7.24 (br. d, J = 3.6 Hz, 
1H), 7.32 (dd, J = 3.2, 1.6 Hz, 1H), 7.48 (d, J = 13.2 Hz, 1H). 
Methyl 2-methyl-3-(5-methyl-3-phenyl-1,2-oxazol-4-yl)prop-2-
enoate (104) was obtained in accordance with general procedure 
F from the reaction of 5-methyl-3-phenylisoxazole-4-
carboxaldehyde (187 mg, 1.0 mmol, 1.0 equiv.) and methyl 2-bromopropionate (145 µL, 1.3 
mmol, 1.3 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 
1.3 equiv.) using PCg (16 mg, 0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. 
The crude product was purified via flash column chromatography (1% diethyl ether in 
benzene, E-104: Rf = 0.30, Z-104: Rf = 0.17) to afford both E-104 as a yellow solid and Z-
104 as a yellow oil (250 mg, 97%, E/Z 70:30). E-104: 1H NMR (400 MHz, CDCl3) δ: 1.79 
(d, J = 1.6 Hz, 3H), 2.38 (d, J = 0.4 Hz, 3H), 3.81 (s, 3H), 7.36 (br. s, 1H), 7.42-7.45 (m, 
3H), 7.61-7.66 (m, 2H); 13C NMR (100MHz, CDCl3) δ: 12.5, 14.9, 52.3, 110.7, 128.0, 
128.0, 128.9, 129.2, 129.9, 132.2, 161.4, 167.2, 168.0; mp 93-95 °C. Z-104: 1H NMR (400 
MHz, CDCl3) δ: 2.11 (d, J = 1.6 Hz, 3H), 2.33 (s, 3H), 3.52 (s, 3H), 6.47 (br. s, 1H), 7.35-
7.50 (m, 3H), 7.60-7.70 (m, 2H); 13C NMR (100MHz, CDCl3) δ: 12.1, 21.3, 51.9, 111.3, 
125.4, 128.0, 128.8, 129.6, 129.7, 133.3, 161.2, 167.2, 168.0; HRMS [M+H]+: m/z calcd. 
258.1130, found 258.1129.  
3-(3,7-Dimethyloct-6-en-1-ylidene)dihydrofuran-2(3H)-
one[38] (105) was obtained in accordance with general 
procedure F from the reaction of (±)-citronellal (180 µL, 
1.0 mmol, 1.0 equiv.), a-bromo-g-butyrolactone (120 µL, 1.3 mmol, 1.3 equiv.), PMHS 
(310 µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using PCb (21 
mg, 0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. The crude product was 
purified via flash column chromatography (benzene, E-105: Rf = 0.19, Z-105: Rf = 0.32) to 
afford E-105 and Z-105 as pale yellow oils (258 mg, 71%, E/Z 70:30). E-105: 1H NMR (400 
MHz, CDCl3) δ: 0.90 (d, J = 6.8 Hz, 3H), 1.13-1.22 (m, 1H), 1.29-1.40 (m, 1H), 1.57 (br. s, 
CO2Me
N
O
Ph
104 
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3H), 1.61-1.69 (m, 4H), 1.88-2.05 (m, 3H), 2.13-2.20 (m, 1H), 2.81-2.86 (m, 2H), 4.35 (t, J 
= 7.6 Hz, 2H), 5.02-5.07 (m, 1H), 6.74 (tt, J = 7.6, 2.8 Hz, 1H). Z-105: 1H NMR (400 MHz, 
CDCl3) δ: 0.90 (d, J = 6.4 Hz, 3H), 1.13-1.22 (m, 1H), 1.29-1.40 (m, 1H), 1.54-1.62 (m, 
4H), 1.66 (d, J = 0.8 Hz, 3H), 1.89-2.06 (m, 2H), 2.57-2.70 (m, 2H), 2.91 (tq, J = 7.2, 2.0 
Hz, 2H), 4.30 (t, J = 7.2 Hz, 2H), 5.05-5.09 (m, 1H), 6.24 (tt, J = 7.6, 2.4 Hz 1H). 
 3-Phenyl-1-(adamant-1-yl)prop-2-en-1-one[39] (106) was 
obtained in accordance with general procedure F from the 
reaction of benzaldehyde (100 µL, 1.0 mmol, 1.0 equiv.), 1-(1-
adamantyl)-2-bromoethanone (334 mg, 1.3 mmol, 1.3 equiv.), 
PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) using 
PCg (16 mg, 0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. The crude 
product was purified via flash column chromatography (benzene/hexane, 50:50, Rf = 0.33) 
to afford an isomeric mixture of 106 as a white solid (213 mg, 80%, E/Z 93:7). E-106: 1H 
NMR (400 MHz, CDCl3) δ: 1.76 (br q, J = 12.4 Hz, 6H), 1.89 (d, J = 2.0 Hz, 6H), 2.09 (br 
s, 3H), 7.16 (d, J = 15.6 Hz, 1H), 7.37-7.39 (m, 3H), 7.57-7.59 (m, 2H), 7.67 (d, J = 15.6 
Hz, 1H). 
 (E)-5,6-Dimethoxy-2-(3,4,5-
trimethoxybenzylidene)-2,3-dihydro-1H-inden-1-
one (107) was obtained in accordance with general 
procedure F from the reaction of 3,4,5-
trimethoxybenzaldehyde (196 mg, 1.0 mmol, 1.0 
equiv.), 2-bromo-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one (351 mg, 1.3 mmol, 1.3 
equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and DIPEA (226 µL, 1.3 mmol, 1.3 equiv.) 
using PCg (16 mg, 0.1 mmol, 10 mol %) in CPME (1.0 mL) at 100 °C for 24 h. The crude 
product was purified via flash column chromatography (benzene/diethyl ether, 50:50, Rf = 
0.29) to afford 107 as a pale yellow solid (275 mg, 74%, E/Z >95:5). 1H NMR (400 MHz, 
CDCl3) δ: 3.90 (s, 3H), 3.90-3.95 (m, 11H), 3.99 (s, 3H), 6.86 (s, 2H), 6.98 (s, 1H), 7.31 (s, 
O
106 
MeO
MeO
OMe
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1H), 7.48 (br. s, 1H); 13C NMR (100MHz, CDCl3) δ: 32.0, 56.2, 56.4, 61.1, 105. 1, 107.3, 
107.9, 131.1, 132.7, 134.5, 139.5, 144.7, 149.7, 153.4, 155.4, 193.1; mp 207-208 °C; HRMS 
[M+H]+: m/z calcd. 371.1495, found 371.1502. 
107 was obtained on a 7.7 mmol scale according to general procedure F from the reaction 
of 3,4,5-trimethoxybenzaldehyde (2.0 g, 10.2 mmol, 1.0 equiv.), 2-bromo-5,6-dimethoxy-
2,3-dihydro-1H-inden-1-one (3.6 g, 13.2 mmol 1.3 equiv.), PMHS (3.2 mL, 51.0 mmol, 5.0 
equiv.) and DIPEA (2.3 mL, 13.2 mmol, 1.3 equiv.) using PCg (160 mg, 1 mmol, 10 mol 
%) in CPME (10 mL). The reaction was prepared in a 100 mL pressure vessel under an inert 
atmosphere and run at 100 °C for 24 h. The crude reaction mixture was stirred in EtOAc, 
filtered through Celite®, dried in vacuo and recrystallised from EtOH to yield pure 107 as a 
yellow solid (2.87 g, 76%, E/Z >95:5). 
4,8-Dimethylnona-1,7-dien-1-yl)benzene[40] (108) was 
prepared in accordance with general procedure E1 from 
the reaction of (±)-citronellal (216 µL, 1.2 mmol, 1.2 
equiv.), benzyl bromide (120 µL, 1.0 mmol, 1.0 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 
equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (42 mg, 0.2 mmol, 20 mol %) in 
in toluene (1.0 mL) at 110 °C for 24 h. The crude product was purified via flash column 
chromatography (hexane, Rf = 0.49) to afford an isomeric mixture of 108 as a colourless 
liquid (148 mg, 65%, E/Z 80:20). E-108: 1H NMR (400 MHz, CDCl3) δ: 0.96 (d, J = 6.4 Hz, 
3H), 1.16-1.29 (m, 1H), 1.38-1.48 (m, 1H), 1.54-1.72 (m, 1H), 1.64 (s, 3H), 1.72 (s, 3H), 
1.96-2.41 (m, 4H), 5.10-5.16 (m, 1H), 6.24 (dt, J = 15.6, 7.6 Hz, 1H), 6.40 (d, J = 16.0 Hz, 
1H), 7.20-7.38 (m, 5H). Z-108: 1H NMR (400 MHz, CDCl3) δ: 0.94 (d, J = 6.4 Hz, 3H), 
1.16-1.29 (m, 1H), 1.38-1.48 (m, 1H), 1.54-1.72 (m, 7H), 1.96-2.41 (m, 4H), 5.10-5.16 (m, 
1H), 5.72 (dt, J = 11.6, 7.2 Hz, 1H), 6.48 (d, J = 11.6 Hz, 1H), 7.20-7.38 (m, 5H). 
9-[(E)-2-Phenylethenyl]anthracene (109) was prepared in 
accordance with general procedure E1 from the reaction of 9-
109 
108 
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anthracenecarboxaldehyde (247 mg, 1.2 mmol, 1.2 equiv.), benzyl bromide (120 µL, 1.0 
mmol, 1.0 equiv.), PMHS (310 µL, 5.0 mmol, 5.0 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 
equiv.) using PCb (21 mg, 0.1 mmol, 10 mol %) in in toluene (1.0 mL) at 110 °C for 24 h. 
The crude product was purified via flash column chromatography (hexane, Rf = 0.19) to 
afford 109 as a bright yellow solid (180 mg, 64%, E/Z >95:5). 1H NMR (400 MHz, CDCl3) 
δ: 6.97 (d, J = 16.4 Hz, 1H), 7.37 (t, J = 7.2 Hz, 1H), 7.45-7.50 (m, 6H), 7.69 (d, J = 7.2 Hz, 
2H), 7.93 (d, J = 16.8 Hz, 1H), 8.01-8.05 (m, 2H), 8.35-8.38 (m, 2H), 8.42 (s, 1H); 13C 
NMR (100MHz, CDCl3) δ: 125.0, 125.3, 125.6, 126.2, 126.6, 126.7, 128.2, 128.8, 129.0, 
129.9 131.6, 132.9, 137.5; HRMS [M]+: m/z calcd. 280.1252, found 280.1253. 
1-[2-(4-Methoxyphenyl)ethenyl]-2-methylbenzene[41] 
(110) was prepared in accordance with general procedure 
E1 from the reaction of 4-anisaldehyde (146 µL, 1.2 mmol, 
1.2 equiv.), 2-methylbenzyl chloride (132 µL, 1.0 mmol, 1.0 equiv.), PMHS (310 µL, 5.0 
mmol, 5.0 equiv.) and 54 (280 mg, 2.0 mmol, 2.0 equiv.) using PCb (21 mg, 0.1 mmol, 10 
mol %) in in toluene (1.0 mL) at 110 °C for 24 h. the crude product was purified via flash 
column chromatography (5% ethyl acetate/hexane, E-110 Rf = 0.36, Z-110 Rf = 0.42) to 
afford an isomeric mixture of 110 as a colourless oil (164 mg, 73%, E/Z 80:20). E-110 1H 
NMR (400 MHz, CDCl3) δ: 2.47 (s, 3H), 3.86 (s, 3H), 6.95 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 
16.0 Hz, 1H), 7.20-7.27 (m, 3H), 7.24 (d, J = 16.0 Hz, 1H), 7.51 (d, J = 8.8 Hz, 2H), 7.62 
(d, J = 7.6 Hz, 1H). Z-110 1H NMR (400 MHz, CDCl3) δ: 2.31 (s, 3H), 3.78 (s, 3H), 6.59 (d, 
J = 2.0 Hz, 2H), 6.74 (d, J = 8.8 Hz, 2H), 7.09 (d, J = 8.8 Hz, 2H), 7.12 (d, J = 8.4 Hz, 1H), 
7.20-7.27 (m, 3H).  
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